{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/724-US10,975,364(Active) re (Done on website already).pdf"}, "page_content": "USO10975364B2\n\n( 12 ) United States Patent\n\n( 10 ) Patent No .:\n\nUS 10,975,364 B2\n\nZheng et al .\n\n( 45 ) Date of Patent :\n\nApr. 13 , 2021\n\n( 54 ) MODIFIED PROTEIN AND METHOD FOR\n\nOTHER PUBLICATIONS\n\nALTERING GENOME OF CELL\n\nBroun et al . , Catalytic plasticity of fatty acid modification enzymes\n\nunderlying chemical diversity of plant lipids . Science , 1998 , vol .\n\n( 71 ) Applicant : City University of Hong Kong ,\n\n282 : 1315-1317 . ( Year : 1998 ) . *\n\nKowloon ( HK )\n\nChica et al . , Semi - rational approaches to engineering enzyme\n\nactivity : combining the benefits of directed evolution and rational\n\n( 72 ) Inventors : Zongli Zheng , Kowloon ( HK ) ; Jiahai\n\ndesign . Curr . Opi . Biotechnol . , 2005 , vol . 16 : 378-384 . ( Year :\n\nShi , Singapore ( SG ) ; Yuanyan Tan ,\n\n2005 ) . *\n\nShatin ( HK )\n\nDevos et al . , Practical limits of function prediction . Proteins :\n\nStructure , Function , and Genetics . 2000 , vol . 41 : 98-107 . ( Year :\n\n( 73 ) Assignee : City University of Hong Kong ,\n\n2000 ) . *\n\nKowloon ( HK )\n\nSeffernick et al . , Melamine deaminase and Atrazine chlorohydrolase :\n\n98 percent identical but functionally different . J. Bacteriol . , 2001 ,\n\nSubject to any disclaimer , the term of this\n\n( * ) Notice :\n\nvol . 183 ( 8 ) : 2405-2410 . ( Year : 2001 ) . *\n\nSen et al . , Developments in directed evolution for improving\n\npatent is extended or adjusted under 35\n\nenzyme functions . Appl . Biochem . Biotechnol . , 2007 , vol . 143 :\n\nU.S.C. 154 ( b ) by 0 days .\n\n212-223 . ( Year : 2007 ) . *\n\nWhisstock et al . , Prediction of protein function from protein sequence .\n\n( 21 ) Appl . No .: 16 / 552,034\n\nQ. Rev. Biophysics . , 2003 , vol . 36 ( 3 ) : 307-340 . ( Year : 2003 ) . *\n\nWitkowski et al . , Conversion of b - ketoacyl synthase to a Malonyl\n\nAug. 27 , 2019\n\n( 22 ) Filed :\n\nDecarboxylase by replacement of the active cysteine with gluta\n\nmine . Biochemistry , 1999 , vol . 38 : 11643-11650 . ( Year : 1999 ) . *\n\n( 65 )\n\nPrior Publication Data\n\ncited by examiner\n\nMar. 4 , 2021\n\nUS 2021/0062169 A1\n\nPrimary Examiner \u2014 Ganapathirama Raghu\n\n( 51 ) Int . Ci .\n\n( 74 ) Attorney , Agent , or Firm \u2014 Renner Kenner Greive\n\n( 2006.01 )\n\nC12N 9/22\n\nBobak Taylor & Weber\n\n( 2006.01 )\n\nC12N 15/11\n\n( 2006.01 )\n\nC12N 15/90\n\nABSTRACT\n\n( 57 )\n\n( 52 ) U.S. CI .\n\nA modified Streptococcus aureus Cas9 ( SaCas9 ) protein\n\nC12N 9/22 ( 2013.01 ) ; C12N 15/11\n\nCPC\n\n( 2013.01 ) ; C12N 15/902 ( 2013.01 ) ; C12N\n\nwith a mutation at an N413 position , and optionally one or\n\n2310/20 ( 2017.05 ) ; C12N 2800/80 ( 2013.01 )\n\nmore of a nuclear localization sequence , a cell penetrating\n\npeptide sequence , an affinity tag and / or a fusion base editor\n\n( 58 ) Field of Classification Search\n\nprotein , and a kit that comprises said modified protein . A\n\nCPC\n\nC12N 9/22 ; C12N 15/11 ; C12N 15/902 ;\n\nmethod for altering the genome of a cell , the method\n\nC12N 2310/20 ; C12N 2800/80\n\nincluding the step of using the modified protein of the\n\nSee application file for complete search history .\n\ninvention .\n\n( 56 )\n\nReferences Cited\n\n28 Claims , 19 Drawing Sheets\n\nU.S. PATENT DOCUMENTS\n\n( 7 of 19 Drawing Sheet ( s ) Filed in Color )\n\nSpecification includes a Sequence Listing .\n\n3/2019 Joung et al .\n\n2019/0071657 Al\n\nUS010975364B2\n\na2) United States Patent\n\n(10) Patent No US 10,975,364 B2\n\nZheng et al.\n\n(45) Date of Patent: Apr. 13, 2021\n\nMODIFIED PROTEIN AND METHOD FOR ALTERING GENOME OF CELL (54)\n\nOTHER PUBLICATIONS\n\net al., Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Science, 1998, 1315-1317. (Year: 1998).*\n\n(71) Applicant: City University of Hong Kong, Kowloon (HK)\n\nChica et al., Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr. Opi. Biotechnol., 2005, vol. 16: 378-384. (Year: 2005).\n\nInventors: Zongli Zheng, Kowloon (HK), Jiahai Shi, Singapore (SG); Yuanyan Tan, Shatin (HK)\n\nDevos et al., Practical limits of function prediction. Proteins: Structure, Function, and Genetics. 2000, vol. 41: 98-107. (Year: 2000).*\n\n(73) Assignee: City University of Hong Kong, Kowloon (HK)\n\nSeffernick et al., Melamine deaminase and Atrazine chlorohydrolase: percent identical but functionally different. J. Bacteriol., 2001, 183 (8): 2405-2410. (Year: 2001).*\n\notice: subject to any disclaimer, the term of this Noti Subj disclai \u4e5f fthi patent is extended or adjusted under U.S.C. 154(b) by 0 days.\n\net al., Developments in directed evolution for improving enzyme functions. Appl. Biochem. Biotechnol., 2007, vol. 143: 212-223. (Year: 2007).*\n\nWhisstock et al., Prediction of protein function from protein sequence. Q. Rev. Biophysics., 2003, vol. 36 (3): 307-340. (Year: 2003).*\n\n(21) Appl. No.: 16/552,034\n\nWitkowski et al., Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with gluta- mine. Biochemistry, 1999, vol. 38: 11643-11650. (Year: 1999),*\n\n(22) Filed: Aug. 27, 2019\n\nPrior Publication Data (65)\n\n* cited by examiner\n\nUS 2021/0062169 Al Mar. 4, 2021\n\nPrimary Examiner \u2014 Ganapathirama Raghu\n\nInt. Cl. G61)\n\n(74) Attorney, Agent, or Firm \u2014 Renner Kenner Greive Bobak Taylor & Weber\n\nCI2N 9/22 CI2N 15/1 CI2N 15/90 (2006.01) (2006.01) (2006.01)\n\n(57) ABSTRACT\n\nUS. Cl. CPC (52) CI2N 9/22 (2013.01); CI2N 15/l1 (2013.01); C12N 15/902 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)\n\nA modified Streptococcus aureus Cas9 (SaCas9) protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an aflinity tag and/or a fusion base editor protein, and a kit that comprises said modified protein. A method for altering the genome of a cell, the method including the step of using the modified protein of the invention.\n\nField of Classification Search CPC C12N 9/22; C12N 15/11; C12N 15/902; C12N 2310/20; C12N 2800/80 See application file for complete search history. (58)\n\n(56) References Cited\n\n28 Claims, 19 Drawing Sheets (7 of 19 Drawing Sheet(s) Filed in Color)\n\nU.S. PATENT DOCUMENTS\n\nSpecification includes a Sequence Listing.\n\n2019/0071657 Al 3/2019 Joung et al.\n\n(72)\n\n)\n\n35\n\nBroun\n\nvol.\n\n282:\n\n98 vol. Sen\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 1 of 19\n\nFigure 1A\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nSheet 1 of 19\n\nApr. 13, 2021\n\nFigure 1A\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 2 of 19\n\nCZ 130\n\nV3100\n\nFigure 1B\n\n017 ou D020\n\n70\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nSheet 2 of 19\n\nApr. 13, 2021\n\nERS Bg meee sancinamians oper gation y\n\naT ansly\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 3 of 19\n\nFigure 1F\n\nI\n\n3\n\nPhosphate\n\nlock\n\nloop\n\nFigure 1E\n\nFigure 1C\n\nFigure 1D\n\nNNORRT )\n\nMX1.6 ( PAM\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 3 0f 19\n\ndoo \u2018po geydsoug OT aungi4 S98 aq) LPN ELEN oad \u4eba 6\n\nT ain \u5f15 ij\n\n4 T ounsi4\n\naT sein8l:\n\nSO ONN\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13 , 2021\n\nSheet 4 of 19\n\nLILI Figure 1G\n\n?\n\n32\n\n?\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 4 of 19\n\nEee en \u00a5 \u540c lle \u5df2 \u751f \u5230 y i 1 : | \u624d | \u548c | \u548c \u548c a 4 \uff0c \uff0c i ; \u548c i 1 j cf 1 u i : i Z| Me 3 | \u5173 \u548c \u7ef4\u548c yoRee TB\n\nOT ain8l\n\nx\n\nat\n\ner\n\n\u20act\n\naa\n\nSmee Kee e \u4eba \u4e2d \u5165 wom rar oe SE\n\ntt\n\noF\n\n5\n\n8\n\n\u00e9\n\n9\n\n\u00a7\n\n:ON ai 03s\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13 , 2021\n\nSheet 5 of 19\n\nFigure 20\n\n?\n\n13\n\nFigure 2B\n\n2\n\nEMXI ( PAN NN RRT )\n\nFigure 2A\n\nM\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 5 of 19\n\n(PAMINNARRT) Figure 2C ERtet 4 8 e e \u8fd9\n\nPAM MN RAT VEGFA_S & 8 &\n\nEMX1_S (PAMNNORRT ag 8 R A\n\nFigure 2B\n\napne: jo eneomy\n\nFigure 2A\n\nSpat po RSS\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 6 of 19\n\n;\n\n?\n\nx\n\nS\n\n1\n\n.\n\nFigure 2D\n\n**********\n\n.\n\n..\n\n..\n\n<\n\n3\n\n\n\n? ? %%\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 6 of 19\n\nRoe es & bev etee re By ce rtmbip anes 2 SER oe q & 3 \u540c $ = aes \u20ac EGER en kena oe 2 a 2 CRN bo BORE Eee PAR EG ee OM cM Bat te \u540c \u5168 x \u4e86 \u4eba \u5404 \u570b \u5247 \u904e ee \u904e ee ey x . x pyres Reece beta erence \u4e86 & fe Reo e ae \u516d \u5340 \u591a BEB OSE SS oaaen amet ie \u4e86 es \u548c Rei ea ncl ad esH onload g re ae QB iri Qin dhee Gi ke Sli bebe batead Gin be eG ORE ER EOD Poe GST EVRA RR KUNE TE BORAT TIO ae a gle ee See ee 5 si eta Dre \u548c 7\n\n4 ay @ PBe\n\n\u5168 z 2\n\nx B ae \u5674 \u6e2c\n\n\u958b\n\nFigure 2D\n\nSGRASSISSS SHARES\n\nSIGS S BAS GEES SRE BSIESSSS\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 7 of 19\n\nHF\n\nSaCas9\n\nFigure 3A\n\nFANCF 13\n\nR245A\n\n8\n\nreads\n\nof\n\nPercentage\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 7 of 19\n\nAH-6SEDES VGPCH LAA FANCF 12 hm gD my 100 sppai jo abequsae, \u751f 5 = & \u540c\n\nFigure 3A\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13 , 2021\n\nSheet 8 of 19\n\nR245A\n\nSaCas9 - HF\n\n\"\n\n3 6\n\n33\n\n6\n\nGCGAG\n\nRua\n\nGAG\n\nGG : AG\n\nFigure 3B\n\nT\n\n\n\n1 GORAGGOOOG\n\nGGNNGRRI\n\nGOGOA\n\nOGGI\n\n3\n\n\n\nNG X\n\n2\n\nNO :\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 8 of 19\n\nR245A SaCas9-HF 35 @ \u7238 wr a MP kk kg OR RD\n\n\u53ea ENE ER SE = ENE OO IN OO GO U3 SP oP OS Oy\n\nDal af pe OC OO af OOGSI- UGS G + 2 & 8 & 8 & &@ e 2 & 2 8 & \u548c \u591a > & \u00a9 \u548c #8 \u56db @ \u540d\n\n\u00a5\n\nFigure 3B\n\nSEQ ID NO: FANCF_13\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 9 of 19\n\non - large of - target\n\n10 11 12 13 14 15 16 17 18 19 20 21 22 X Y *\n\nFigure 30\n\nFANCF.13 ( WT - SaCas9 )\n\nChromos\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 9 of 19\n\nOY\n\nzw\n\n17\n\nFANGF_13 (WT-SaGasg)\n\n&\n\n7\n\n6\n\nFigure 3C 342111273 4418418 Chromosome 344\n\ngab zise\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 10 of 19\n\non - larget offwtarget\n\nFANCF 13 ( SaCas9 - R245A )\n\n1 2 3 4 5 6 7 B 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y Chromosome\n\nFigure 3D\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 10 0f 19\n\nA\n\nM\n\nOC\n\nSEG\n\nLL\n\nSL\n\nSL\n\nGk\n\nBF\n\n2\n\nde ajn8lj \u8bc1 SG PEEL TLL\n\nZEIT\n\nBS\n\n--\n\n. {vereu-eseoes} SELL donwd\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 11 of 19\n\nori - target of - largot\n\nom\n\nFANCF_13 ( SaCas9 - HF )\n\nFigure 3E\n\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 0 19 20 21 22 X Y Oworr\u00e1sok\n\nWIND\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nSheet 11 of 19\n\nApr. 13, 2021\n\nGS\n\nLe\n\nOL\n\nGE\n\nLL\n\nOE\n\n(4H-650985) EL 4ONVE\n\nSa\n\n&\n\nJE analy\n\nCaP SOLUD EE PECL SE LL GE\n\nAM\n\nOE\n\npba - pabeyuo -\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 12 of 19\n\nFigure 3F\n\nOOOO\n\n.\n\n?\n\n?\n\n?\n\n?\n\n>\n\n?\n\n\n\n2\n\n4\n\n\n\n*\n\n?\n\n?\n\n?\n\n\n\n\n\n\n\n\n\n?\n\n\n\n?\n\n\n\n\n\n\n\n\n\n?\n\n\n\n>\n\n<\n\n?\n\n\n\n?\n\nx\n\n\n\n\n\n\n\n\n\n+\n\n\n\n?\n\n\n\n3\n\n?\n\n?\n\n?\n\n87 8\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 12 of 19\n\nFigure\n\nBS RO OR OE BET FG & > SE \u6b21 UTS dae wa \u7528 \u3008 \u80f0 ?\u201c \u7e7c \"772 \u7e7c ~, BES oR eR ERR ER RK Ee RO Re Re Ee SEF FA, Baie @ ..e. podem B aged eras Ea ce OOo hs @ >> Hi a \u5e97 \u6642 \u756b ee ae a eee Pree RISERS en Banc ne cs eee an es a Bhs We so oe a e+ \u00a9 HaRORUOMO EET EEIGID Ue bbe \u548c \u548c kk 8 IND pope LENS Ohad EOIN eg Oe SERR PERO ROHR RR CRE REE EOE RE OSES ay ge AS URE RE OER OES eke eS ve cao TRS ee. 8 Be ake \u9084 As eet ieee oe ee MR sie\n\n85\n\nBE\n\nWek\n\n3F\n\na OE\n\nesse\n\ncs\n\na\n\nsens\n\nSERN\n\nGSS S SSSSSS SSS VG\n\nU.S. Patent\n\nApr.13 , 2021\n\nUS10,975,364 B2\n\nSheet 13 of 19\n\nFigure 3G\n\net\n\n? ? 14\n\n2\n\n???????\n\n?\n\n\n\n\n\n?????? - ??\n\n???????\n\n47 ???????\n\n***\n\n\n\n**\n\n\n\n?\n\n\n\n\n\n?\n\n3 .\n\n2\n\n.\n\n.\n\n\n\n?\n\n\n\n.\n\n?\n\nSEQ ID\n\n92\n\n94\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 13 0f 19\n\n# ~ \u529e SHE QOS VSR LAL a a ce Fe EK Se HH SESERIES VERT 2k \u591a \u591a # ~ & Es & 882 Bes\n\nD\u00a2 aungiy\n\n204 \u00a304 904\n\nSOL POL ak\n\nZE \u00a304\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 14 of 19\n\nwwwwwww\n\n8\n\nFigure 4A\n\n\n\n?\n\nsites\n\ntarget\n\n\n\noff\n\nof\n\nNo.\n\nsites\n\ntarget\n\n\n\noff\n\nof\n\nNo.\n\nsites\n\ntarget\n\n\n\noff\n\nof\n\nNo.\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 14 of 19\n\n-| eg \u20ac o| \u201cos \u00ab| 14 w| <\u00ab \u00ab| , << \u00ab| & x #\u20ac \u00ab| ya \u00ab| 1 \u20ac ~| Pa \u00ab| a \u20ac \u00ab| x 3 2 8 & $9 8 * 8 RF =\n\n\u00a2\n\ni\n\nrat\n\n\u4eba\n\nF< SAUS J08ie}]-JJO JO \u2018ON\n\nEs e 2 3 Uy MATS RIE.\n\nSOUS 1984el-jjo JOON\n\nSAHS WBse}-yo Jo ON\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 15 of 19\n\nUn\n\nFigure 4B\n\n?\n\nE ?\n\n***\n\n3\n\n4\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 15 of 19\n\nFigure 4B\n\n0\n\nBi\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 16 of 19\n\nFigure 5A\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 16 of 19\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13 , 2021\n\nSheet 17 of 19\n\n\n\n>\n\n\n\n\n\n\n\n22 *\n\n?\n\n.\n\n?\n\n\n\n2\n\n\n\n\n\n**\n\n2\n\n\n\n# ?\n\n2\n\n2\n\nY\n\n22\n\n?\n\n\n\n2\n\n\n\n?\n\n\n\n\n\n?\n\n? *\n\n?\n\n? ?\n\n?\n\nmogu\n\ncontent go\n\nFigure 5B\n\nen\n\nhoy\n\n>\n\nW\n\n?\n\n**\n\n\n\n\n\n\n\n\n\n\n\n\n\n? .\n\n**\n\n\n\n?\n\n?\n\n?\n\nX\n\n\n\nSEQD\n\n824\n\n? ? ? ? ? ? ? ?\n\nSUL\n\n78 73\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 17 0f 19\n\n~ ~ eo ~ ww ~ ~ ~ ~ \u570b ~ ~ ~ ~ ~ \u201d \u570b ~ ~ \u540c ~ \u591a \u9084 ~ ~ eh H # 2 ge Fe Re oe\n\n~ \u883b * Re ~ < * ee aa Ons \u591a < 4g ee 8: xe \u00a2 > :\u8f66 a \u7684 \u591a * ne oe ee & x def OR KR 6 oe lags < x \u7e7c >*\u3002\u3002*x > \u4e4b Sei pty 8 : pane eee ar 8 x See enuw eae ih \u540c \u56db ee tas \u00e9 x > oy \u00e9 < a SR < we tex : BEL * 5 ony nae eb & > xy seo ee BEL x pare co get xe > Bee yet 4x rr \u00abx wx ec oe +e eee ate BEL ee ee \u7684 cae eh eae ae Oct \u4eba tray pa Ree Ree Pras ws a ar Pra \"ge 2 aie * aah we Bane ee \u201cx a \"se seh we x xe \u4eba wy a G24 cae vue ee we + Es 2\n\nOPS BW RA ee RM RRR HER RRR HAR \u958b \u540d : ~ x > \u00a3 ~ \u591a x55 \u4e8c & \u00a32 y & a be ~ a &* Ea ae ar Eee ee BSE ee SS car Es eer ee . . \u2014 EHR > \u5c0f ~ $8 ae \u6c49\u65cf \u540c See BMH \u672c \u00a3 WHS oss , pe en eee 602g \u201cSOME ae : He BSE be ee eee Re\n\ndg 34n3i\n\nfea oS\n\ng \u00a3\n\n59\n\nve\n\n28 2 oe ay ras GL Buh atk BLE \u00a32 BL ee ah\n\noe\n\ng 3\n\n:\n\nee\n\nBP\n\nabs \u751f\u8ba1 ELS ah 38\n\nae aE\n\nze\n\nOLE\n\nSe\n\n9% 2%\n\nU.S. Patent\n\nApr. 13 , 2021\n\nUS 10,975,364 B2\n\nSheet 18 of 19\n\n.\n\nFigure 5C\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 18 of 19\n\nFigure SC\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13 , 2021\n\nSheet 19 of 19\n\n\n\n\n\n**\n\n** *\n\n\n\n?\n\n\n\n\n\n\n\n\n\nSEQD\n\n170 878\n\n375 176\n\n167\n\nFigure 5D\n\n\n\n\n\n?\n\n\n\n\n\n\n\n: *\n\n?\n\n\n\n\n\n\n\n\n\n\n\n\n\n149 350\n\n352\n\n154\n\n162\n\n94\n\n92\n\nU.S. Patent\n\nUS 10,975,364 B2\n\nApr. 13, 2021\n\nSheet 19 0f 19\n\n~ B +S \u00a5 eos \u516d 2 . \u00e9 \u00bb z ek ee ee \u4eba \u689d \u689d \u53ca \u6f51 Og oe ee \u00ae oof \u00a38 Hee \u548c xx \u548c 223 \u8aaa \u5316 \u4eba \u00a9. \u548c * ee \u201d & ~ Es ~ te . \u591a as out ^ \u6709 \u7e7c = > Shh \u672c * & es rors \u767c Eg \u201c & ae 43 \u591a ~ \u8173 xx faa < ~ & as AL S RE Pes aE Lb ee et \u4eba ES ae GOL RE \u540c = ae R94 283. ee \u201d a hs 2a \u5982 Be \u95dc x ee 994 i = \u5e7e Pa SS get \u7d66 Bed 3 a4 $94 eh Ae e ihe ae ae\n\nBoy zs bot 8 296 26 96 \u8bf7\n\nag aun3iy\n\n~\n\ne\n\nPs bae eens\n\n\u7ed9\n\nbe ako Sees RR RRR tees aa x oe es \u548c errr RMR RHEE -\u6751 \u548c ee eeeee See eee SR RRB Oe Se eb eee RoR RR Rw \u4eba eR RR RK 8 8 8 RS eH ee\n\n6h SS 23% BSE 5h vat \u4eba zat Gt\n\nrh ae apt 2 aa 4k 6 eg a2\n\n99 SO \u2018ON SENS qibas\n\nUS 10,975,364 B2\n\n1\n\n2\n\nIn an embodiment , the modified protein comprises alanine\n\nMODIFIED PROTEIN AND METHOD FOR\n\nat the N413 position . In an embodiment , the modified\n\nALTERING GENOME OF CELL\n\nprotein comprises alanine at the N413 , R245 , N419 and / or\n\nR654 position .\n\nSEQUENCE LISTING\n\nIn a second aspect , the invention pertains to a method for\n\n5\n\nThe\n\nSequence\n\nListing\n\nfile\n\nentitled\n\naltering a genome of a cell . The method comprises the step\n\n\" mkcp406sequencelisting \" having a size of 72,282 bytes\n\nof using the modified protein .\n\nand a creation date of Dec. 4 , 2020 , is incorporated herein\n\nIn an embodiment , the modified protein is expressed in\n\nby reference in its entirety .\n\nthe cell , or the cell is contacted with the modified protein and\n\n10\n\na guide RNA having a region complementary to a selected\n\nTECHNICAL FIELD\n\nportion of the genome of the cell .\n\nIn a third aspect , the invention pertains to a kit comprising\n\nThe present invention relates to a modified protein and its\n\nthe modified protein . In an embodiment , the kit comprises a\n\nuse in altering the genome of a cell . Particularly , but not\n\nmodified Streptococcus aureus Cas9 ( SaCas9 ) protein with\n\n15\n\nexclusively , the invention relates to a modified Streptococ-\n\na mutation at an N413 position , and optionally one or more\n\ncus aureus Cas9 ( SaCas9 ) protein and its use in genomic\n\nof a nuclear localization sequence , a cell penetrating peptide\n\nengineering , genome targeting and genome editing tech\n\nsequence , an affinity tag and / or a fusion base editor protein .\n\nnologies .\n\nIn an embodiment , the modified protein comprises an\n\n20 amino acid sequence as defined in SEQ ID NO :\n\n1 or a\n\nBACKGROUND OF THE INVENTION\n\nhomologue thereof . In a further embodiment , the modified\n\nprotein comprises an amino acid sequence as defined in SEQ\n\nGenome engineering technologies have enabled system\n\nID NO : 2 or a homologue thereof .\n\natic interrogation of genome function and hold great poten-\n\nIn an embodiment , the modified protein comprising a\n\ntial for gene therapy . The clustered regularly interspaced 25 sequence as defined in SEQ ID NO : 1 or SEQ ID NO : 2 or\n\nshort palindromic repeat ( CRISPR ) associated protein ( Cas )\n\na homologue thereof further comprises one or more muta\n\nsystem enables efficient DNA modification guided by a\n\ntions at R245 , N419 and / or R654 positions .\n\ncomplementary RNA and in the presence of a protospacer\n\nIn an embodiment , the modified protein further comprises\n\nadjacent motif ( PAM ) . However , non - perfect guide - RNA-\n\nmutations at R245 , N419 and R654 positions , preferably the\n\ntarget - DNA matching has been known to occur which can 30 modified protein comprises an amino acid sequence as\n\nresult in modifications at genomic loci other than the\n\ndefined in SEQ ID NO : 3 or a homologue thereof .\n\nintended locus . This off - target activity can limit the broad\n\nIn an embodiment , the modified protein further comprises\n\nmutations R245 , N419 and R654 positions , preferably the\n\napplication of this technology . Accordingly , modified pro\n\nteins for altering the genome of a cell with application in\n\nmodified protein comprises an amino acid sequence as\n\ngenome editing and gene therapy are desired .\n\n35 defined in SEQ ID NO : 4 or a homologue thereof .\n\nIn an embodiment , the mutation is a single amino acid\n\nsubstitution .\n\nSUMMARY OF THE INVENTION\n\nIn an embodiment , the modified protein comprises alanine\n\nIn a first aspect , the invention provides a modified protein .\n\nat the N413 position . In a further embodiment , the modified\n\nPreferably , the modified protein is a Streptococcus aureus 40 protein comprises alanine at the N413 , R245 , N419 and / or\n\nCas9 ( SaCas9 ) protein with a mutation at an N413 position ,\n\nR654 positions .\n\nand optionally one or more of a nuclear localization\n\nAccordingly , the invention provides a novel and effective\n\nsequence , a cell penetrating peptide sequence , an affinity tag\n\nmodified protein for altering the genome of a cell with\n\napplication in genome editing and gene therapy . The modi\n\nand / or a fusion base editor protein .\n\nIn an embodiment , the modified protein comprises an 45 fied protein of the invention , specifically the modified Strep\n\namino acid sequence as defined in SEQ ID NO :\n\n1 or a\n\ntococcus aureus Cas9 ( SaCas9 ) protein with a mutation at an\n\nhomologue thereof .\n\nN413 position , confers high genome - wide specificity and\n\nIn an embodiment , the modified protein comprises an\n\nretains high editing efficiency . The provision of the modified\n\namino acid sequence as defined in SEQ ID NO : 2 or a\n\nSaCas9 protein of the present invention and a guide RNA\n\nhomologue thereof .\n\n50 ( gRNA ) establishes a gene - editing system in a cell . The\n\nIn an embodiment , the modified protein further comprises\n\nCas9 protein is guided by the gRNA to cut a target gene at\n\none or more mutations at R245 , N419 and / or R654 posi-\n\na specific location on a target DNA molecule of a cell . The\n\napplication of the modified SaCas9 protein of the invention\n\ntions .\n\nIn an embodiment , the modified protein comprises an\n\nadvantageously decreases nuclease activity at one or more\n\namino acid sequence as defined in SEQ ID NO : 3 or a 55 off - target positions on a target DNA molecule thereby\n\nenabling genome - editing applications with high genome\n\nhomologue thereof .\n\nIn an embodiment , the modified protein comprises an\n\nwide precision . This results in significant reductions of\n\namino acid sequence as defined in SEQ ID NO : 4 or a\n\noff - target activity and improved specificity of the SaCas9\n\nhomologue thereof .\n\nprotein . The modified protein and the related kit comprising\n\nIn an embodiment , the modified protein with optionally at 60 it are also parts of the invention .\n\nleast one additional mutation selected from the group con-\n\nThose skilled in the art will appreciate that the invention\n\nsisting of R245 , N419 and R654 positions decreases nucle-\n\ndescribed herein is susceptible to variations and modifica\n\nase activity at one or more sites on a target DNA molecule .\n\ntions other than those specifically described . The invention\n\nIn an embodiment , the one or more sites are off - target\n\nincludes all such variations and modifications . The invention\n\nsites on the target DNA molecule .\n\n65 also includes all steps and features referred to or indicated in\n\nIn an embodiment , the mutation is a single amino acid\n\nthe specification , individually or collectively , and any and all\n\ncombinations of the steps or features .\n\nsubstitution .\n\nUS 10,975,364 B2\n\n1\n\n2\n\nMODIFIED PROTEIN AND METHOD FOR ALIERING GENOME OF CELL\n\nin an embodiment, the modified protein comprises alanine the N413 position. In an embodiment, the modified protein comprises alanine at the N413, R245, N419 and/or R654 position.\n\nSEQUENCE LISTING\n\nin a second aspect, the invention pertains to a method for altering a genome of a cell. The method comprises the step of using the modified protein.\n\nThe Sequence Listing file entitled \u201cmkcp406sequencelisting\u201dhaving a size of 72,282 bytes and a creation date of Dec. 4, 2020, is incorporated herein by reference in its entirety.\n\nin an embodiment, the modified protein is expressed in the cell, or the cell is contacted with the modified protein and a guide RNA having a region complementary to a selected portion of the genome of the cell.\n\nTECHNICAL FIELD\n\nin a third aspect, the invention pertains to a kit comprising the modified protein. In an embodiment, the kit comprises a modified Streptococcus aureus Cas9 (SaCas9) protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein.\n\nThe present invention relates to a modified protein and its use in altering the genome of a cell. Particularly, but not exclusively, the invention relates to a modified Streptococ- cus aureus Cas9 (SaCas9) protein and its use in genomic engineering, genome targeting and genome editing tech- nologies.\n\nin an embodiment, the modified protein comprises amino acid sequence as defined in SEQ ID NO: 1 or homologue thereof. In a further embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 2 or a homologue thereof.\n\nBACKGROUND OF THE INVENTION\n\nengineering technologies system- atic interrogation of genome function and hold great poten- tial for gene therapy. The clustered regularly interspaced short palindromic repeat (CRISPR) associated protein (Cas) system enables efficient DNA modification guided by a complementary RNA and in the presence of a protospacer adjacent motif (PAM). However, non-perfect guide-RNA- target-DNA matching has been known to occur which can result in modifications at genomic loci other than the intended locus. This off-target activity can limit the broad application of this technology. Accordingly, modified pro- teins for altering the genome of a cell with application in editing and therapy are desired.\n\nIn an embodiment, the modified protein comprising sequence as defined in SEQ ID NO: 1 or SEQ ID NO: 2 homologue thereof further comprises one or more muta- tions at R245, N419 and/or R654 positions.\n\nin an embodiment, the mod mutations at R245, N419 and modified protein comprises defined in SEQ ID NO: 3 or lified protein further comprises R654 positions, preferably the an amino acid sequence as a homologue thereof.\n\nin an embodiment, the mod mutations at R245, N419 an modified protein comprises ified protein further comprises R654 positions, preferably the an amino acid sequence defined in SEQ ID NO: 4 or a homologue thereof.\n\nin an embodiment, the mutation is a single amino substitution.\n\nSUMMARY OF THE INVENTION\n\nin an embodiment, the modified protein comprises alanine the N413 position. In a further embodiment, the modified protein comprises alanine at the N413, R245, N419 and/or R654 positions.\n\nIna first aspect, the invention provides a modified protein. Preferably, the modified protein is a Streptococcus aureus Cas9 (SaCas9) protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein.\n\nmodified protein for altering the genome of a cell with application in genome editing and gene therapy. The modi- fied protein of the invention, specifically the modified Strep- tococcus aureus Cas9 (SaCas9) protein with a mutation at an N413 position, confers high genome-wide specificity and retains high editing efficiency. The provision of the modified SaCas9 protein of the present invention and a guide RNA (gRNA) establishes a gene-editing system in a cell. The Cas9 protein is guided by the gRNA to cut a target gene at a specific location on a target DNA molecule of a cell. The application of the modified SaCas9 protein of the invention advantageously decreases nuclease activity at one or more off-target positions on a target DNA molecule thereby enabling genome-editing applications with high genome- wide precision. This results in significant reductions of off-target activity and improved specificity of the SaCas9 protein. The modified protein and the related kit comprising\n\nIn an embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 1 or a homologue thereof.\n\nin an embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 2 or homologue thereof.\n\nin an embodiment, the modified protein further comprises one or more mutations at R245, N419 and/or R654 posi- tions.\n\nin an embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 3 or a homologue thereof.\n\nIn an embodiment, protein comprises an amino acid sequence as defined in SEQ ID NO: 4 or a homologue thereof.\n\nin an embodiment, the modified protein with optionally least one additional mutation selected from the group con- sisting of R245, N419 and R654 positions decreases nucle- ase activity at one or more sites on a target DNA molecule.\n\nThose skilled in the art will appreciate that the invention described herein is susceptible to variations and modifica- tions other than those specifically described. The invention includes all such variations and modifications. The invention also includes all steps and features referred to or indicated in the specification, individually or collectively, and any and all combinations of the steps or features.\n\nmn an embodiment, the one or more sites are off-target sites on the target DNA molecule.\n\nin an embodiment, the mutation is a single amino substitution.\n\nGenome\n\nhave enabled\n\ngenome\n\ngene\n\na\n\nthe modified\n\nat\n\nacid\n\n10\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\n35\n\n60\n\n65\n\nat\n\nan\n\na\n\na\n\nor\n\na\n\nas\n\nacid\n\nat\n\nAccordingly, the invention provides a novel and effective\n\nit are also parts of the invention.\n\nUS 10,975,364 B2\n\n3\n\n4\n\nOther features and aspects of the invention will become\n\nFIG . 3A is a bar graph showing the percentage of edited\n\napparent by consideration of the following detailed descrip-\n\nreads detected by GUIDE - seq at on - target site ( green ) and\n\ntion and accompanying drawings .\n\noff - target sites ( ordered by number of mismatches from 1 to\n\n9 ) by wild - type SaCas9 ( WT ) , SaCas9 modified protein\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\n5 R245A ( i.e. with a mutation at position R245 ) , and SaCas9\n\nmodified protein HF with mutations at positions R245 ,\n\nFIG . 1A is a figure of a crystal structure of wild - type\n\nN413 , N419 and R654A ( SaCas9 - HF ) at FANCF_13 , i.e.\n\nmodified Cas9 protein comprising an amino acid sequence\n\nStreptococcus aureus Cas9 ( SaCas9 ) interacting with a\n\nas defined in SEQ ID NO : 3 .\n\nguide RNA ( GRNA ) -target DNA heteroduplex . A magnified\n\nstructure of the active site shows the amino acid residues at\n\nFIG . 3B shows genome - wide cleavage sites detected by\n\n10\n\nGUIDE - seq on FANCF_13 . Read counts listed on the right\n\nthe R245 , N413 , N419 and R654 ( in red ) positions ( also\n\nrepresent the number of GUIDE - Seq reads ; on - target site is\n\nknown as amino acid residues R245 , N413 , N419 and R654 )\n\nindicated by \u201c * \u201d and mismatched bases in off - target sites\n\nthat form polar contacts within 3.0 \u00c5 distance from the target\n\nwith the on - target site are highlighted .\n\nDNA ( in green ) .\n\nFIG . 3C shows on - target and off - target cleavages detected\n\n15\n\nFIG . 1B is a diagram showing SaCas9 amino acid resi\n\nby GUIDE - Seq of wild - type SaCas9 ( WT ) .\n\ndues in contact with the gRNA - target DNA heteroduplex\n\nFIG . 3D shows on - target and off - target cleavages detected\n\nlabeled with protospacer positions , with 21 being most\n\nby GUIDE - Seq of SaCas9 modified protein R245A .\n\nproximal to the protospacer adjacent motif ( PAM ) on the\n\nFIG . 3E shows on - target and off - target cleavages detected\n\ntarget DNA .\n\n20 by GUIDE - Seq of SaCas9 modified protein SaCas9 - HF with\n\nFIG . 1C is a diagram showing the structural domains of\n\nmutations at positions R245 , N413 , N419 and R654 , i.e.\n\nSaCas9 and the positions of four amino acid residues , R245 ,\n\nmodified Cas9 protein comprising an amino acid sequence\n\nN413 , N419 and R654 .\n\nas defined in SEQ ID NO : 3 .\n\nFIG . 1D is a bar graph showing the percentage of inser-\n\nFIG . 3F shows genome - wide cleavage sites detected by\n\ntions or deletions of bases ( indels ) on human endogenous 25 GUIDE - Seq at canonical NNGRRT PAM sites .\n\nsite EMX1_6 in HEK293T cells using wild - type SaCas9\n\nFIG . 3G shows genome - wide cleavage sites detected by\n\n( WT ) , single amino acid substitution SaCas9 modified pro-\n\nGUIDE - Seq at non - canonical NNNRRT PAM sites .\n\nteins R245A , N413A , N419A and R654A , and a no - Cas9\n\nFIG . 4A is a bar graph showing the number of off - target\n\nnegative control ( NC ) .\n\nsites identified at EMX1_6 , FANCF_13 and VEGFA_8\n\nFIG . 1E is a bar graph showing the percentage of indels 30 using GUIDE - Seq by different SaCas9 residue mutation\n\non human endogenous site VEGFA_8 in HEK293T cells\n\ncombinations .\n\nusing wild - type SaCas9 ( WT ) , single amino acid substitu-\n\nFIG . 4B is a bar graph showing the percentage of edited\n\ntion SaCas9 modified proteins R245A , N4\n\nN419A and\n\nreads detected by GUIDE - Seq at on - target site ( in green ) and\n\noff - target sites ( ordered by the number of mismatches from\n\nR654A , and a no - Cas9 negative control ( NC ) .\n\nFIG . 1F is a bar graph showing the percentage of indels 35 1 to 7 ) among total edited reads by each SaCas9 modified\n\non human endogenous site EMX1_1 in HEK293T cells\n\nprotein .\n\nusing wild - type SaCas9 ( WT ) , single amino acid substitu-\n\nFIG . 5A is a venn diagram comparing the number of\n\ntion SaCas9 modified proteins R245A , N413A , N419A and\n\noff - target sites between a modified protein comprising muta\n\ntions at E782 , N968 and R1015 positions indicated as\n\nR654A , and a no - Cas9 negative control ( NC ) .\n\nFIG . 1G shows human cell EGFP disruption activities of 40 \u201c KKH \u201d in the figure ) and a modified protein with mutations\n\nwild - type SaCas9 ( WT ) and SaCas9 modified proteins\n\nat E782 , N968 , R1015 , R245 , N413 , N419 and R654 posi\n\nR245A , N413A , N419A and R654A using target protospacer\n\ntions comprising an amino acid sequence as defined in SEQ\n\nmatched or mis - matched gRNA .\n\nID NO : 4 ( KKH - SaCas9 - HF , indicated as KKH - HF in the\n\nFIG . 2A is a bar graph showing the percentage of edited\n\nfigure ) when targeting six sites including EMX1_6 ,\n\nreads detected by GUIDE - seq at on - target site ( green ) and 45 RUNX1_13 , RUNX1_14 ,\n\nFANCF_10 , FANCF_13 ,\n\noff - target sites ( ordered by number of mismatches from 1 to\n\nVEGFA_8 with canonical NNGRRT PAM .\n\n7 ) among total edited reads by VVT SaCas9 and SaCas9\n\nFIG . 5B shows GUIDE - Seq detected cleavage sites by a\n\nmodified proteins R245A , N413A , N419A and R654A at\n\nmodified protein comprising mutations at E782 , N968 and\n\nR1015 positions ( indicated as \u201c KKH \u201d in the figure ) and a\n\nEMX1_6 .\n\nFIG . 2B is a bar graph showing the percentage of edited 50 modified protein with mutations at E782 , N968 , R1015 ,\n\nreads detected by GUIDE - seq at on - target site ( green ) and\n\nR245 , N413 , N419 and R654 positions comprising an amino\n\noff - target sites ( ordered by number of mismatches from 1 to\n\nacid sequence as defined in SEQ ID NO : 4 ( KKH - SaCas9\n\n7 ) among total edited reads by VVT SaCas9 and SaCas9\n\nHF , indicated as \u201c KKH - HF \u201d in the figure ) when targeting six\n\nmodified proteins R245A , N413A , N419A and R654A at\n\nsites with canonical NNGRRT PAM . Read counts listed on\n\n55 the right represent the number of GUIDE - Seq reads . On\n\nVEGFA_8 .\n\nFIG . 2C is a bar graph showing the percentage of edited\n\ntarget site is indicated with \u201c * \u201d . Mismatched bases in\n\nreads detected by GUIDE - seq at on - target site ( green ) and\n\noff - target sites with the on - target site are highlighted .\n\noff - target sites ( ordered by number of mismatches from 1 to\n\nFIG . 5C is a venn diagram comparing the number of\n\n7 ) among total edited reads by VVT SaCas9 and SaCas9\n\noff - target sites between a modified protein comprising muta\n\nmodified proteins R245A , N413A , N419A and R654A at 60 tions at E782 , N968 and R1015 positions ( indicated as\n\n\u201c KKH \u201d in the figure ) and a modified protein with mutations\n\nEMX1_1 .\n\nFIG . 2D shows genome - wide cleavage sites detected by\n\nat E782 , N968 , R1015 , R245 , N413 , N419 and R654 posi\n\nGUIDE - Seq on EMX1_6 , VEGFA_8 and EMX1_1 . Read\n\ntions comprising an amino acid sequence as defined in SEQ\n\ncounts listed on the right represent the number of GUIDE-\n\nID NO : 4 ( KKH - SaCas9 - HF , indicated as \u201c KKH - HF \u201d in the\n\nSeq reads ; on - target site is indicated by \u201c * \u201d and mismatched 65 figure ) when targeting five sites including EMX1_1 ,\n\nbases in off - target sites with the on - target site are high-\n\nEMX1_4 , EMX1_10 , FANCF_9 and FANCF_16 with non\n\nlighted\n\ncanonical NNNRRT PAM .\n\nUS 10,975,364 B2\n\n3\n\n4\n\nFIG. 3A is a bar graph showing the percentage of edited treads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches from 1 to 9) by wild-type SaCas9 (WT), SaCas9 modified protein R24S5A (i.e. with a mutation at position R245), and SaCas9 modified protein HF with mutations at positions R245, N413, N419 and R654A (SaCas9-HF) at FANCF_13, ie. modified Cas9 protein comprising an amino acid sequence as defined in SEQ ID NO: 3.\n\nOther features and aspects of the invention will become apparent by consideration of the following detailed descrip- tion and accompanying drawings.\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\nFIG. 1A is a figure of a crystal structure of wild-type Streptococcus aureus Cas9 (SaCas9) interacting with a guide RNA (gRNA)-target DNA heteroduplex. A magnified structure of the active site shows the amino acid residues at the R245, N413, N419 and R654 (in red) positions (also known as amino acid residues R245, N413, N419 and R654) that form polar contacts within 3.0 A distance from the target DNA (in green).\n\nFIG. 3B shows genome-wide cleavage sites detected GUIDE-seq on FANCF_13. Read counts listed on the right represent the number of GUIDE-Seq reads; on-target site indicated by \u201c*\u201d and mismatched bases in off-target sites with the on-target site are highlighted.\n\nFIG. 3C shows on-target and off-target cleavages detected GUIDE-Seq of wild-type SaCas9 (WT).\n\nFIG. 1B is a diagram showing SaCas9 amino acid resi- dues in contact with the gRNA-target DNA heteroduplex labeled with protospacer positions, with 21 being most proximal to the protospacer adjacent motif (PAM) on the target DNA.\n\nFIG. 3D shows on-target and off-target cleavages detected GUIDE-Seq of SaCas9 modified protein R245A.\n\nFIG. 3E shows on-target and off-target cleavages detected by GUIDE-Seq of SaCas9 modified protein SaCas9-HF with mutations at positions R245, N413, N419 and R654, i.e. modified Cas9 protein comprising an amino acid sequence as defined in SEQ ID NO: 3.\n\nFIG. 1C is a diagram showing the structural domains of SaCas9 and the positions of four amino acid residues, R245, N413, N419 and R654.\n\nFIG. 1D is a bar graph showing the percentage of inser- tions or deletions of bases (indels) on human endogenous site EMX1_6 in HEK293T cells using wild-type SaCas9 (WT), single amino acid substitution SaCas9 modified pro- teins R245A, N413A, N419A and R654A, and a no-Cas9 negative control (NC).\n\nFIG. 3F shows genome-wide cleavage sites detected DE-Sed at canonical NNGRRT PAM sites.\n\nG. 3G shows genome-wide cleavage sites detected DE-Seq at non-canonical NNNRRT PAM sites.\n\nG. 4A is a bar graph showing the number of off-target sites identified at EMX1_6, FANCF_13 and VEGFA using GUIDE-Seq by different SaCas9 residue mutation combinations.\n\nFIG. 1E is a bar graph showing the percentage of human endogenous site VEGFA_8 in HEK293T cells using wild-type SaCas9 (WT), single amino acid substitu- SaCas9 modified proteins R245A, N413A, N419A and R654A, and a no-Cas9 negative control (NC).\n\nG. 4B is a bar graph showing the percentage of edited reads detected by GUIDE-Seq at on-target site (in green) and off-target sites (ordered by the number of mismatches from 1 to 7) among total edited reads by each SaCas9 modified protein.\n\nFIG. 1F is a bar graph showing the percentage of indels on human endogenous site EMX1_1 in HEK293T cells using wild-type SaCas9 (WT), single amino acid substitu- tion SaCas9 modified proteins R245A, N413A, N419A and. R654A, and a no-Cas9 negative control (NC).\n\nFIG. 5A is a venn diagram comparing the number of off-target sites between a modified protein comprising muta- tions at E782, N968 and R1015 positions (indicated as \u201cKKH\u201d in the figure) and a modified protein with mutations at E782, N968, R1015, R245, N413, N419 and R654 posi- tions comprising an amino acid sequence as defined in SEQ ID NO: 4 (KKH-SaCas9-HF, indicated as KKH-HF in the figure) when targeting six sites including EMX1 6\uff0c RUNX1_13, RUNX1_14, FANCF_10, \u00a9 FANCF_13, VEGFA_8 with canonical NNGRRT PAM.\n\nFIG. 1G shows human cell EGFP disruption activities o wild-type SaCas9 (WT) and SaCas9 modified proteins R245A, N413A, N419A and R654A using target protospacer matched or mis-matched gRNA.\n\nFIG. 2A is a bar graph showing the percentage of edited reads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches from 1 to 7) among total edited reads by VVT SaCas9 and SaCas9 modified proteins R245A, N413A, N419A and R654A at EMX1_6.\n\nFIG. SB shows GUIDE-Seq detected cleavage sites by a modified protein comprising mutations at E782, N968 and. R1015 positions (indicated as \u201cKKH\u201d in the figure) and a modified protein with mutations at E782, N968, R1015, R245, N413, N419 and R654 positions comprising an amino acid sequence as defined in SEQ ID NO: 4 (KKH-SaCas9- HF, indicated as \u201cKKH-HF\u201d in the figure) when targeting six sites with canonical NNGRRT PAM. Read counts listed on the right represent the number of GUIDE-Seq reads. On- target site is indicated with \u201c*\u201d\u2019. Mismatched bases in off-target sites with the on-target site are highlighted.\n\nFIG. 2B is a bar graph showing the percentage of edited reads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches from 1 to 7) among total edited reads by VVT SaCas9 and SaCas9 modified proteins R245A, N413A, N419A and R654A at VEGFA_8.\n\nFIG. 2C is a bar graph showing the percentage of edited reads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches from 1 to 7) among total edited reads by VVT SaCas9 and SaCas9 modified proteins R245A, N413A, N419A and R654A at EMX1_1.\n\nFIG. 5C is a venn diagram comparing the number of off-target sites between a modified protein comprising muta- tions at E782, N968 and R1015 positions (indicated as \u201cKKH\u201d in the figure) and a modified protein with mutations at E782, N968, R1015, R245, N413, N419 and R654 posi- tions comprising an amino acid sequence as defined in SEQ ID NO: 4 (KKH-SaCas9-HF, indicated as \u201cKKH-HF\u201d in the figure) when targeting five sites including EMX1_1, EMX1_4, EMX1_10, FANCF_9 and FANCF_16 with non- canonical NNNRRT PAM.\n\nFIG. 2D shows genome-wide cleavage sites detected by GUIDE-Seq on EMX1_6, VEGFA_8 and EMX1_1. Read counts listed on the right represent the number of GUIDE- Seq reads; on-target site is indicated by \u201c*\u201d and mismatched bases in off-target sites with the on-target site are high- lighted.\n\nindels\n\non\n\ntion\n\n15\n\n20\n\n25\n\n40\n\n45\n\n50\n\n35\n\n60\n\n65\n\nby\n\nis\n\nby\n\nby\n\n8\n\nby\n\nby\n\nUS 10,975,364 B2\n\n5\n\n6\n\nFIG . 5D shows GUIDE - Seq detected cleavage sites by a\n\nPAM ) may be inversely correlated with the proportion of\n\nmodified protein comprising mutations at E782 , N968 and\n\nSaCas9 in an activated state and that wild - type SaCas9\n\nR1015 positions ( indicated as \u201c KKH \u201d in the figure ) and a\n\namino acid residues in proximity of the guide RNA - target\n\nmodified protein with mutations at E782 , N968 , R1015 ,\n\nDNA heteroduplex could lower the threshold for activating\n\nR245 , N413 , N419 and R654 positions comprising an amino 5 the Cas9 nuclease domain , thus resulting in potentially more\n\nacid sequence as defined in SEQ ID NO : 4 ( KKH - SaCas9-\n\nbinding at off - target sites .\n\nHF , indicated as \u201c KKH - HF \u201d in the figure ) when targeting six\n\nThe modified protein as described herein advantageously\n\nsites with non - canonical NNNRRT PAM . Read counts listed\n\nprovides an improved Cas9 protein with reduced nuclease\n\non the right represent the number of GUIDE - Seq reads .\n\nactivity at one or more sites on a target DNA molecule ,\n\nOn - target site is indicated with \u201c * \u201d . Mismatched bases in 10 specifically at one or more off - target sites on a target DNA\n\noff - target sites with the on - target site are highlighted .\n\nmolecule , such that off - target activities and undesired off\n\ntarget mutations on the target DNA molecule are reduced .\n\nThe term \" off - target sites \u201d as used herein refers to non\n\nDETAILED DESCRIPTION OF THE\n\nspecific binding of the modified protein at locations other\n\nEMBODIMENTS\n\n15 than the predetermined target sequence . The term \u201c on - target\n\nUnless otherwise defined , all technical terms used herein\n\nsites \u201d used herein refers to binding of the modified protein\n\nhave the same meaning as commonly understood by one\n\nat the predetermined target sequence . On - target and off\n\ntarget site binding may be compared at various target sites ,\n\nskilled in the art to which the invention belongs .\n\nAs used herein , \u201c comprising \u201d means including the fol-\n\nfor example human endogenous sites . The target sites\n\nlowing elements but not excluding others . \u201c Essentially con- 20 include , but are not limited to , EMX1_6 , EMX1_1 ,\n\nsisting of means that the material consists of the respective\n\nEMX1_4 , EMX1_10 , VEGFA_8 , FANCF_13 , FANCF_10 ,\n\nelement along with usually and unavoidable impurities such\n\nFANCF_9 , FANCF_16 , RUNX1_13 , and RUNX1_14 .\n\nas side products and components usually resulting from the\n\nThe present invention in the first aspect provides a modi\n\nrespective preparation or method for obtaining the material\n\nfied Cas9 protein with a mutation at an N413 position , i.e.\n\nsuch as traces of further components or solvents . \u201c Consist- 25 a mutation of the amino acid at N413 , and optionally one or\n\ning of \u201d means that the material solely consists of , i.e. is\n\nmore of a nuclear localization sequence , a cell penetrating\n\nformed by the respective element . As used herein , the forms\n\npeptide sequence , an affinity tag and / or a fusion base editor\n\n\u201c a , \u201d \u201c an , \u201d and \u201c the , \u201d are intended to include the singular and\n\nprotein . Preferably , the modified protein is a Streptococcus\n\nplural forms unless the context clearly indicates otherwise .\n\naureus Cas9 protein . A mutation of an amino acid alters the\n\nThe present invention relates to a modified protein and its 30 amino acid to an amino acid other than the wild - type amino\n\nuse in altering the genome of a cell . Particularly , the inven-\n\nacid . Alternatively , a mutation may be resulted from a\n\ntion relates to a modified Streptococcus aureus Cas9 ( Sa\n\ndeletion of an amino acid residue in the amino acid sequence\n\nCas9 ) protein and its use in genomic engineering , genome\n\nor an addition of one or more amino acid residues into the\n\ntargeting and genome editing technologies . For example ,\n\namino acid sequence , thereby altering the binding activity\n\none of the applications of the modified proteins is as 35 between the amino acid sequence and the target sequence . In\n\nRNA - guided clustered , regularly interspaced , short palin-\n\nan example embodiment , the mutation is a single amino acid\n\ndromic repeats ( CRISPR ) -Cas9 proteins , for example a\n\nsubstitution whereby the wild - type amino acid is changed to\n\nSaCas9 modified protein . A limitation of CRISPR - SaCas9\n\nany amino acid other than the wild - type amino acid . In a\n\nproteins that restricts broad application are their activities on\n\npreferred embodiment , the mutation changes the wild - type\n\noff - target sites with the potential to induce undesired off- 40 amino acid to alanine .\n\ntarget mutations and disrupt the functionality of otherwise\n\nIn an example embodiment , the modified Cas9 protein\n\nnormal genes .\n\nincludes an amino acid sequence as defined in SEQ ID NO :\n\nThe provision of the modified SaCas9 protein of the\n\n1 or a homologue thereof wherein the modified protein\n\npresent invention and a guide RNA ( GRNA ) establishes a\n\ncomprising the amino acid sequence includes a mutation at\n\ngene - editing system in a cell . CRISPR - SaCas9 proteins , 45 an N413 position . In a preferred embodiment , the modified\n\nguided by the gRNA , bind and cleave a predetermined target\n\nprotein comprising or consisting of the amino acid sequence\n\nsequence of a target gene at a specific location , i.e. an\n\nincludes an alanine at the N413 position .\n\non - target site , on a target DNA molecule , thereby resulting\n\nIn another example embodiment , the modified protein\n\nin a double stranded chromosomal break at the on - target site\n\nincludes an amino acid sequence as defined in SEQ ID NO :\n\nthat leads to site - specific modifications by the cell . The 50 2 or a homologue thereof wherein the modified protein\n\n\" target gene \u201d as used herein refers to a gene of interest . The\n\ncomprising or consisting of the amino acid sequence\n\nCas9 protein recognizes a short DNA sequence , the proto-\n\nincludes three E782K , N968K , R1015H substitutions and a\n\nspacer adjustment motif ( PAM ) , found downstream of the\n\nmutation at an N413 position . In a preferred embodiment ,\n\ntarget sequence , usually three to four nucleotides down-\n\nthe modified protein comprising or consisting of the amino\n\nstream from the cut site . The PAM sequence is an essential 55 acid sequence includes an alanine at the N413 position .\n\ncomponent of the CRISPR - Cas9 system and the Cas9 pro-\n\nIn some embodiments , the modified protein includes one ,\n\ntein will not bind to or cleave the target DNA sequence\n\ntwo , or three mutations at the R245 , N419 or R654 positions\n\nwithout the downstream PAM sequence . The SaCas9 pro-\n\nin addition to a mutation at the N413 position . For example ,\n\ntein , for example , recognizes the canonical PAM sequence\n\nthe modified protein may include one or more mutations at\n\nNNGRRT or the non - canonical PAM sequence NNNRRT .\n\n60 R245 and / or N419 and a further mutation at R654 . In a\n\nNon - specific binding at locations other than the target\n\npreferred embodiment , the modified protein comprises an\n\nsequence , i.e. at off - target sites , of the CRISPR - Cas9 has\n\namino acid sequence as defined in SEQ ID NO : 3 or a\n\nbeen known to occur , thus resulting in cleaving of off - target\n\nhomologue thereof and includes a mutation at N413 , N419 ,\n\nsequences and causing non - specific genetic modifications .\n\nR245 and R654 positions , also referred to as SaCas9 - HF . In\n\nThe inventors have found that the number of mismatched 65 an embodiment , the mutation at one or more of the N413 ,\n\nbases in the guide RNA - target DNA heteroduplex at a\n\nN419 , R245 and / or R654 positions is a single amino acid\n\nPAM - distal region ( for example , positions 10 to 20 from the\n\nsubstitution . In a preferred embodiment , the modified pro\n\nUS 10,975,364 B2\n\n5\n\n6\n\nPAM) may be inversely correlated with the proportion of SaCas9 in an activated state and that wild-type SaCas9 amino acid residues in proximity of the guide RNA-target DNA heteroduplex could lower the threshold for activating the Cas9 nuclease domain, thus resulting in potentially more binding at off-target sites.\n\nFIG. 5D shows GUIDE-Seq detected cleavage sites by a modified protein comprising mutations at E782, N968 and R1015 positions (indicated as \u201cKKH\u201d in the figure) and a modified protein with mutations at E782, N968, R1015, R245, N413, N419 and R654 positions comprising an amino acid sequence as defined in SEQ ID NO: 4 (KKH-SaCas9- HF, indicated as \u201cKKH-HF\u201d in the figure) when targeting six sites with non-canonical NNNRRT PAM. Read counts listed on the right represent the number of GUIDE-Seq reads. On-target site is indicated with \u201c*\u201d. Mismatched bases in off-target sites with the site are highlighted.\n\nprovides an improved Cas9 protein with reduced nuclease activity at one or more sites on a target DNA molecule, specifically at one or more off-target sites on a target DNA molecule, such that off-target activities and undesired off- target mutations on the target DNA molecule are reduced. The term \u201coff-target sites\u201d as used herein refers to non- specific binding of the modified protein at locations other than the predetermined target sequence. The term \u201con-target sites\u201d used herein refers to binding of the modified protein at the predetermined target sequence. On-target and off- target site binding may be compared at various target sites, for example human endogenous sites. The target sites include, but are not limited to, EMX1_6, EMX1_1, EMX1_4, EMX1_10, VEGFA_8, FANCF_13, FANCF_10,\n\nDETAILED DESCRIPTION OF THE\n\nEMBODIMENTS\n\nUnless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one skilled in the art to which the invention belongs.\n\nAs used herein, \u201ccomprising\u201d means including the fol- lowing elements but not excluding others. \u201cEssentially con- sisting of\u2019 means that the material consists of the respective element along with usually and unavoidable impurities such as side products and components usually resulting from the respective preparation or method for obtaining the material such as traces of further components or solvents. \u201cConsist- ing of\u2019 means that the material solely consists of, i.e. is formed by the respective element. As used herein, the forms \u201ca,\u201d \u201can,\u201d and \u201cthe,\u201d are intended to include the singular and plural forms unless the context clearly indicates otherwise.\n\nfied Cas9 protein with a mutation at an N413 position, i.e. a mutation of the amino acid at N413, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein. Preferably, the modified protein is a Streptococcus aureus Cas9 protein. A mutation of an amino acid alters the amino acid to an amino acid other than the wild-type amino acid. Alternatively, a mutation may be resulted from a deletion of an amino acid residue in the amino acid sequence or an addition of one or more amino acid residues into the amino acid sequence, thereby altering the binding activity between the amino acid sequence and the target sequence. In an example embodiment, the mutation is a single amino acid. substitution whereby the wild-type amino acid is changed to any amino acid other than the wild-type amino acid. In a preferred embodiment, the mutation changes the wild-type\n\npresent to a protein use in altering the genome of a cell. Particularly, the inven- tion relates to a modified Streptococcus aureus Cas9 (Sa- Cas9) protein and its use in genomic engineering, genome targeting and genome editing technologies. For example, one of the applications of the modified proteins is as RNA-guided clustered, regularly interspaced, short palin- dromic repeats (CRISPR)-Cas9 proteins, for example a SaCas9 modified protein. A limitation of CRISPR-SaCas9 proteins that restricts broad application are their activities on off-target sites with the potential to induce undesired off- target mutations and disrupt the functionality of otherwise normal\n\nIn an example embodiment, the modified Cas9 protein includes an amino acid sequence as defined in SEQ ID NO: 1 or a homologue thereof wherein the modified protein comprising the amino acid sequence includes a mutation at an N413 position. In a preferred embodiment, the modified protein comprising or consisting of the amino acid sequence includes an alanine at the N413 position.\n\npresent invention and gene-editing system a guide RNA (gRNA) establishes a in a cell. CRISPR-SaCas9 proteins, guided by the gRNA, bind and cleave a predetermined target sequence of a target gene at a specific location, ie. an on-target site, on a target DNA molecule, thereby resulting in a double stranded chromosomal break at the on-target site that leads to site-specific modifications by the cell. The \u201ctarget gene\u201d as used herein refers to a gene of interest. The Cas9 protein recognizes a short DNA sequence, the proto- spacer adjustment motif (PAM), found downstream of the target sequence, usually three to four nucleotides down- stream from the cut site. The PAM sequence is an essential component of the CRISPR-Cas9 system and the Cas9 pro- tein will not bind to or cleave the target DNA sequence without the downstream PAM sequence. The SaCas9 pro- tein, for example, recognizes the canonical PAM sequence\n\nIn another example embodiment, the modified protein includes an amino acid sequence as defined in SEQ ID NO: 2 or a homologue thereof wherein the modified protein comprising or consisting of the amino acid sequence includes three E782K, N968K, R1015H substitutions and a mutation at an N413 position. In a preferred embodiment, the modified protein comprising or consisting of the amino acid sequence includes an alanine at the N413 position.\n\nIn some embodiments, the modified protein includes one, two, or three mutations at the R245, N419 or R654 positions in addition to a mutation at the N413 position. For example, the modified protein may include one or more mutations at R245 and/or N419 and a further mutation at R654. In a preferred embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 3 or a homologue thereof and includes a mutation at N413, N419, R245 and R654 positions, also referred to as SaCas9-HF. In an embodiment, the mutation at one or more of the N413, N419, R245 and/or R654 positions is a single amino acid substitution. In embodiment, the modified\n\nNon-specific binding at locations other than the target sequence, i.e. at off-target sites, of the CRISPR-Cas9 has been known to occur, thus resulting in cleaving of off-target sequences and causing non-specific genetic modifications. The inventors have found that the number of mismatched bases in the guide RNA-target DNA heteroduplex at a PAM-distal region (for example, positions 10 to 20 from the\n\non-target\n\nThe\n\ninvention relates\n\nmodified\n\nand its\n\ngenes. The provision of the modified SaCas9 protein of the\n\nNNGRRT or the non-canonical PAM sequence NNNRRT.\n\n10\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\n35\n\n60\n\n65\n\nThe modified protein as described herein advantageously\n\nFANCF_9, FANCF_16, RUNX1_13, and RUNX1_14. The present invention in the first aspect provides a modi-\n\namino acid to alanine.\n\na preferred\n\npro-\n\nUS 10,975,364 B2\n\n7\n\n8\n\ntein comprising or consisting of the amino acid sequence\n\ngenome of a cell or a subject . Accordingly , the present\n\nincludes an alanine at the N413 , N419 , R245 and / or R654\n\ninvention also pertains to a kit comprising the modified\n\npositions .\n\nprotein as described above .\n\nIn an embodiment , the modified protein includes one ,\n\nIn an embodiment , the kit includes a modified Cas9\n\ntwo , or all three of the following mutations at the R245 ,\n\n5 protein with a mutation at an N413 position , and optionally\n\nN419 or R654 positions and three E782K , N968K and\n\none or more of a nuclear localization sequence ,\n\ncell\n\nR1015H mutations and a mutation at an N413 position . In a\n\npenetrating peptide sequence , an affinity tag and / or a fusion\n\nparticular embodiment , the modified protein comprises an\n\nbase editor protein . In one embodiment , the modified protein\n\namino acid sequence as defined in SEQ ID NO : 4 of a\n\nincludes an amino acid sequence as defined in SEQ ID NO :\n\nhomologue thereof wherein the modified protein includes 10 1 or a homologue thereof wherein the modified protein\n\nmutations at the N413 , N419 , R245 and R654 positions and\n\ncomprising the amino acid sequence includes a mutation at\n\nthree E782K , N968K , R1015H mutations , also referred to as\n\nan N413 position .\n\nKKH - SaCas9 - HF . In an embodiment , the mutation at one or\n\nIn a further embodiment , the modified protein with a\n\nmore of the N413 , N419 , R245 and / or R654 positions is a\n\nsingle amino acid substitution . Preferably , the modified 15 mutation at an N413 position further includes one or more\n\nmutations at the R245 , N419 or R654 positions . In a\n\nprotein comprising or consisting of the amino acid sequence\n\nparticular embodiment , the modified protein comprises an\n\nincludes an alanine at the N413 , N419 , R245 and / or R654\n\namino acid sequence as defined in SEQ ID NO : 3 or a\n\npositions .\n\nThe term \u201c homologue \u201d used herein refers to amino acids\n\nhomologue thereof that includes a mutation at N413 , N419 ,\n\nhaving a sequence identity of at least 50 % , at least 60 % , at 20 R245 and R654 positions . In a preferred embodiment , the\n\nleast 70 % , at least 80 % , at least 90 % or at least 95 % to the\n\nmutation is a single amino acid substitution . In another\n\nmodified protein according to the present invention . In an\n\npreferred embodiment , the modified protein includes an\n\nembodiment , the homologue of the modified protein has at\n\nalanine at the N413 position , and / or optionally at the N419 ,\n\nleast 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or\n\nR245 and R654 positions .\n\n99 % overall sequence identity to the modified protein . In a 25\n\nIn some embodiments , the modified protein with a muta\n\nparticular embodiment , the modified protein consists of a\n\ntion at an N413 position further includes three E782K ,\n\nsequence of SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 3 ,\n\nN968K and R1015H mutations . In a particular embodiment ,\n\nthe modified protein includes an amino acid sequence as\n\nSEQ ID NO : 4 or a homologue thereof .\n\nThe term ' cell penetrating peptides ' used herein refers to\n\ndefined in SEQ ID NO : 2 or a homologue thereof .\n\npeptides that facilitate the movement of a wide range of 30\n\nIn an embodiment , the modified protein comprising a\n\nbiomolecules across the cell membrane into the cytoplasm\n\nmutation at an N413 position and three mutations E782K ,\n\nor an organelle . Examples of biomolecules that cell pen-\n\nN968K and R1015H further includes one or more mutations\n\nat the\n\n15 , N419 and / or R654 positions . In a particular\n\netrating peptides can deliver include , but are no limited to ,\n\nplasmid DNA , oligonucleotides , nanoparticles , peptide-\n\nembodiment , the modified protein comprises an amino acid\n\nnucleic acid ( PNA ) , siRNA , proteins , peptides and / or lipo- 35 sequence as defined in SEQ ID NO : 4 or a homologue\n\nsomes . Examples of cell penetrating peptides commonly\n\nthereof that includes a mutation at N413 , N419 , R245 and\n\nused in the art include trans - activating transcriptional acti-\n\nR654 positions and three mutations E782K , N968K and\n\nvator ( TAT ) , penetratin , etc. The modified protein of the\n\nR1015H . In a preferred embodiment , the mutation at the\n\npresent invention can include a cell penetrating peptide\n\nN413 , N419 , R245 and / or R654 positions is a single amino\n\n40 acid substitution . In another preferred embodiment , the\n\nsequence .\n\nThe term \u201c nuclear localization sequence ' used herein\n\nmodified protein includes an alanine at the N413 position ,\n\nrefers to amino acid sequence that facilitates the transport of\n\nand / or optionally at the N419 , R245 and R654 positions .\n\nproteins into the nucleus of a cell . Examples known in the\n\nPreferably , the kit further comprises ORNA that guides the\n\nart include SV40 large T antigen NLS and nucleoplasmin\n\nmodified Cas9 protein of the invention to cut a target gene\n\nNLS . The modified protein of the present invention can 45 at a specific location on a target DNA molecule of a cell . The\n\ninclude , alternatively or in addition to the cell penetrating\n\ngRNA may be ligated into a vector , such as a commercially\n\navailable vector or a vector prepared and synthesized in a\n\npeptide sequence , a nuclear localization sequence .\n\nThe term \u201c affinity tag ' as used herein facilitates the\n\nlaboratory . A person skilled in the art would appreciate the\n\npurification of recombinant modified proteins , for example\n\nappropriate vector for carrying the gRNA molecule of the\n\nGST , FLAG or hexahistidine sequences . The term ' fusion 50 invention , and the conditions for inserting the gRNA mol\n\nbase editor protein ' as used herein refers to proteins that\n\necule into the vector . The presence of the gRNA and the\n\nmodified Cas9 protein provides suitable conditions for alter\n\nenable the direct conversion or editing of bases .\n\nIn a preferred embodiment , the modified protein with a\n\ning the target gene in that particular cell .\n\nmutation at the N413 position and at least one additional\n\nPreferably , the kit further comprises an inducible pro\n\nmutation at the R245 , N419 and / or R654 positions decrease 55 moter . The term \u201c inducible promoter \u201d as used herein refers\n\nnuclease activity at one or more sites on a target DNA to a chemical or molecule that can control gene expression\n\nmolecule . In a preferred embodiment , the sites are off - target\n\nof a particular gene , in particular inducing a target gene to\n\nsites . Preferably , the mutation changes the wild - type amino\n\nexpress in a system . The inducible promoter may include a\n\ntetracycline including tetracycline - type antibiotic or its\n\nacid to alanine .\n\nThe modified SaCas9 protein of the present invention is 60 derivative which is capable of inducing the expression of a\n\nderived from an isolated SaCas9 protein . The isolated\n\ntarget gene .\n\nSaCas9 protein may be commercially available or artificially\n\nIt would be appreciated that the kit may further comprise\n\nsynthesized . The isolated SaCas9 protein is then subject to\n\nother suitable excipients such as buffers or reagents for\n\namino acid modification particularly at the N413 position ,\n\nfacilitating the application of the kit . Preferably , the kit may\n\nunder suitable conditions , to produce the modified SaCas9 65 be applied in various applications such as medical applica\n\nprotein as described above . The modified SaCas9 protein\n\ntions including therapies and diagnosis , researches and the\n\nmay be provided in a kit which is suitable for altering the\n\nlike . Accordingly , the modified SaCas9 protein and the kit of\n\nUS 10,975,364 B2\n\n8\n\n7\n\ncomprising or consisting of the amino acid sequence includes an alanine at the N413, N419, R245 and/or R654 positions.\n\ngenome of a cell or a subject. Accordingly, the present invention also pertains to a kit comprising the modified protein as described above.\n\nIn an embodiment, the modified protein includes one, two, or all three of the following mutations at the R245, N419 or R654 positions and three E782K,N968K and R1015H mutations and a mutation at an N413 position. In a particular embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 4 of a homologue thereof wherein the modified protein includes mutations at the N413, N419, R245 and R654 positions and three E782K,N968K,R1015H mutations, also referred to as KKH-SaCas9-HF. In an embodiment, the mutation at one or more of the N413, N419, R245 and/or R654 positions is a single amino acid substitution. Preferably, the modified protein comprising or consisting of the amino acid sequence includes an alanine at the N413, N419, R245 and/or R654 positions.\n\nIn an embodiment, the kit includes a modified Cas9 protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein. In one embodiment, the modified protein includes an amino acid sequence as defined in SEQ ID NO: 1 or a homologue thereof wherein the modified protein comprising the amino acid sequence includes a mutation at an N413 position.\n\nIn a further embodiment, the modified protein with a mutation at an N413 position further includes one or more mutations at the R245, N419 or R654 positions. In a particular embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 3 or a homologue thereof that includes a mutation at N413, N419, R245 and R654 positions. In a preferred embodiment, the mutation is a single amino acid substitution. In another preferred embodiment, the modified protein includes an alanine at the N413 position, and/or optionally at the N419, R245 and R654 positions.\n\nThe term \u201chomologue\u201d used herein refers to amino acids having a sequence identity of at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% to the modified protein according to the present invention. In an embodiment, the homologue of the modified protein has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% overall sequence identity to the modified protein. In a particular embodiment, the modified protein consists of a sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a homologue thereof.\n\nIn some embodiments, the modified protein with a muta- tion at an N413 position further includes three E782K, N968K and R1015H mutations. In a particular embodiment, the modified protein includes an amino acid sequence as defined in SEQ ID NO: 2 or a homologue thereof.\n\nThe term \u2018cell penetrating peptides\u2019 used herein refers to peptides that facilitate the movement of a wide range of biomolecules across the cell membrane into the cytoplasm or an organelle. Examples of biomolecules that cell pen- etrating peptides can deliver include, but are not limited to, plasmid DNA, oligonucleotides, nanoparticles, peptide- nucleic acid (PNA), siRNA, proteins, peptides and/or lipo- somes. Examples of cell penetrating peptides commonly used in the art include trans-activating transcriptional acti- vator (TAT), penetratin, etc. The modified protein of the present invention can include a cell penetrating peptide sequence.\n\nIn an embodiment, the modified protein comprising a mutation at an N413 position and three mutations E782K, N968K and R1015H further includes one or more mutations at the R245, N419 and/or R654 positions. In a particular embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 4 or a homologue thereof that includes a mutation at N413, N419, R245 and R654 positions and three mutations E782K, N968K and. R1015H. In a preferred embodiment, the mutation at the N413, N419, R245 and/or R654 positions is a single amino acid substitution. In another preferred embodiment, the modified protein includes an alanine at the N413 position, and/or optionally at the N419, R245 and R654 positions.\n\nThe term \u2018nuclear localization sequence\u2019 used herein refers to amino acid sequence that facilitates the transport of proteins into the nucleus of a cell. Examples known in the art include SV40 large T antigen NLS and nucleoplasmin NLS. The modified protein of the present invention can include, alternatively or in addition to the cell penetrating peptide sequence, a nuclear localization sequence.\n\nPreferably, the kit further comprises gRNA that guides the modified Cas9 protein of the invention to cut a target gene at a specific location on a target DNA molecule of a cell. The gRNA may be ligated into a vector, such as a commercially available vector or a vector prepared and synthesized in a laboratory. A person skilled in the art would appreciate the appropriate vector for carrying the gRNA molecule of the invention, and the conditions for inserting the gRNA mol- ecule into the vector. The presence of the gRNA and the modified Cas9 protein provides suitable conditions for alter- ing the target gene in that particular cell.\n\nThe term \u2018affinity tag\u2019 as used herein facilitates the purification of recombinant modified proteins, for example GST, FLAG or hexahistidine sequences. The term \u2018fusion base editor protein\u2019 as used herein refers to proteins that enable the direct conversion or editing of bases.\n\nIn a preferred embodiment, the modified protein with a mutation at the N413 position and at least one additional mutation at the R245, N419 and/or R654 positions decrease nuclease activity at one or more sites on a target DNA molecule. In a preferred embodiment, the sites are off-target sites. Preferably, the mutation changes the wild-type amino acid to alanine.\n\nThe modified SaCas9 protein of the present invention is derived from an isolated SaCas9 protein. The isolated SaCas9 protein may be commercially available or artificially synthesized. The isolated SaCas9 protein is then subject to amino acid modification particularly at the N413 position, under suitable conditions, to produce the modified SaCas9 protein as described above. The modified SaCas9 protein may be provided in a kit which is suitable for altering the\n\nt would be appreciated that the kit may further comprise other suitable excipients such as buffers or reagents for facilitating the application of the kit. Preferably, the kit may be applied in various applications such as medical applica- tions including therapies and diagnosis, researches and the like. Accordingly, the modified SaCas9 protein and the kit of\n\ntein\n\n25\n\n35\n\n40\n\n45\n\n60\n\n65\n\nreferably, the kit further comprises an inducible pro- moter. The term \u201cinducible promoter\u201d as used herein refers to a chemical or molecule that can control gene expression of a particular gene, in particular inducing a target gene to express in a system. The inducible promoter may include a tetracycline including tetracycline-type antibiotic or its derivative which is capable of inducing the expression of a\n\ntarget gene.\n\nUS 10,975,364 B2\n\n10\n\n9\n\nthe present invention may be used in the preparation of a\n\noptionally one or more of a nuclear localization sequence , a\n\nmedicament for treatment and / or in the preparation of an\n\ncell penetrating peptide sequence , an affinity tag and / or a\n\nagent for research study .\n\nfusion base editor protein . The inventors unexpectedly\n\nThe present invention further pertains to a CRIPSR sys-\n\nfound that modification of the amino acid residues at the\n\ntem comprising a modified SaCas9 protein as described 5 N413 position and optionally one or more mutations at the\n\nabove or a gene encoding said SaCas9 protein , a gRNA as\n\nR245 , N419 and / or R654 positions decreased nuclease\n\ndescribed above , and optionally an inducible promoter . In an\n\nactivity at one or more off - target sites on a target DNA\n\nembodiment , the gene encoding the modified SaCas9 pro-\n\nmolecule , such that non - specific binding and off - target\n\ntein may be provided in a recombinant vector .\n\ncleavages were reduced without compromising on - target\n\nThe term \u201c recombinant vector \u201d as used herein refers to a 10 binding . The modified SaCas9 protein of the invention has\n\nvector such as a plasmid that contains a foreign nucleic acid\n\nadvantageously enhanced targeting specificity and thus\n\nintroduced therein . The recombinant vector is then inserted\n\nbroader application .\n\ninto a cell for example through infection . The transcription\n\nThe invention is now described in the following non\n\nof the recombinant vector allows the transcription of the\n\nlimiting examples .\n\nforeign nucleic acid and thus may result in expression of the 15\n\nforeign nucleic acid . A person skilled in the art would\n\nEXAMPLES\n\nappreciate suitable methods for introducing the recombinant\n\nThe mutant proteins were generated by the site - specific\n\nvector into a cell for infection .\n\nIn a further aspect , the invention provides a method for\n\nmutagenesis approach using overlapping PCR primers that\n\naltering the genome of a cell , the method including the step 20 contain desired mutant bases to amplify the wild - type pro\n\nof using a modified SaCas9 protein of the invention with a\n\ntein encoding DNA sequence , and cloned into expression\n\nmutation at an N413 position , and optionally one or more of\n\nvector . To compare the effect of wild - type and mutant\n\na nuclear localization sequence , a cell penetrating peptide\n\nproteins in nuclease activity , the GUIDE - seq ( genome - wide\n\nsequence , an affinity tag and / or a fusion base editor protein .\n\nunbiased identification of double - stranded breaks enabled\n\nThe method of altering the genome of the cell may include , 25 by sequencing ) was used . Briefly , double - stranded oligo\n\nfor example , contacting the cell with , or expressing in the\n\ndeoxyribonucleotides ( dsODNs ) were co - delivered with\n\ncell , the modified SaCas9 protein as described above , and a\n\nCas9 and target guide ( sgRNA ) -expressing plasmid ( s ) into\n\ngRNA having a region complementary to a selected portion\n\ntarget cells . Following the Cas9 gene editing that introduced\n\nof the genome of the cell with optimal nucleotide spacing at\n\ndouble strand breaks in on- and off - targets of the genome ,\n\nthe genomic target site .\n\n30 the dsODNs were randomly integrated into the breaks\n\nIn one embodiment , the modified protein includes an\n\n( DSBs ) . DNA was extracted from the cells , and sequencing\n\namino acid sequence as defined in SEQ ID NO :\n\n1 or a\n\nlibraries were prepared by enriching the dsODNs and their\n\nhomologue thereof wherein the modified protein comprising\n\nflanking sequences and used for next - generation sequencing .\n\nthe amino acid sequence includes a mutation at an N413\n\nThe resulting number of reads is proportional to the DSB\n\nposition .\n\n35 events occurred during the experiment , and the read\n\nIn a further embodiment , the modified protein including a\n\nsequences were aligned to a reference genome to identify\n\nmutation at an N413 position further includes one or more\n\nDSBs introduced by Cas9 .\n\nmutations at the R245 , N419 or R654 positions . In a\n\nExample 1\n\nparticular embodiment , the modified protein comprises an\n\namino acid sequence as defined in SEQ ID NO : 3 or a 40\n\nhomologue thereof that includes a mutation at N413 , N419 ,\n\nStructure - Guided Protein Engineering for\n\nHigh - Fidelity SaCas9\n\nR245 and R654 positions . In a preferred embodiment , the\n\nmutation is a single amino acid substitution . In a most\n\npreferred embodiment , the modified protein includes an\n\nWith reference to FIG . 1A , the inventors identified , by\n\nalanine at the N413 position , and / or optionally at the N419 , 45 generating crystal structure data of the SaCas9 / sgRNA\n\nR245 and R654 positions .\n\ntarget - DNA complex , four amino acid residues , specifically\n\nIn some embodiments , the modified protein includes an\n\nR245 , N413 , N419 , and R654 form polar contacts within 3.0\n\namino acid sequence as defined in SEQ ID NO : 2 or a\n\n\u00c5 distance from the DNA target ( as illustrated in FIG . 1B ) .\n\nhomologue thereof wherein the modified protein comprising\n\nAs shown in FIG . 1C , three of these amino acid residues ,\n\nthe amino acid sequence includes three E782K , N968K , 50 specifically R245 , N413 and N419 , are located in the\n\nR1015H mutations and a mutation at an N413 position .\n\nrecognition lobe and one amino acid residue , R654 , is\n\nIn an embodiment , the modified protein comprising muta-\n\nlocated in the RuvC - III domain .\n\ntions at E782 , N968 , R1015 and N413 positions further\n\nThe inventors first constructed four modified SaCas9\n\nincludes one or more mutations at the R245 , N419 and / or\n\nproteins wherein the modified proteins were single amino\n\nR654 positions . In a particular embodiment , the modified 55 acid substitution mutants whereby the wild - type amino acid\n\nprotein comprises an amino acid sequence as defined in SEQ\n\nwas substituted with alanine . The single amino acid substi\n\nID NO : 4 or a homologue thereof that includes a mutation\n\ntution mutations were in the R245 , N413 , N419 , and R654\n\nat N413 , N419 , R245 , R654 , E782 , N968 and R1015 posi-\n\npositions and the mutants were R245A , N413A , N419A , and\n\ntions . In a preferred embodiment , the mutation is a single\n\nR654A , respectively . It was tested whether these mutants\n\namino acid substitution . In a most preferred embodiment , 60 showed comparable on - target activities compared to the\n\nthe modified protein includes an alanine at the N413 posi-\n\nwild - type ( WT ) SaCas9 using targeted deep sequencing on\n\ntion , and / or optionally at the N419 , R245 and R654 posi-\n\nthree human endogenous sites , EMX1 site 6 ( EMX1_6 ) ,\n\nVEGFA site 8 ( VEGFA_8 ) , and EMX1 site 1 ( EMX1_1 )\n\ntions .\n\nAccordingly , the invention provides a novel and effective\n\n( FIG . 1d ) .\n\napproach for altering the genome of a cell , for example by 65\n\nThe three target sites were selected to assess both of\n\ncontacting a cell with , or expressing in the cell , a modified\n\ncanonical NNGRRT PAM ( EMX_6 and VEGFA_8 were\n\nSaCas9 protein with a mutation at an N413 position , and\n\nboth edited at high efficiencies ) and a non - canonical\n\nUS 10,975,364 B2\n\n10\n\n9\n\npresent invention may be used in the preparation of medicament for treatment and/or in the preparation of for research study.\n\noptionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an aflinity tag and/or a fusion base editor protein. The inventors unexpectedly found that modification of the amino acid residues at the N413 position and optionally one or more mutations at the R245, N419 and/or R654 positions decreased nuclease activity at one or more off-target sites on a target DNA molecule, such that non-specific binding and off-target cleavages were reduced without compromising on-target binding. The modified SaCas9 protein of the invention has advantageously enhanced targeting specificity and thus\n\nThe present invention further pertains to a CRIPSR sys- tem comprising a modified SaCas9 protein as described above or a gene encoding said SaCas9 protein, a gRNA as described above, and optionally an inducible promoter. In an embodiment, the gene encoding the modified SaCas9 pro- tein may be provided in a recombinant vector.\n\nThe term \u201crecombinant vector\u201d as used herein refers to a vector such as a plasmid that contains a foreign nucleic acid introduced therein. The recombinant vector is then inserted into a cell for example through infection. The transcription of the recombinant vector allows the transcription of the foreign nucleic acid and thus may result in expression of the foreign nucleic acid. A person skilled in the art would appreciate suitable methods for introducing the recombinant vector into a cell for infection.\n\nThe invention is now described in the following non- limiting examples.\n\nEXAMPLES\n\nby mutagenesis approach using overlapping PCR primers that contain desired mutant bases to amplify the wild-type pro- tein encoding DNA sequence, and cloned into expression vector. To compare the effect of wild-type and mutant proteins in nuclease activity, the GUIDE-seq (genome-wide unbiased identification of double-stranded breaks enabled by sequencing) was used. Briefly, double-stranded oligo deoxyribonucleotides (dsODNs) were co-delivered with Cas9 and target guide (sgRNA)-expressing plasmid(s) into target cells. Following the Cas9 gene editing that introduced double strand breaks in on- and off-targets of the genome, the dsODNs were randomly integrated into the breaks (DSBs). DNA was extracted from the cells, and sequencing libraries were prepared by enriching the dsODNs and their flanking sequences and used for next-generation sequencing. The resulting number of reads is proportional to the DSB events occurred during the experiment, and the read sequences were aligned to a reference genome to identify\n\nIn a further aspect, the invention provides a method for altering the genome of a cell, the method including the step of using a modified SaCas9 protein of the invention with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein. The method of altering the genome of the cell may include, for example, contacting the cell with, or expressing in the cell, the modified SaCas9 protein as described above, and a gRNA having a region complementary to a selected portion of the genome of the cell with optimal nucleotide spacing at the genomic target site.\n\nIn one embodiment, the modified protein includes amino acid sequence as defined in SEQ ID NO: 1 or homologue thereof wherein the modified protein comprising amino acid sequence includes a mutation at an N413 position.\n\nIna further embodiment, the modified protein including a mutation at an N413 position further includes one or more mutations at the R245, N419 or R654 positions. In a particular embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 3 or a homologue thereof that includes a mutation at N413, N419, R245 and R654 positions. In a preferred embodiment, the mutation is a single amino acid substitution. In a most preferred embodiment, the modified protein includes an alanine at the N413 position, and/or optionally at the N419, R245 and R654\n\nExample 1\n\nStructure-Guided Protein Engineering for High-Fidelity SaCas9\n\nWith reference to FIG. 1A, the inventors identified, by generating crystal structure data of the SaCas9/sgRNA- target-DNA complex, four amino acid residues, specifically R245,N413, N419, and R654 form polar contacts within 3.0 A distance from the DNA target (as illustrated in FIG. 1B). As shown in FIG. 1C, three of these amino acid residues, specifically R245, N413 and N419, are located in the recognition lobe and one amino acid residue, R654, is located in the RuvC-II domain.\n\nIn some embodiments, the modified protein includes an amino acid sequence as defined in SEQ ID NO: 2 or homologue thereof wherein the modified protein comprising amino acid sequence includes three E782K, N968K, R1015H mutations and a mutation at an N413 position.\n\nIn an embodiment, the modified protein comprising muta- tions at E782, N968, R1015 and N413 positions further includes one or more mutations at the R245, N419 and/or R654 positions. In a particular embodiment, the modified protein comprises an amino acid sequence as defined in SEQ D NO: 4 or a homologue thereof that includes a mutation at N413, N419, R245, R654, E782, N968 and R1015 posi- tions. In a preferred embodiment, the mutation is a single amino acid substitution. In a most preferred embodiment, the modified protein includes an alanine at the N413 posi- tion, and/or optionally at the N419, R245 and R654 posi- tions.\n\nThe inventors first constructed four modified SaCas9 proteins wherein the modified proteins were single amino acid substitution mutants whereby the wild-type amino acid. was substituted with alanine. The single amino acid substi- tution mutations were in the R245, N413, N419, and R654 positions and the mutants were R245A, N413A, N419A, and R654A, respectively. It was tested whether these mutants showed comparable on-target activities compared to the wild-type (WT) SaCas9 using targeted deep sequencing on three human endogenous sites, EMX1 site 6 (EMX1_6), VEGFA site 8 (VEGFA_8), and EMX1 site 1 (EMX1_1) 1a).\n\nAccordingly, the invention provides a novel and effective approach for altering the genome of a cell, for example by contacting a cell with, or expressing in the cell, a modified SaCas9 protein with a mutation at an N413 position, and\n\nThe three target sites were selected to assess both canonical NNGRRT PAM (EMX_6 and VEGFA_8 were edited at high efficiencies) and a non-canonical\n\nthe\n\na\n\nan\n\nagent\n\nan\n\na\n\nthe\n\npositions.\n\na\n\nthe\n\n25\n\n30\n\n35\n\n40\n\n45\n\n60\n\n65\n\nbroader application.\n\nThe mutant proteins were generated\n\nthe site-specific\n\nDSBs introduced by Cas9.\n\n(FIG.\n\nof\n\nboth\n\nUS 10,975,364 B2\n\n12\n\n11\n\nNNARRT PAM ( EMX1_1 ) for which about 20 % the cleav-\n\nmodified protein was also evaluated in view of data showing\n\nage efficiency of canonical PAM in an EGFR disruption\n\nconsistently high on - target cleavage efficiency .\n\nassay was achieved but which has never been tested on a\n\nAs seen in FIG . 3B , FIG . 3C and FIG . 3F , among the six\n\nhuman endogenous target . These targets are also associated\n\ncanonical PAM sites , FANCF_13 showed nine off - target\n\nwith a substantial number of off - target sites in the human 5 sites by WT - SaCas9 and no detectable off - target sites by\n\ngenome and well suited for downstream evaluation of tar-\n\nSaCas9 - HF , illustrating the marked improved specificity of\n\ngeting specificity .\n\nSaCas9 - HF in comparison to WT - SaCas9 and improved\n\nUsing targeted deep sequencing , the inventors unexpect-\n\nspecificity over the R245A modified protein .\n\nedly found that all four single SaCas9 mutants ( i.e. R245A ,\n\nWith reference to FIG . 3F , SaCas9 - HF showed significant\n\nN413A , N419A , and R654A ) retained comparable on - target\n\n10\n\nreductions of off - target activity for EMX1_6 and the known\n\nactivities in comparison to WT SaCas9 , ranging from\n\npromiscuous site VEGFA_8 in comparison to WT - SaCas9\n\napproximately 20 % -60 % activity across the three human\n\nand the R245A mutant . Nearly no off - target activity by\n\nendogenous sites EMX1_6 , VEGFA_8 , EMX1_1 as shown WT - SaCas9 was detected for FANCF_10 , RUNX1_13 and\n\nin FIGS . 1D - 1F . At the non - canonical PAM NNARRT\n\nendogenous site EMX_1 , SaCas9 modified proteins is RUNX1_14 . Unexpectedly , SaCas9 - HF advantageously\n\nachieved about 8.6- , 3.2- and 0.74 - fold the GUIDE - Seq\n\nachieved 17-23 % indel editing outcome .\n\nreads of WT - SaCas9 , respectively , for the three sites . Fur\n\nThe inventors used an EGFP - disruption assay to evaluate\n\nther , SaCas9 - HF showed no cleavage at the sole off - target\n\nSaCas9 cleavage efficiency on expressed eGFP with full\n\nsite when targeting RUNX1_13 by WT - SaCas9 .\n\nmatch and tiling 2 - base mismatch guide sequences , as\n\nAs seen in FIG . 3G , for the five non - canonical PAM sites ,\n\nillustrated in FIG . 16. The R245A , N419A and R654A 20\n\nmutants possessed similar cleavage efficacy to the WT 1 to 4 off - target sites were detected for WT - SaCas9 and this\n\nSaCas9 . All the SaCas9 proteins tested were highly sensitive\n\nwas significantly reduced to 0 to 2 for SaCas9 - HF . SaCas9\n\nHF also had significantly fewer off - target sites compared to\n\nto mismatches between guide RNA ( GRNA ) and the target at\n\nthe PAM - proximal positions 1 to 6 , relatively less sensitive\n\nthe R245A mutant on EMX1_1 , EMX1_4 and EMX1_10 .\n\nat positions 7 to 18 and insensitive at positions 19 to 21. In 25 WT - SaCas9 and the R245A mutant had substantial level of\n\nthe EGFP - disruption assay , no noticeable cleavage differ-\n\nactivity on EMX1_1 that contains a NNARRT PAM and\n\nence was observed between WT and the R245A , N413A ,\n\nactivity on NNYRRT PAM sites .\n\nN419A , and R654A SaCas9 mutants using the mismatched\n\nExample 4\n\nguides .\n\n30\n\nExample 2\n\nEpistasis Effect of SaCas9 Residues on Targeting\n\nSpecificity\n\nGenome - Wide Targeting Specificity by the Single\n\nSubstitution SaCas9 Mutants\n\nThe inventors constructed all combinations of modified\n\n35\n\nproteins , i.e. double / triple / quadruple mutants from the four\n\nThe inventors evaluated genome - wide targeting activity\n\nR245A , N413A , N419A , and R654A mutations to test for\n\nof the R245A , N413A , N419A , and R654A mutants at the\n\nimproved DNA specificity . GUIDE - seq were performed on\n\nEMX1_6 , VEGFA_8 , EMX1_1 endogenous sites using\n\nthe modified proteins with one or more mutations of R245A ,\n\nGUIDE - seq17 . With reference to FIGS . 2A , 2B and 2C , it\n\nwas unexpectedly found that the four single mutants showed 40 N413A , N419A , and R654A targeting three endogenous\n\nhuman sites . GUIDE - Seq showed significant improvement\n\nimproved specificity of varied levels at a canonical PAM\n\nby SaCas9 - HF ( modified protein with mutations of R245A ,\n\n( EMX1_6 ) , a known promiscuous ( VEGFA_8 ) site and a\n\nN413A , N419A , and R654A ) at three endogenous sites ,\n\nnon - canonical PAM ( EMX1_1 ) site . As seen in FIG . 2A , the\n\nnamely EMX1_6 , VEGFA_8 and FANCF_13 .\n\nN413A mutant showed significantly higher specificity at\n\nEMX1_6 site compared to VVT ( wildtype ) . As shown in 45\n\nWith reference to FIG . 4A and FIG . 4B , it was found that\n\nFIG . 2D , the R245A mutant nearly halved the number of\n\nmutants harboring the R245A , N413A , N419A , and R654A\n\noff - target sites at both of the canonical PAM sites , improved\n\nmutations generally had a low number of off - target sites . The\n\non- to off - target read ratio and retained a comparable number\n\nmodified protein harboring R245A and N413A mutations\n\nof on - target reads ( 70 % , 98 % and 84 % , respectively , at the\n\nand the modified protein harboring R245A , N413A , N419A\n\nthree sites ) when compared to WT - SaCas9 . The other three 50 mutations had significantly low off - target activity . Mutation\n\nsingle mutants , i.e. N413A , N419A , and R654A improved\n\nat the N413 position had a significant effect on the number\n\non- to off - target ratio across the three sites .\n\nof off - target sites , for example , with reference to FIG . 4A , at\n\nVEGFA_8 , the modified protein harboring N413A and\n\nExample 3\n\nR245A mutations had significantly lower number of off\n\n55\n\ntarget sites compared to the modified protein without a\n\nGenome - Wide Targeting Specificity at Expanded\n\nmutation at the N413 position and harboring R245A - N419\n\nEndogenous Sites\n\nmutations . The positive effect of a mutation at the N413\n\nposition in reducing the number of off - target sites at\n\nTo further evaluate SaCas9 mutant genome - wide target\n\ning specificity , the inventors performed GUIDE - seq analy- 60 VEGFA_8 is also exemplified in FIG . 4A where the modi\n\nfied protein harboring the R245A , N413A , N419A , and\n\nses to include all of the eleven endogenous sites ( 6 canonical\n\nR654A mutations , i.e. SaCas9 - HF , had a significantly lower\n\nand 5 non - canonical PAMs ) previously subjected to\n\nnumber of off - target sites compared to the modified protein\n\nGUIDE - seq . A quadruple mutant , i.e. a modified protein\n\ncontaining four amino acid substitutions referred to as\n\nharboring R245A , N419A and R654A mutations , i.e. with\n\nSaCas9 - HF ( with the following four amino acid mutations : 65 out a mutation at the N413 position , showing the advanta\n\nR245A , N413A , N419A , and R654A ) , was generated to test\n\ngeous effect of the mutation at the N413 position in improv\n\nthe combined effectiveness of four mutations . The R245A\n\ning specificity of the SaCas9 protein .\n\nUS 10,975,364 B2\n\n12\n\n11\n\nNNARRT PAM (EMX1_1) for which about 20% the cleav- age efficiency of canonical PAM in an EGFR disruption assay was achieved but which has never been tested on a human endogenous target. These targets are also associated with a substantial number of off-target sites in the human genome and well suited for downstream evaluation of tar- geting specificity.\n\nmodified protein was also evaluated in view of data showing consistently high on-target cleavage efficiency.\n\nAs seen in FIG. 3B, FIG. 3C and FIG. 3F, among the six canonical PAM sites, FANCF_13 showed nine off-target sites by WT-SaCas9 and no detectable off-target sites by SaCas9-HF, illustrating the marked improved specificity of SaCas9-HF in comparison to WT-SaCas9 and improved specificity over the R245A modified protein.\n\nUsing targeted deep sequencing, the inventors unexpect- edly found that all four single SaCas9 mutants (ie. R245A, N413A, N419A, and R654A) retained comparable on-target activities in comparison to WT SaCas9, ranging from approximately 20%-60% activity across the three human endogenous sites EMX1_6, VEGFA_8, EMX1_1 as shown in FIGS. 1D-1F. At the non-canonical PAM NNARRT endogenous site EMX_1, SaCas9 modified proteins achieved 17-23% indel editing outcome.\n\nWith reference to FIG. 3F, SaCas9-HF showed significant reductions of off-target activity for EMX1_6 and the known promiscuous site VEGFA_8 in comparison to WT-SaCas9 and the R245A mutant. Nearly no off-target activity by WT-SaCas9 was detected for FANCF_10, RUNX1_13 and RUNX1_14. Unexpectedly, SaCas9-HF advantageously achieved about 8.6-, 3.2- and 0.74-fold the GUIDE-Seq reads of WT-SaCas9, respectively, for the three sites. Fur- ther, SaCas9-HF showed no cleavage at the sole off-target site when targeting RUNX1_13 by WT-SaCas9.\n\nThe inventors used an EGFP-disruption assay to evaluate SaCas9 cleavage efficiency on expressed eGFP with full- match and tiling 2-base mismatch guide sequences, as illustrated in FIG. 1G. The R245A, N419A and R654A mutants possessed similar cleavage eflicacy to the WT- SaCas9. All the SaCas9 proteins tested were highly sensitive to mismatches between guide RNA (gRNA) and the target at the PAM-proximal positions 1 to 6, relatively less sensitive at positions 7 to 18 and insensitive at positions 19 to 21. In the EGFP-disruption assay, no noticeable cleavage differ- ence was observed between WT and the R245A, N413A, N419A, and R654A SaCas9 mutants using the mismatched guides.\n\nAs seen in FIG. 3G, for the five non-canonical PAM sites, 1 to 4 off-target sites were detected for WT-SaCas9 and this was significantly reduced to 0 to 2 for SaCas9-HF. SaCas9- HF also had significantly fewer off-target sites compared to the R245A mutant on EMX1_1, EMX1_4 and EMX1_10. WT-SaCas9 and the R245A mutant had substantial level of activity on EMX1_1 that contains a NNARRT PAM and. activity on NNYRRT PAM sites.\n\nExample 4\n\n30\n\nExample 2\n\nEpistasis Effect of SaCas9 Residues on Targeting Specificity\n\nGenome-Wide Targeting Specificity by the Single Substitution SaCas9 Mutants\n\nThe inventors constructed all combinations of modified proteins, i.e. double/triple/quadruple mutants from the four R245A, N413A, N419A, and R654A mutations to test for improved DNA specificity. GUIDE-seq were performed on the modified proteins with one or more mutations of R245A, N413A, N419A, and R654A targeting three endogenous human sites. GUIDE-Seq showed significant improvement by SaCas9-HF (modified protein with mutations of R245A, N413A, N419A, and R654A) at three endogenous sites, namely EMX1_6, VEGFA_8 and FANCF_13.\n\n35\n\nThe inventors evaluated genome-wide targeting activity of the R245A, N413A, N419A, and R654A mutants at the EMX1_6, VEGFA_8, EMX1_1 endogenous sites using GUIDE-seq17. With reference to FIGS. 2A, 2B and 2C, it was unexpectedly found that the four single mutants showed improved specificity of varied levels at a canonical PAM (EMX1_6), a known promiscuous (VEGFA_8) site and a non-canonical PAM (EMX1_1) site. As seen in FIG. 2A, the N413A mutant showed significantly higher specificity at EMX1_6 site compared to VVT (wildtype). As shown in FIG. 2D, the R245A mutant nearly halved the number of off-target sites at both of the canonical PAM sites, improved on- to off-target read ratio and retained a comparable number of on-target reads (70%, 98% and 84%, respectively, at the three sites) when compared to WT-SaCas9. The other three single mutants, i.e. N413A, N419A, and R654A improved on- to off-target ratio across the three sites.\n\nWith reference to FIG. 4A and FIG. 4B, it was found that mutants harboring the R245A, N413A, N419A, and R654A, mutations generally had a low number of off-target sites. The modified protein harboring R245A and N413A mutations and the modified protein harboring R245A, N413A, N419A mutations had significantly low off-target activity. Mutation at the N413 position had a significant effect on the number of off-target sites, for example, with reference to FIG. 4A, at VEGFA_8, the modified protein harboring N413A and R245A mutations had significantly lower number of off- target sites compared to the modified protein without a mutation at the N413 position and harboring R245A-N419 mutations. The positive effect of a mutation at the N413 position in reducing the number of off-target sites at VEGFA_8 is also exemplified in FIG. 4A where the modi- fied protein harboring the R245A, N413A, N419A, and. R654A mutations, i.e. SaCas9-HF, had a significantly lower number of off-target sites compared to the modified protein harboring R245A, N419A and R654A mutations, i.e. with- out a mutation at the N413 position, showing the advanta- geous effect of the mutation at the N413 position in improv-\n\nExample 3\n\n35\n\nGenome-Wide Targeting Specificity at Expanded Endogenous Sites\n\nTo further evaluate SaCas9 mutant genome-wide target- ing specificity, the inventors performed GUIDE-seq analy- ses to include all of the eleven endogenous sites (6 canonical and 5 non-canonical PAMs) previously subjected to GUIDE-seg. A quadruple mutant, i.e. a modified protein containing four amino acid substitutions referred to as SaCas9-HF (with the following four amino acid mutations: R245A, N413A, N419A, and R654A), was generated to test the combined effectiveness of four mutations. The R245A\n\n25\n\n40\n\n45\n\n60\n\n65\n\ning specificity of the SaCas9 protein.\n\nUS 10,975,364 B2\n\n14\n\n13\n\nExample 5\n\nThe inventors sought to test their hypothesis of improving\n\nthe targeting accuracy of SaCas9 by modifying amino acid\n\nresidues in close polar contact with the gRNA - target DNA\n\nImproved Specificity on KKH - SaCas9\n\ninterface in the PAM - distal region . Using GUIDE - Seq ( ge\n\nThe inventors tested the targeting specificity of a modified 5 nome - wide unbiased identification of double - stranded\n\nbreaks enabled by sequencing ) , it was found that one engi\n\nprotein with mutations of R245A , N413A , N419A , R654A ,\n\nneered modified SaCas9 protein , SaCas9 - HF ( with muta\n\nE782K , N968K and R1015H ( referred to as KKH - SaCas9\n\ntions of N413A , R245A , N419A and R654A ) advantageously\n\nHF , i.e. the modified protein comprising an amino acid\n\nand significantly reduced off - target cleavages without com\n\nsequence as defined by SEQ ID NO : 2 ) and compared this\n\nwith an SaCas9 variant with mutations of E782K . N968K 10 promising on - target activity . Of five endogenous target sites\n\nin human cells tested using SaCas9 - HF , significantly less or\n\nand R1015H at all of the eleven endogenous target sites ( 6\n\nno off - target activity was detected at the target sites . Further ,\n\ncontaining canonical PAM of WT - SaCas9 and 5 containing\n\nadding these residue modifications onto the KKH - SaCas9\n\nKKH targeting PAM ) using GUIDE - Seq as shown in FIGS .\n\nvariant previously described ( i.e. with mutations of E782K ,\n\n5B and 5D .\n\nIt was found that KKH - SaCas9 - HF had\n\nN968K and R1015H ) to target a broader PAM range\n\n15\n\nenhanced targeting specificity and significantly reduced the\n\n( NNNRRT ) also resulted in significantly reduced off - target\n\nnumber of off - target sites ( FIG . 5A ) whilst increasing on-\n\nactivity of KKH - SaCas9 - HF when compared with KKH\n\ntarget cleavage frequency at four canonical PAM sites ( FIG .\n\nSaCas9 across endogenous target sites in human cells tested .\n\n5A and FIG . 5B ) . With reference to FIG . 5C , KKH - SaCas9-\n\nThus , the present invention provides an improved modified\n\nHF significantly reduced the number of off - target sites\n\nSaCas9 protein for use in altering the genome of a cell with\n\n20\n\ncompared to the SaCas9 variant with mutations of E782K ,\n\nincreased specificity enabling genome - editing applications\n\nwith high genome - wide precision .\n\nN968K and R1015H .\n\nSEQUENCE LISTING\n\n< 160 > NUMBER OF SEQ ID NOS : 180\n\n< 210 > SEQ ID NO 1\n\n< 211 > LENGTH : 1086\n\n< 212 > TYPE : PRT\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 1\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val\n\n1\n\n15\n\n10\n\n5\n\nGly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly\n\n20\n\n25\n\n30\n\nVal Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg\n\n45\n\n40\n\n35\n\nSer Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile\n\n55\n\n50\n\n60\n\nGin Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His\n\n70\n\n65\n\n75\n\n80\n\nSer Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu\n\n85\n\n90\n\n95\n\nSer Gin Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu\n\n105\n\n110\n\n100\n\nAla Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr\n\n120\n\n125\n\n115\n\nGly Asn Glu Leu Ser Thr Lys Glu Gin Ile Ser Arg Asn Ser Lys Ala\n\n140\n\n135\n\n130\n\nLeu Glu Glu Lys Tyr Val Ala Glu Leu Gin Leu Glu Arg Leu Lys Lys\n\n160\n\n145\n\n150\n\n155\n\nAsp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr\n\n175\n\n165\n\n170\n\nVal Lys Glu Ala Lys Gin Leu Leu Lys Val Gln Lys Ala Tyr His Gin\n\n185\n\n180\n\n190\n\nLeu Asp Gin Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg\n\n195\n\n200\n\n205\n\nUS 10,975,364 B2\n\n13\n\n14\n\nThe inventors sought to test their hypothesis of improving the targeting accuracy of SaCas9 by modifying amino acid residues in close polar contact with the gRNA-target DNA interface in the PAM-distal region. Using GUIDE-Seq (ge- nome-wide unbiased identification of double-stranded breaks enabled by sequencing), it was found that one engi- neered modified SaCas9 protein, SaCas9-HF (with muta- tions of N413A,R245A,N419A and R654A) advantageously and significantly reduced off-target cleavages without com- promising on-target activity. Of five endogenous target sites in human cells tested using SaCas9-HF, significantly less or no off-target activity was detected at the target sites. Further, adding these residue modifications onto the KKH-SaCas9 variant previously described (i.e. with mutations of E782K, N968K and R1015H) to target a broader PAM range (NNNRRT) also resulted in significantly reduced off-target activity of KKH-SaCas9-HF when compared with KKH- SaCas9 across endogenous target sites in human cells tested. Thus, the present invention provides an improved modified SaCas9 protein for use in altering the genome of a cell with increased specificity enabling genome-editing applications with high genome-wide precision.\n\nExample 5\n\nImproved Specificity on KKH-SaCas9\n\nThe inventors tested the targeting specificity of a modified protein with mutations of R245A, N413A, N419A, R654A, E782K, N968K and R1015H (referred to as KKH-SaCas9- HF, ie. the modified protein comprising an amino acid sequence as defined by SEQ ID NO: 2) and compared this with an SaCas9 variant with mutations of E782K, N968K and R1015H at all of the eleven endogenous target sites (6 containing canonical PAM of WT-SaCas9 and 5 containing KKH targeting PAM) using GUIDE-Seq as shown in FIGS. 5B and 5D. It was found that KKH-SaCas9-HF had enhanced targeting specificity and significantly reduced the number of off-target sites (FIG. 5A) whilst increasing on- target cleavage frequency at four canonical PAM sites (FIG. SA and FIG. 5B). With reference to FIG. 5C, KKH-SaCas9- HF significantly reduced the number of off-target sites compared to the SaCas9 variant with mutations of E782K, N968K and R1015H.\n\nSEQUENCE LISTING\n\n<160> NUMBER OF SEQ ID Nos: 180\n\n<210> <211> <212> <213> <220> <223> SEQ ID NO 1 LENGTH: 1086 TYPE: PRT ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 1\n\nIle Leu Gly Leu Asp Ile Ile 10 Gly Lys Arg Asn Gly 1 Thr Ser Val 15\n\nGly Ile 20 Tyr Gly Asp Tyr Glu Arg Asp Val Ile Ala Gly\n\nval Phe Glu Asn Glu Asn Asn 40 Arg Lys Arg Arg\n\nLys Ala Leu 50 Gly Arg Lys Arg Arg His Arg\n\nVal Phe Asn Leu 75 Leu 70 Arg Lys Asp Thr\n\nSer Glu Leu Ser Ile Asn Pro Tyr Ala Arg Val Lys Leu\n\nGln Glu Glu Glu Phe 105 Leu Ala Ala Leu 100 Ser Lys Leu Leu 110\n\nval Asn Val Asn Glu Val 120 Lys Arg His 115 Arg Gly Glu\n\nGly Asn Glu Thr Glu Gln Ile 130 Leu Ser Lys 135 Ser Arg 140 Ser Lys Ala\n\nGlu Glu val 150 Ala Glu Gln Leu Glu 155 Leu Leu 145 Lys Tyr Leu Lys Lys 160\n\nAsp Gly Glu Val Arg Ser Ile Asn Phe 165 Gly Arg 170 Lys Ser Asp 175 Tyr\n\nval Glu Ala 180 Lys Lys Gln Leu Leu Lys Val Gln Ala 185 Lys Tyr His Gln 1380\n\nGln 195 Phe Ile Thr 200 Ile Leu 205 Leu Asp Ser Asp Tyr Leu Glu Thr Arg\n\n5\n\nSer\n\nGin\n\n65\n\nAla\n\n10\n\n15\n\n20\n\nIle\n\nHis\n\n80\n\nThr\n\nUS 10,975,364 B2\n\n15\n\n16\n\ncontinued\n\nArg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys\n\n210\n\n215\n\n220\n\nAsp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe\n\n230\n\n235\n\n225\n\n240\n\nPro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr\n\n245\n\n250\n\n255\n\nAsn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn\n\n270\n\n265\n\n260\n\nGlu Lys Leu Glu Tyr Tyr Glu Lys Phe Gin Ile Ile Glu Asn Val Phe\n\n275\n\n280\n\n285\n\nLys Gin Lys Lys Lys Pro Thr Leu Lys Gin Ile Ala Lys Glu Ile Leu\n\n290\n\n300\n\n295\n\nVal Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys\n\n320\n\n305\n\n310\n\n315\n\nPro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr\n\n325\n\n330\n\n335\n\nAla Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gin Ile Ala\n\n340\n\n345\n\n350\n\nLys Ile Leu Thr Ile Tyr Gin Ser Ser Glu Asp Ile Gin Glu Glu Leu\n\n360\n\n365\n\n355\n\nThr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gin Ile Ser\n\n370\n\n375\n\n380\n\nAsn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile\n\n390\n\n385\n\n400\n\n395\n\nAsn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Ala Gln Ile Ala\n\n410\n\n415\n\n405\n\nIle Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gin\n\n420\n\n430\n\n425\n\nGin Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro\n\n440\n\n435\n\n445\n\nVal Val Lys Arg Ser Phe Ile Gin Ser Ile Lys Val Ile Asn Ala Ile\n\n460\n\n455\n\n450\n\nIle Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg\n\n470\n\n475\n\n480\n\n465\n\nGlu Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys\n\n490\n\n495\n\n485\n\nArg Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr\n\n510\n\n500\n\n505\n\nGly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp\n\n525\n\n520\n\n515\n\nMet Gin Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu\n\n535\n\n540\n\n530\n\nAsp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro\n\n545\n\n550\n\n555\n\n560\n\nArg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys\n\n575\n\n565\n\n570\n\nGin Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gin Tyr Leu\n\n590\n\n580\n\n585\n\nSer Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile\n\n605\n\n595\n\n600\n\nLeu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu\n\n620\n\n610\n\n615\n\nTyr Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp\n\nUS 10,975,364 B2\n\n16\n\n15\n\n-cont inued\n\nThr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp 210 215 220\n\nTle Lys Glu Trp Tyr 230 Glu Met Leu Met Gly 235 His cys Thr Tyr\n\nPro Glu Glu Leu Arg 245 Ser Val Lys Tyr Ala 250 Tyr Asn Ala Asp Leu 255 Tyr\n\nAsn Ala Leu Asn 260 Asp Leu Asn Asn Leu 265 Val Tle Thr Arg Asp 270 Glu Asn\n\nLys Leu 275 Glu Tyr Tyr Glu Lys 280 Phe Gin Tle Tle Glu 285 Asn Val\n\nLys Gin 290 Lys Lys Lys Pro Thr 295 Leu Lys Gin Tle Ala 300 Lys Glu Tle Leu\n\nVal 305 Asn Glu Glu Asp Tle 310 Lys Gly Tyr Arg Val 315 Thr Ser Thr Gly Lys 320\n\nGlu Phe Thr Asn 325 Leu Lys val Tyr His 330 Asp Tle Lys Asp Tle 335\n\nAla Arg Lys Glu 340 Ile Ile Glu Asn Ala 345, Glu Leu Leu Asp Gln 350 Ile Ala\n\nLys Ile Leu 355 Thr Ile Tyr Gln Ser 360 Ser Glu Asp Tle Gln 365 Glu Glu Leu\n\nThr Asn 370 Leu Asn Ser Glu Leu 375 Thr Gin Glu Glu Tle 380 Glu Glin Tle Ser\n\nLeu Lys Gly Tyr Thr 390 Gly Thr His Asn Leu 395 Ser Leu Lys Ala\n\nAsn Leu Tle Leu Asp 405 Glu Leu Trp His Thr 410 Asn Asp Ala Gln Ile 415 Ala\n\nIle Phe Asn Arg 420 Leu Lys Leu Val Pro 425 Lys Lys val Asp Leu 430 Ser Gln\n\nGin Lys Glu 435 Tle Pro Thr Thr Leu 440 Val Asp Asp Phe Tle 445 Leu Ser Pro\n\nVal 450 Lys Arg Ser Phe Tle 455 Gin Ser Tle Lys Val 460 Tle Asn Ala Tle\n\nLys Lys Tyr Gly Leu 470 Pro Asn Asp Ile Tle 475 Tle Glu Leu Ala Arg 4380\n\nLys Asn Ser Lys 485 Asp Ala Gln Lys Met. 490 Tle Asn Glu Met Gin 495 Lys\n\nArg Asn Arg Gln 500 Thr Asn Glu Arg Ile 505 Glu Glu Tle Ile Arg 510 Thr Thr\n\nGly Lys Glu 515 Asn Ala Lys Tyr Tle Glu Lys Tle Lys 525 Leu His Asp\n\nMet Gin 530 Glu Gly Lys cys Leu 535 Ser Leu Glu Ala 540 Tle Pro Leu Glu\n\nAsp 545 Leu Leu Asn Asn Pro 550 Phe Asn Tyr Glu val sss Asp His Ile Ile Pro 560\n\nArg Ser val Ser Phe 565 Asp Asn Ser Phe Asn 570 Asn Lys Val Leu Val 575 Lys\n\nGin Glu Glu Asn 580 Ser Lys Lys Gly Asn 585 Arg Thr Pro Phe Gin 590 Tyr Leu\n\nSer Ser Ser 595 Asp Ser Lys Tle Ser 600 Tyr Glu Thr Phe Lys 605 Lys His Ile\n\nLeu Asn 610 Leu Ala Lys Gly Lys 615 Gly Arg Tle Ser Lys 620 Thr Lys Lys Glu\n\nTyr Leu Leu Glu Glu Arg Asp Tle Asn Arg Phe Ser Val Gln Lys Asp\n\nArg\n\nLys\n\nAsp 225\n\nGlu\n\nPro\n\nAsn\n\n385\n\nPhe\n\n240\n\nPhe\n\nThr\n\nTle\n\n400\n\nUS 10,975,364 B2\n\n17\n\n18\n\ncontinued\n\n640\n\n625\n\n630\n\n635\n\nPhe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu\n\n645\n\n655\n\n650\n\nMet Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys\n\n665\n\n660\n\n670\n\nVal Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp\n\n675\n\n680\n\n685\n\nLys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp\n\n695\n\n690\n\n700\n\nAla Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys\n\n715\n\n710\n\n705\n\n720\n\nLeu Asp Lys Ala Lys Lys Val Met Glu Asn Gin Met Phe Glu Glu Lys\n\n725\n\n730\n\n735\n\nGln Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gin Glu Tyr Lys Glu\n\n745\n\n740\n\n750\n\nIle Phe Ile Thr Pro His Gin Ile Lys His Ile Lys Asp Phe Lys Asp\n\n765\n\n760\n\n755\n\nTyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile\n\n780\n\n775\n\n770\n\nAsn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu\n\n790\n\n795\n\n800\n\n785\n\nIle Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu\n\n815\n\n810\n\n805\n\nLys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His\n\n830\n\n820\n\n825\n\nAsp Pro Gin Thr Tyr Gin Lys Leu Lys Leu Ile Met Glu Gin Tyr Gly\n\n840\n\n845\n\n835\n\nAsp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr\n\n850\n\n855\n\n860\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile\n\n870\n\n880\n\n865\n\n875\n\nLys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp\n\n885\n\n895\n\n890\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr\n\n900\n\n905\n\n910\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val\n\n915\n\n920\n\n925\n\nLys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser\n\n935\n\n930\n\n940\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala\n\n945\n\n955\n\n960\n\n950\n\nGlu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly\n\n970\n\n965\n\n975\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile\n\n985\n\n980\n\n990\n\nTyr Arg Glu Tyr Leu Glu Asn Met\n\nGlu Val Asn Met Ile Asp Ile Thr\n\n995\n\n1005\n\n1000\n\nAsn Asp Lys Arg Pro Pro Arg\n\nAla Ser Lys\n\nIle Ile Lys Thr Ile\n\n1015\n\n1010\n\n1020\n\nSer Ile Lys Lys Tyr\n\nSer Thr Asp Ile Leu Gly Asn Leu\n\nThr Gln\n\n1035\n\n1025\n\n1030\n\nLys Lys Gly\n\nTyr Glu\n\nVal Lys Ser Lys Lys\n\nHis Pro Gin Ile Ile\n\n1045\n\n1050\n\n1040\n\nUS 10,975,364 B2\n\n17\n\n18\n\n-cont inued\n\n625\n\nPhe Ile Asn Arg Asn 645 Leu val Asp Thr Arg Tyr Ala Thr Arg Gly Leu 650 655\n\nMet Asn Leu Leu 660 Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys 665 670\n\nLys Ser 675 Ile Asn Gly Gly Phe 680 Thr Ser Phe Leu Arg Arg Lys 685\n\nPhe 690 Lys Lys Glu Arg Asn 695 Lys Gly Tyr Lys His His Ala Glu Asp 700\n\nLeu Ile Ile Ala Asn 710 Ala Asp Phe Ile Phe Lys Glu Trp Lys 715\n\nLeu Asp Lys Ala Lys 725 Lys val Met Glu Asn Gln Met Phe Glu Glu Lys 730 735\n\nGin Ala Glu Ser 740 Met Pro Glu Tle Glu Thr Glu Gln Glu Tyr Lys Glu 745 750\n\nIle Phe Tle 755 Thr Pro His Gln Tle 760 Lys His Ile Lys Asp Phe Lys Asp 765\n\nTyr Lys 770 Tyr Ser His Arg val 775 Asp Lys Lys Pro Asn Arg Glu Leu Ile 780\n\nAsp Thr Leu Tyr Ser 790 Thr Arg Lys Asp Asp Lys Gly Asn Thr 795\n\nTle Val Asn Asn Leu 805 Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu 810 815\n\nLys Lys Leu Ile 820 Asn Lys ser Pro Glu Lys Leu Leu Met Tyr His His 825 830\n\nAsp Pro Gln 835 Thr Tyr Gln Lys Leu 840 Lys Leu Ile Met Glu Gln Tyr Gly 845\n\nAsp Glu 850 Lys Asn Pro Leu Tyr 855 Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr 860\n\nLeu 865 Thr Lys Tyr Ser Lys 870 Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 875 880\n\nLys Tyr Tyr Gly Asn 885 Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp 890 895\n\nTyr Pro Asn Ser 900 Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 905 910\n\nArg Phe Asp 915 val Tyr Leu Asp Asn 920 Gly Val Tyr Lys Phe Val Thr Val 925\n\nLys Asn 930 Leu Asp val Ile Lys 935 Lys Glu Asn Tyr Tyr Glu Val Asn Ser 940\n\nLys 945 cys Tyr Glu Glu Ala 950 Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 955 960\n\nGlu Phe Tle Ala Ser 965 Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly 970 975\n\nGlu Leu Tyr Arg 980 val Ile Gly val Asn Asn Asp Leu Leu Asn Arg Ile 985 990\n\nGlu Val Asn 995 Met Ile Asp Tle Thr 1000 Tyr Arg Glu Tyr Leu Glu Asn Met 1005\n\nAsn Asp Lys Arg Pro Pro Arg 1010 Tl 1015 e Ile Lys Thr Ile Ala Ser Lys 1020\n\nThr Gln Ser Ile Lys Lys Tyr 1025 Se 1030 x Thr Asp Ile Leu Gly Asn Leu 1035\n\nTyr Glu Val Lys Ser Lys Lys 1040 Hi 1045 s Pro Gln Ile Ile Lys Lys Gly 1050\n\nAla\n\n705\n\nAsn\n\n785\n\n630\n\n635\n\n640\n\nTrp\n\nLys 720\n\nLeu\n\n800\n\nUS 10,975,364 B2\n\n20\n\n19\n\ncontinued\n\nPro Lys Lys Lys Arg\n\nLys Val Ser Ser Asp Tyr Lys Asp\n\nGly Ser\n\n1055\n\n1060\n\n1065\n\nHis Asp Gly Asp Tyr Lys Asp\n\nLys Asp Asp\n\nHis Asp Ile Asp Tyr\n\n1070\n\n1075\n\n1080\n\nAsp Asp Lys\n\n1085\n\n< 210 > SEQ ID NO 2\n\n< 211 > LENGTH : 1086\n\n< 212 > TYPE : PRT\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 2\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val\n\n15\n\n10\n\n5\n\n1\n\nGly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly\n\n30\n\n20\n\n25\n\nVal Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg\n\n35\n\n40\n\n45\n\nSer Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile\n\n60\n\n55\n\n50\n\nGln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His\n\n70\n\n80\n\n65\n\n75\n\nSer Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu\n\n90\n\n95\n\n85\n\nSer Gin Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu\n\n100\n\n105\n\n110\n\nAla Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr\n\n120\n\n125\n\n115\n\nGly Asn Glu Leu Ser Thr Lys Glu Gin Ile Ser Arg Asn Ser Lys Ala\n\n135\n\n140\n\n130\n\nLeu Glu Glu Lys Tyr Val Ala Glu Leu Gin Leu Glu Arg Leu Lys Lys\n\n145\n\n155\n\n160\n\n150\n\nAsp Gly Glu Val Arg Gly Ser\n\nle Asn Arg Phe Lys Thr Ser Asp Tyr\n\n170\n\n175\n\n165\n\nVal Lys Glu Ala Lys Gin Leu Leu Lys Val Gln Lys Ala Tyr His Gin\n\n180\n\n185\n\n190\n\nLeu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg\n\n205\n\n195\n\n200\n\nArg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys\n\n215\n\n220\n\n210\n\nAsp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe\n\n225\n\n235\n\n240\n\n230\n\nPro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr\n\n245\n\n250\n\n255\n\nAsn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn\n\n270\n\n260\n\n265\n\nGlu Lys Leu Glu Tyr Tyr Glu Lys Phe Gin Ile Ile Glu Asn Val Phe\n\n275\n\n285\n\n280\n\nLys Gin Lys Lys Lys Pro Thr Leu Lys Gin Ile Ala Lys Glu Ile Leu\n\n290\n\n300\n\n295\n\nVal Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys\n\n310\n\n320\n\n315\n\n305\n\nUS 10,975,364 B2\n\n19\n\n-cont inued\n\nGly Ser Pro Lys Lys Lys Arg Lys Val Ser Ser Asp Tyr Lys Asp 1055 1060 1065\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp 1070 1075 1080\n\nAsp Asp Lys\n\n<210> SEQ ID NO 2 <211> LENGTH: 1086 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 2\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val 1 5 10 15\n\nTyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala 20 25 30\n\nVal Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg 35 40 45\n\nSer Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile 50 55 60\n\nGln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His 65 70 75 80\n\nSer Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu 85 90 95\n\nSer Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu 100 105 110\n\nAla Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr 115 120 125\n\nGly Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala 130 135 140\n\nLeu Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys 145 150 155 160\n\nAsp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr 165 170 175\n\nVal Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln 180 185 190\n\nLeu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg 195 200 205\n\nThr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp 210 215 220\n\nAsp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe 225 230 235 240\n\nPro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr 245 250 255\n\nAsn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn 260 265 270\n\nGlu Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe 275 280 285\n\nLys Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu 290 295 300\n\nVal Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys 305 310 315 320\n\n1085\n\nGly\n\nGly\n\nArg\n\nLys\n\nUS 10,975,364 B2\n\n22\n\n21\n\ncontinued\n\nPro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr\n\n325\n\n330\n\n335\n\nAla Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gin Ile Ala\n\n340\n\n350\n\n345\n\nLys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gin Glu Glu Leu\n\n360\n\n365\n\n355\n\nThr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser\n\n370\n\n380\n\n375\n\nAsn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile\n\n395\n\n385\n\n390\n\n400\n\nAsn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Ala Gln Ile Ala\n\n410\n\n415\n\n405\n\nIle Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln\n\n430\n\n420\n\n425\n\nGln Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro\n\n445\n\n435\n\n440\n\nVal Val Lys Arg Ser Phe Ile Gin Ser Ile Lys Val Ile Asn Ala Ile\n\n450\n\n455\n\n460\n\nIle Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg\n\n480\n\n470\n\n475\n\n465\n\nGlu Lys Asn Ser Lys Asp Ala Gin Lys Met Ile Asn Glu Met Gln Lys\n\n485\n\n490\n\n495\n\nArg Asn Arg Gin Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr\n\n505\n\n510\n\n500\n\nGly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp\n\n515\n\n520\n\n525\n\nMet Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu\n\n530\n\n535\n\n540\n\nAsp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro\n\n555\n\n545\n\n560\n\n550\n\nArg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys\n\n575\n\n565\n\n570\n\nGin Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gin Tyr Leu\n\n590\n\n580\n\n585\n\nSer Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile\n\n600\n\n595\n\n605\n\nLeu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu\n\n615\n\n610\n\n620\n\nTyr Leu Leu lu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp\n\n630\n\n635\n\n640\n\n625\n\nPhe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu\n\n655\n\n650\n\n645\n\nMet Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys\n\n670\n\n660\n\n665\n\nVal Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp\n\n680\n\n675\n\n685\n\nLys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp\n\n695\n\n690\n\n700\n\nAla Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys\n\n705\n\n710\n\n715\n\n720\n\nLeu Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys\n\n725\n\n730\n\n735\n\nUS 10,975,364 B2\n\n22\n\n21\n\n-cont inued\n\nPro Glu Phe Thr Asn 325 Leu Lys Val Tyr His 330 Asp Ile Lys Asp Ile 335 Thr\n\nAla Arg Lys Glu 340 Tle Tle Glu Asn Ala 345 Glu Leu Leu Asp Glin 350 Tle Ala\n\nLys Ile Leu 355 Thr Ile Tyr Gln Ser 360 Ser Glu Asp Tle Gin 365 Glu Glu Leu\n\nThr Asn 370 Leu Asn Ser Glu Leu 375 Thr Gln Glu Glu Tle 380 Glu Gln Ile Ser\n\nAsn 385 Leu Lys Gly Tyr Thr 390 Gly Thr His Asn Leu 395 Ser Leu Lys Ala Ile 400\n\nLeu Tle Leu Asp 405 Glu Leu Trp His Thr 410 Asn Asp Ala Glin Tle 415\n\nIle Phe Asn Arg 420 Leu Lys Leu val Pro 425 Lys Lys Val Asp Leu 430 Ser Gln\n\nGin Lys Glu 435 Tle Pro Thr Thr Leu 440 Val Asp Asp Phe Tle 445 Leu Ser Pro\n\nVal 450 Lys Arg Ser Phe Ile 455 Gln Ser Ile Lys Val 460 Ile Asn Ala Tle\n\nLys Lys Tyr Gly Leu 470 Pro Asn Asp Ile Tle 475 Tle Glu Leu Ala 480\n\nLys Asn Ser Lys 485 Asp Ala Gin Lys Met 490 Tle Asn Glu Met Gin 495 Lys\n\nArg Asn Arg Gln 500 Thr Asn Glu Arg Ile 505 Glu Glu Tle Ile Arg 510 Thr Thr\n\nGly Lys Glu 515 Asn Ala Lys Tyr Leu 520 Ile Glu Lys Tle Lys 525 Leu His Asp\n\nGin 530 Glu Gly Lys cys Leu 535 Tyr Ser Leu Glu Ala 540 Ile Pro Leu\n\nLeu Leu Asn Asn Pro 550 Phe Asn Tyr Glu Val 555 Asp His Tle Tle\n\nArg Ser val Ser Phe 565 Asp Asn Ser Phe Asn 570 Asn Lys Val Leu Val 575, Lys\n\nGin Glu Glu Asn 580 Ser Lys Lys Gly Asn 585 Arg Thr Pro Phe Gln 590 Tyr Leu\n\nSer Ser Ser 595 Asp Ser Lys Ile Ser 600 Tyr Glu Thr Phe Lys 605 Lys His Ile\n\nLeu Asn 610 Leu Ala Lys Gly Lys 615 Gly Arg Ile Ser Lys 620 Thr Lys Lys Glu\n\nLeu Leu Glu Glu Arg 630 Asp Tle Asn Arg Phe 635 Ser Val Glin Lys\n\nPhe Ile Asn Arg Asn 645 Leu val Asp Thr Arg 650 Tyr Ala Thr Arg Gly 655 Leu\n\nMet Asn Leu Leu 660 Arg Ser Tyr Phe Arg 665 Val Asn Asn Leu Asp 670 Val Lys\n\nval Lys Ser 675 Ile Asn Gly Gly Phe 680 Thr Ser Phe Leu Arg 685 Arg Lys Trp\n\nPhe 690 Lys Lys Glu Arg Asn 695 Lys Gly Tyr Lys His 700 His Ala Glu\n\nAla 705, Leu Tle Ile Ala Asn 710 Ala Asp Phe Ile Phe 715 Lys Glu Trp Lys Lys 720\n\nLeu Asp Lys Ala Lys 725 Lys val Met Glu Asn 730 Gln Met Phe Glu Glu 735, Lys\n\nAsn\n\nMet\n\nAsp 545\n\nTyr 625\n\nLys\n\nAla\n\nArg\n\nGlu\n\nPro\n\n560\n\nAsp 640\n\nAsp\n\nUS 10,975,364 B2\n\n24\n\n23\n\ncontinued\n\nGin Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gin Glu Tyr Lys Glu\n\n750\n\n740\n\n745\n\nIle Phe Ile Thr Pro His Gin Ile Lys His Ile Lys Asp Phe Lys Asp\n\n760\n\n755\n\n765\n\nTyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Lys Leu Ile\n\n770\n\n775\n\n780\n\nAsn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu\n\n790\n\n795\n\n785\n\n800\n\nIle Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu\n\n815\n\n805\n\n810\n\nLys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His\n\n825\n\n820\n\n830\n\nAsp Pro Gin Thr Tyr Gin Lys Leu Lys Leu Ile Met Glu Gin Tyr Gly\n\n840\n\n845\n\n835\n\nAsp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr\n\n855\n\n860\n\n850\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile\n\n875\n\n870\n\n880\n\n865\n\nLys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp\n\n885\n\n890\n\n895\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr\n\n900\n\n905\n\n910\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val\n\n925\n\n915\n\n920\n\nLys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser\n\n940\n\n930\n\n935\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala\n\n960\n\n945\n\n950\n\n955\n\nGlu Phe Ile Ala Ser Phe Tyr Lys Asn Asp Leu Ile Lys Ile Asn Gly\n\n975\n\n965\n\n970\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile\n\n990\n\n985\n\n980\n\nTyr Arg Glu Tyr Leu\n\nGlu Val Asn Met Ile Asp Ile Thr\n\nGlu Asn Met\n\n1005\n\n1000\n\n995\n\nAsn Asp\n\nLys Arg Pro Pro His\n\nAla Ser Lys\n\nIle Ile Lys Thr Ile\n\n1010\n\n1015\n\n1020\n\nSer Ile Lys Lys Tyr\n\nSer Thr Asp Ile Leu Gly Asn Leu\n\nThr Gln\n\n1030\n\n1025\n\n1035\n\nLys Lys Gly\n\nTyr Glu\n\nVal Lys Ser Lys Lys\n\nHis Pro Gln Ile Ile\n\n1045\n\n1050\n\n1040\n\nGly Ser\n\nPro Lys Lys Lys Arg\n\nTyr Lys Asp\n\nLys Val Ser Ser Asp\n\n1065\n\n1060\n\n1055\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp\n\n1070\n\n1075\n\n1080\n\nLys\n\nAsp Asp\n\n1085\n\n< 210 > SEQ ID NO 3\n\n< 211 > LENGTH : 1086\n\n< 212 > TYPE : PRT\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 3\n\nUS 10,975,364 B2\n\n23\n\n-cont inued\n\nGln Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu 740 745 750\n\nIle Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp 755 760 765\n\nLys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Lys Leu 770 775 780\n\nAsp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr 790 795\n\nVal Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys 805 810 815\n\nLys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His 820 825 830\n\nAsp Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly 835 840 845\n\nGlu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn 850 855 860\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 865 870 875 880\n\nLys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp 885 890 895\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 900 905 910\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr val 915 920 925\n\nLys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser 930 935 940\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 945 950 955 960\n\nGlu Phe Ile Ala Ser Phe Tyr Lys Asn Asp Leu Ile Lys Ile Asn Gly 965 970 975\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 980 985 990\n\nGlu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met 995 1000 1005\n\nAsn Asp Lys Arg Pro Pro His Ile Ile Lys Thr Ile Ala Ser Lys 1010 1015 1020\n\nThr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu 1025 1030 1035\n\nTyr Glu val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050\n\nGly Ser Pro Lys Lys Lys Arg Lys Val Ser Ser Asp Tyr Lys Asp 1055 1060 1065\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp 1070 1075 1080\n\nAsp Asp Lys\n\n<210> SEQ ID NO 3 <211> LENGTH: 1086 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 3\n\nTyr\n\nIle\n\nAsn\n\nLeu\n\n785\n\n800\n\nIle\n\nLeu\n\nAsp\n\nTyr\n\nUS 10,975,364 B2\n\n26\n\n25\n\ncontinued\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val\n\n10\n\n15\n\n5\n\n1\n\nGly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly\n\n20\n\n30\n\n25\n\nVal Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg\n\n45\n\n40\n\n35\n\nSer Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile\n\n60\n\n50\n\n55\n\nGin Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His\n\n70\n\n65\n\n75\n\n80\n\nSer Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu\n\n85\n\n95\n\n90\n\nSer Gin Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu\n\n105\n\n110\n\n100\n\nAla Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr\n\n120\n\n125\n\n115\n\nGly Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala\n\n140\n\n130\n\n135\n\nLeu Glu Glu Lys Tyr Val Ala Glu Leu Gin Leu Glu Arg Leu Lys Lys\n\n145\n\n150\n\n155\n\n160\n\nAsp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr\n\n175\n\n170\n\n165\n\nVal Lys Glu Ala Lys Gin Leu Leu Lys Val Gin Lys Ala Tyr His Gin\n\n185\n\n180\n\n190\n\nLeu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg\n\n195\n\n200\n\n205\n\nArg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys\n\n210\n\n220\n\n215\n\nAsp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe\n\n225\n\n235\n\n240\n\n230\n\nPro Glu Glu Leu Ala Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr\n\n255\n\n250\n\n245\n\nAsn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn\n\n260\n\n265\n\n270\n\nGlu Lys Leu Glu Tyr Tyr Glu Lys Phe Gin Ile Ile Glu Asn Val Phe\n\n285\n\n280\n\n275\n\nLys Gin Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu\n\n295\n\n300\n\n290\n\nVal Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys\n\n310\n\n315\n\n305\n\n320\n\nPro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr\n\n325\n\n330\n\n335\n\nAla Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gin Ile Ala\n\n340\n\n345\n\n350\n\nLys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gin Glu Glu Leu\n\n360\n\n355\n\n365\n\nThr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser\n\n370\n\n375\n\n380\n\nAsn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile\n\n390\n\n395\n\n385\n\n400\n\nAsn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Ala Gin Ile Ala\n\n405\n\n410\n\n415\n\nIle Phe Ala Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gin\n\nUS 10,975,364 B2\n\n25\n\n26\n\n-cont inued\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu 1 5 Asp Ile Gly Ile Thr Ser Val 10 15\n\nGly Tyr Gly Tle 20 Tle Asp Tyr Glu Thr 25 Arg Asp Val Tle Asp 30 Ala Gly\n\nArg Leu 35 Phe Lys Glu Ala Asn 40 Val Glu Asn Asn Glu 45 Gly Arg Arg\n\nSer Lys 50 Arg Gly Ala Arg Leu Lys Arg Arg Arg His Arg Tle\n\nGln 65 Arg Val Lys Lys Leu 70 Phe Asp Tyr Asn 75 Leu Thr Asp His 80\n\nSer Glu Leu Ser Gly 85 Tle Asn Pro Tyr Glu 90 Ala Arg Val Lys Gly 95 Leu\n\nSer Gin Lys Leu 100 Ser Glu Glu Glu Phe 105 Ser Ala Ala Leu Leu 110 His Leu\n\nAla Lys Arg 115 Arg Gly Val His Asn 120 Val Asn Glu Val Glu 125 Glu Asp Thr\n\nAsn 130 Glu Leu Ser Thr Lys 135 Glu Gln Ile Ser Arg 140 Asn Ser Lys\n\nGlu Glu Lys Tyr val 150 Ala Glu Leu Gin Leu 155 Glu Arg Leu Lys\n\nGly Glu Val Arg 165 Gly ser Tle Asn Arg 170 Phe Lys Thr ser Asp 175 Tyr\n\nLys Glu Ala 180 Lys Gin Leu Leu Lys 185 Val Gin Lys Ala Tyr 190 His Gin\n\nLeu Asp Gln 195 Ser Phe Ile Asp Thr 200 Tyr Ile Asp Leu Leu 205 Glu Thr Arg\n\nArg Thr 210 Tyr Tyr Glu Gly Pro 215 Gly Glu Gly Ser Pro 220 Phe Gly Trp Lys\n\nAsp 225 Tle Lys Glu Trp Tyr 230 Glu Met Leu Met Gly 235 His cys Thr Tyr Phe 240\n\nPro Glu Glu Leu Ala 245 Ser Val Lys Tyr Ala 250 Tyr Asn Ala Asp Leu 255\n\nAsn Ala Leu Asn 260 Asp Leu Asn Asn Leu 265 Val Tle Thr Arg Asp 270 Glu Asn\n\nGlu Lys Leu 275 Glu Tyr Tyr Glu Lys 280 Phe Gin Tle Tle Glu 285 Asn Val Phe\n\nLys Gin 290 Lys Lys Lys Pro Thr 295 Leu Lys Gin Tle Ala 300 Lys Glu Ile Leu\n\nVal 305 Asn Glu Glu Asp Tle 310 Lys Gly Tyr Arg Val 315 Thr Ser Thr Gly Lys 320\n\nGlu Phe Thr Asn 325 Leu Lys val Tyr His 330 Asp Tle Lys Asp Tle 335\n\nAla Arg Lys Glu 340 Ile Ile Glu Asn Ala 345, Glu Leu Leu Asp Gln 350 Ile Ala\n\nLys Tle Leu 355 Thr Tle Tyr Gin Ser 360 Ser Glu Asp Tle Gin 365 Glu Glu Leu\n\nThr Asn 370 Leu Asn Ser Glu Leu 375 Thr Gln Glu Glu Tle 380 Glu Gln Ile Ser\n\nAsn 385 Leu Lys Gly Tyr Thr 390 Gly Thr His Asn Leu 395 Ser Leu Lys Ala Ile 400\n\nLeu Tle Leu Asp 405 Glu Leu Trp His Thr 410 Asn Asp Ala Glin Tle 415\n\nIle Phe Ala Arg Leu Lys Leu val Pro Lys Lys Val Asp Leu Ser Gln\n\nPro\n\nAsn\n\nAla\n\nLys 160\n\nTyr\n\nThr\n\nAla\n\nUS 10,975,364 B2\n\n28\n\n27\n\ncontinued\n\n425\n\n430\n\n420\n\nGin Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro\n\n440\n\n445\n\n435\n\nVal Val Lys Arg Ser Phe Ile Gin Ser Ile Lys Val Ile Asn Ala Ile\n\n460\n\n455\n\n450\n\nIle Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg\n\n470\n\n480\n\n475\n\n465\n\nGlu Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gin Lys\n\n485\n\n490\n\n495\n\nArg Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr\n\n510\n\n505\n\n500\n\nGly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp\n\n520\n\n525\n\n515\n\nMet Gin Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu\n\n530\n\n540\n\n535\n\nAsp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro\n\n550\n\n545\n\n560\n\n555\n\nArg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys\n\n570\n\n575\n\n565\n\nGin Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gin Tyr Leu\n\n590\n\n580\n\n585\n\nSer Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile\n\n600\n\n605\n\n595\n\nLeu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu\n\n610\n\n615\n\n620\n\nTyr Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gin Lys Asp\n\n630\n\n635\n\n640\n\n625\n\nPhe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Ala Gly Leu\n\n645\n\n655\n\n650\n\nMet Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys\n\n665\n\n670\n\n660\n\nVal Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp\n\n680\n\n675\n\n685\n\nLys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp\n\n690\n\n700\n\n695\n\nAla Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys\n\n705\n\n710\n\n715\n\n720\n\nLeu Asp Lys Ala Lys Lys Val Met Glu Asn Gin Met Phe Glu Glu Lys\n\n725\n\n730\n\n735\n\nGin Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gin Glu Tyr Lys Glu\n\n750\n\n745\n\n740\n\nIle Phe Ile Thr Pro His Gin Ile Lys His Ile Lys Asp Phe Lys Asp\n\n755\n\n760\n\n765\n\nTyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile\n\n770\n\n775\n\n780\n\nAsn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu\n\n785\n\n795\n\n790\n\n800\n\nIle Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu\n\n810\n\n805\n\n815\n\nLys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His\n\n820\n\n830\n\n825\n\nAsp Pro Gin Thr Tyr Gin Lys Leu Lys Leu Ile Met Glu Gin Tyr Gly\n\n840\n\n845\n\n835\n\nUS 10,975,364 B2\n\n27\n\n28\n\n-cont inued\n\n425\n\n430\n\nGln Lys Glu 435 Pro Thr Thr Leu 440 val Asp Asp Phe Ile 445 Leu Ser Pro\n\nVal 450 Lys Arg Ser Phe Ile 455 Gin Ser Tle Lys Val 460 Tle Asn Ala\n\nLys Lys Tyr Gly Leu 470 Pro Asn Asp Ile Ile Ile 475 Glu Leu Ala Arg 4380\n\nLys Asn Ser Lys 485 Asp Ala Gln Lys Met. 490 Ile Asn Glu Met Gin 495 Lys\n\nArg Asn Arg Gln 500 Thr Asn Glu Arg Ile 505 Glu Glu Ile Ile Arg 510 Thr Thr\n\nGly Lys Glu 515 Asn Ala Lys Tyr Leu 520 Tle Glu Lys Ile Lys 525 Leu His Asp\n\nGin 530 Glu Gly Lys cys Leu 535 Tyr Ser Leu Glu Ala 540 Tle Pro Leu Glu\n\nAsp 545 Leu Leu Asn Asn Pro 550 Phe Asn Tyr Glu val Asp 555 His Ile Ile Pro 560\n\nArg Ser Val Ser Phe 565 Asp Asn Ser Phe Asn 570 Asn Lys val Leu Val 575 Lys\n\nGlu Glu Asn 580 Ser Lys Lys Gly Asn 585 Arg Thr Pro Phe Gin 590 Tyr\n\nSer Ser Ser 595 Asp Ser Lys Ile Ser 600 Tyr Glu Thr Phe Lys 605 Lys His Tle\n\nAsn 610 Leu Ala Lys Gly Lys 615 Gly Arg Ile Ser Lys 620 Thr Lys Lys\n\nLeu Leu Glu Glu Arg 630 Asp Ile Asn Arg Phe Ser 635 val Gin Lys\n\nPhe Ile Asn Arg Asn 645 Leu val Asp Thr Arg 650 Tyr Ala Thr Ala Gly 655 Leu\n\nMet Asn Leu Leu 660 Arg Ser Tyr Phe Arg 665 Val Asn Asn Leu Asp 670 Val Lys\n\nLys Ser 675 Ile Asn Gly Gly Phe 680 Thr Ser Phe Leu Arg 685 Arg Lys Trp\n\nPhe 690 Lys Lys Glu Arg Asn 695 Lys Gly Tyr Lys His 700 His Ala Glu Asp\n\nLeu Ile Ile Ala Asn 710 Ala Asp Phe Ile Phe Lys 715 Glu Trp Lys Lys 720\n\nLeu Asp Lys Ala Lys 725 Lys val Met Glu Asn 730 Gln Met Phe Glu Glu 735 Lys\n\nGin Ala Glu Ser 740 Met Pro Glu Tle Glu 745 Thr Glu Gln Glu Tyr 750 Lys Glu\n\nIle Phe Tle 755 Thr Pro His Gln Tle 760 Lys His Ile Lys Asp 765, Phe Lys Asp\n\nTyr Lys 770 Tyr Ser His Arg val 775 Asp Lys Lys Pro Asn 780 Arg Glu Leu Tle\n\nAsp Thr Leu Tyr Ser 790 Thr Arg Lys Asp Asp Lys 795 Gly Asn Thr\n\nTle Val Asn Asn Leu 805 Asn Gly Leu Tyr Asp 810 Lys Asp Asn Asp Lys 815 Leu\n\nLys Lys Leu Ile 820 Asn Lys Ser Pro Glu 825 Lys Leu Leu Met Tyr 830 His His\n\nAsp Pro Gln 835 Thr Tyr Gln Lys Leu 840 Lys Leu Ile Met Glu 845 Gin Tyr Gly\n\nMet\n\nGln\n\nLeu\n\nTyr 625\n\nAsn\n\n7385,\n\n420\n\nTle\n\nLeu\n\nGlu\n\nAsp 640\n\nLeu\n\n800\n\nUS 10,975,364 B2\n\n30\n\n29\n\ncontinued\n\nAsp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr\n\n855\n\n850\n\n860\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile\n\n870\n\n880\n\n865\n\n875\n\nLys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp\n\n890\n\n885\n\n895\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr\n\n905\n\n900\n\n910\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val\n\n915\n\n925\n\n920\n\nLys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser\n\n935\n\n940\n\n930\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala\n\n955\n\n945\n\n950\n\n960\n\nGlu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly\n\n965\n\n975\n\n970\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile\n\n980\n\n990\n\n985\n\nTyr Arg Glu Tyr Leu\n\nGlu Val Asn Met Ile Asp Ile Thr\n\nGlu Asn Met\n\n1005\n\n995\n\n1000\n\nAsn Asp\n\nAla Ser Lys\n\nLys Arg Pro Pro Arg\n\nIle Ile Lys Thr Ile\n\n1010\n\n1015\n\n1020\n\nSer Ile Lys Lys Tyr\n\nGly Asn Leu\n\nSer Thr Asp Ile Leu\n\nThr Gln\n\n1025\n\n1035\n\n1030\n\nLys Lys Gly\n\nTyr Glu\n\nVal Lys Ser Lys Lys\n\nHis Pro Gln Ile Ile\n\n1045\n\n1050\n\n1040\n\nGly Ser\n\nTyr Lys Asp\n\nPro Lys Lys Lys Arg Lys Val Ser Ser Asp\n\n1065\n\n1060\n\n1055\n\nHis Asp\n\nGly Asp Tyr Lys Asp His Asp Ile Asp Tyr\n\nLys Asp Asp\n\n1070\n\n1075\n\n1080\n\nAsp Asp Lys\n\n1085\n\n< 210 > SEQ ID NO 4\n\n< 211 > LENGTH : 1086\n\n< 212 > TYPE : PRT\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE :\n\n4\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val\n\n10\n\n15\n\n1\n\n5\n\nGly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly\n\n20\n\n25\n\n30\n\nVal Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg\n\n35\n\n40\n\n45\n\nSer Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile\n\n60\n\n50\n\n55\n\nGln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His\n\n65\n\n80\n\n70\n\n75\n\nSer Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu\n\n90\n\n85\n\n95\n\nSer Gin Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu\n\n110\n\n105\n\n100\n\nUS 10,975,364 B2\n\n29\n\n-cont inued\n\nGlu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn 850 855 860\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 865 870 875 880\n\nTyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp 885 890 895\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 900 905 910\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val 915 920 925\n\nAsn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn 930 935 940\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 945 950 955 960\n\nGlu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly 965 970 975\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 980 985 990\n\nGlu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met 995 1000 1005\n\nAsn Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser Lys 1010 1015 1020\n\nThr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu 1025 1030 1035\n\nTyr Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050\n\nGly Ser Pro Lys Lys Lys Arg Lys Val Ser Ser Asp Tyr Lys Asp 1055 1060 1065\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp 1070 1075 1080\n\nAsp Asp Lys 1085\n\n<210> SEQ ID NO 4 <211> LENGTH: 1086 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 4\n\nGly Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val 1 5 10 15\n\nGly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly 20 25 30\n\nval Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg 35 40 45\n\nLys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg 50 55 60\n\nArg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp 70 75\n\nGlu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly 85 90 95\n\nSer Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu 100 105 110\n\nAsp\n\nTyr\n\nLys\n\nAsp\n\nLys\n\nSer\n\nSer\n\nIle\n\nGln\n\nHis\n\n65\n\n80\n\nSer\n\nLeu\n\nUS 10,975,364 B2\n\n32\n\n31\n\ncontinued\n\nAla Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr\n\n115\n\n120\n\n125\n\nGly Asn Glu Leu Ser Thr Lys Glu Gin Ile Ser Arg Asn Ser Lys Ala\n\n135\n\n130\n\n140\n\nLeu Glu Glu Lys Tyr Val Ala Glu Leu Gin Leu Glu Arg Leu Lys Lys\n\n145\n\n150\n\n155\n\n160\n\nAsp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr\n\n165\n\n175\n\n170\n\nVal Lys Glu Ala Lys Gin Leu Leu Lys Val Gln Lys Ala Tyr His Gin\n\n190\n\n180\n\n185\n\nLeu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg\n\n205\n\n195\n\n200\n\nArg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys\n\n210\n\n220\n\n215\n\nAsp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe\n\n240\n\n235\n\n225\n\n230\n\nPro Glu Glu Leu Ala Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr\n\n245\n\n250\n\n255\n\nAsn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn\n\n270\n\n265\n\n260\n\nGlu Lys Leu Glu Tyr Tyr Glu Lys Phe Gin Ile Ile Glu Asn Val Phe\n\n285\n\n275\n\n280\n\nLys Gin Lys Lys Lys Pro Thr Leu Lys Gin Ile Ala Lys Glu Ile Leu\n\n295\n\n290\n\n300\n\nVal Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys\n\n305\n\n315\n\n310\n\n320\n\nPro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr\n\n330\n\n325\n\n335\n\nAla Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gin Ile Ala\n\n345\n\n350\n\n340\n\nLys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gin Glu Glu Leu\n\n355\n\n365\n\n360\n\nThr Asn Leu Asn Ser Glu Leu Thr Gin Glu Glu Ile Glu Gin Ile Ser\n\n380\n\n375\n\n370\n\nAsn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile\n\n400\n\n395\n\n385\n\n390\n\nAsn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Ala Gln Ile Ala\n\n410\n\n405\n\n415\n\nIle Phe Ala Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gin\n\n430\n\n420\n\n425\n\nGin Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro\n\n440\n\n445\n\n435\n\nVal Val Lys Arg Ser Phe Ile Gin Ser Ile Lys Val Ile Asn Ala Ile\n\n450\n\n455\n\n460\n\nIle Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg\n\n470\n\n475\n\n480\n\n465\n\nGlu Lys Asn Ser Lys Asp Ala Gin Lys Met Ile Asn Glu Met Gln Lys\n\n495\n\n485\n\n490\n\nArg Asn Arg Gin Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr\n\n500\n\n510\n\n505\n\nGly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp\n\n515\n\n520\n\n525\n\nUS 10,975,364 B2\n\n32\n\n31\n\n-cont inued\n\nAla Lys Arg 115 Arg Gly val His Asn 120 val Asn Glu val Glu 125 Glu Asp Thr\n\nAsn 130 Glu Leu Ser Thr Lys 135 Glu Gin Tle Ser Arg 140 Asn ser Lys\n\nLeu 145 Glu Glu Lys Tyr Val 150 Ala Glu Leu Gin Leu 155 Glu Arg Leu Lys Lys 160\n\nAsp Gly Glu Val Arg 165 Gly ser Tle Asn Arg 170 Phe Lys Thr Ser Asp 175 Tyr\n\nval Lys Glu Ala 180 Lys Gln Leu Leu Lys 185 Val Gln Lys Ala Tyr 190 His Gln\n\nLeu Asp Gin 195 Ser Phe Tle Asp Thr 200 Tyr Tle Asp Leu Leu 205 Glu Thr Arg\n\nThr 210 Tyr Tyr Glu Gly Pro 215 Gly Glu Gly Ser Pro 220 Phe Gly Trp\n\nAsp 225 Tle Lys Glu Trp Tyr 230 Glu Met Leu Met Gly 235 His cys Thr Tyr Phe 240\n\nPro Glu Glu Leu Ala 245 Ser val Lys Tyr Ala 250 Tyr Asn Ala Asp Leu 255 Tyr\n\nAsn Ala Leu Asn 260 Asp Leu Asn Asn Leu 265 Val Tle Thr Arg Asp 270 Glu Asn\n\nGlu Lys Leu 275 Glu Tyr Tyr Glu Lys 280 Phe Gin Tle Tle Glu 285 Asn Val Phe\n\nLys Gin 290 Lys Lys Lys Pro Thr 295 Leu Lys Gin Tle Ala 300 Lys Glu Ile Leu\n\nVal 305 Asn Glu Glu Asp Ile 310 Lys Gly Tyr Arg val 315 Thr Ser Thr Gly Lys 320\n\nPro Glu Phe Thr Asn 325 Leu Lys Val Tyr His 330 Asp Tle Lys Asp Ile 335 Thr\n\nAla Arg Lys Glu 340 Tle Tle Glu Asn Ala 345 Glu Leu Leu Asp Glin 350 Tle Ala\n\nLys Ile Leu 355 Thr Ile Tyr Gln Ser 360 Ser Glu Asp Tle Gin 365 Glu Glu Leu\n\nThr Asn 370 Leu Asn Ser Glu Leu 375 Thr Gln Glu Glu Tle 380 Glu Gln Ile Ser\n\nAsn 385 Leu Lys Gly Tyr Thr 390 Gly Thr His Asn Leu 395 Ser Leu Lys Ala Ile 400\n\nAsn Leu Ile Leu Asp 405 Glu Leu Trp His Thr 410 Asn Asp Ala Gin Ile 415 Ala\n\nTle Phe Ala Arg 420 Leu Lys Leu val Pro 425 Lys Lys Val Asp Leu 430 Ser Gin\n\nGin Lys Glu 435 Ile Pro Thr Thr Leu 440 Val Asp Asp Phe Ile 445 Leu Ser Pro\n\nVal 450 Lys Arg Ser Phe Ile 455 Gln Ser Ile Lys Val 460 Ile Asn Ala Tle\n\nLys Lys Tyr Gly Leu 470 Pro Asn Asp Ile Tle 475 Tle Glu Leu Ala Arg 480\n\nLys Asn Ser Lys 485 Asp Ala Gin Lys Met 490 Tle Asn Glu Met Gin 495\n\nArg Asn Arg Gln 500 Thr Asn Glu Arg Ile 505 Glu Glu Tle Ile Arg 510 Thr Thr\n\nLys Glu 515 Asn Ala Lys Tyr Leu 520 Ile Glu Lys Tle Lys 525 Leu His\n\nGly\n\nArg\n\nGly\n\nAla\n\nLys\n\nLys\n\nAsp\n\nUS 10,975,364 B2\n\n34\n\n33\n\ncontinued\n\nMet Gin Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu\n\n535\n\n530\n\n540\n\nAsp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro\n\n545\n\n550\n\n555\n\n560\n\nArg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys\n\n565\n\n575\n\n570\n\nGin Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gin Tyr Leu\n\n585\n\n580\n\n590\n\nSer Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile\n\n595\n\n600\n\n605\n\nLeu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu\n\n615\n\n610\n\n620\n\nTyr Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gin Lys Asp\n\n625\n\n635\n\n630\n\n640\n\nPhe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Ala Gly Leu\n\n650\n\n655\n\n645\n\nMet Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys\n\n665\n\n670\n\n660\n\nVal Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp\n\n675\n\n680\n\n685\n\nLys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp\n\n700\n\n690\n\n695\n\nAla Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys\n\n720\n\n710\n\n705\n\n715\n\nLeu Asp Lys Ala Lys Lys Val Met Glu Asn Gin Met Phe Glu Glu Lys\n\n730\n\n735\n\n725\n\nGln Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gin Glu Tyr Lys Glu\n\n750\n\n740\n\n745\n\nIle Phe Ile Thr Pro His Gin Ile Lys His Ile Lys Asp Phe Lys Asp\n\n765\n\n755\n\n760\n\nTyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Lys Leu Ile\n\n780\n\n770\n\n775\n\nAsn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu\n\n790\n\n795\n\n800\n\n785\n\nIle Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu\n\n805\n\n810\n\n815\n\nLys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His\n\n825\n\n830\n\n820\n\nAsp Pro Gin Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gin Tyr Gly\n\n840\n\n845\n\n835\n\nAsp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr\n\n855\n\n850\n\n860\n\nLeu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile\n\n875\n\n865\n\n870\n\n880\n\nLys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp\n\n895\n\n890\n\n885\n\nTyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr\n\n905\n\n910\n\n900\n\nArg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val\n\n915\n\n920\n\n925\n\nLys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser\n\n930\n\n935\n\n940\n\nLys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gin Ala\n\nUS 10,975,364 B2\n\n34\n\n33\n\n-cont inued\n\nGln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu 530 535 540\n\nLeu Leu Asn Asn Pro 550 Phe Asn Tyr Glu Val 555 Asp His Tle Tle\n\nArg Ser val Ser Phe 565 Asp Asn Ser Phe Asn 570 Asn Lys Val Leu Val 575, Lys\n\nGin Glu Glu Asn 580 Ser Lys Lys Gly 585 Arg Thr Pro Phe Gln 590 Tyr Leu\n\nSer Ser 595 Asp Ser Lys Tle Ser 600 Glu Thr Phe Lys 605 Lys His\n\nLeu Asn 610 Leu Ala Lys Gly Lys 615 Gly Tle Ser Lys 620 Thr Lys Lys Glu\n\nTyr 625 Leu Leu Glu Glu Arg 630 Asp Tle Asn Arg Phe 635 Ser Val Glin Lys Asp 640\n\nTle Asn Arg Asn 645 Leu Val Asp Thr Arg 650 Tyr Ala Thr Ala Gly 655\n\nMet Asn Leu Leu 660 Arg Ser Tyr Phe Arg 665 Val Asn Asn Leu Asp 670 Val Lys\n\nval Lys Ser 675 Ile Asn Gly Gly Phe 680 Thr Ser Phe Leu Arg 685 Arg Lys Trp\n\nLys Phe 690 Lys Lys Glu Arg Asn 695 Lys Gly Tyr Lys His 700 His Ala Glu Asp\n\nLeu Tle Tle Ala Asn 710 Ala Asp Phe Tle Phe 715 Lys Glu Trp Lys\n\nAsp Lys Ala Lys 725 Lys Val Met Glu Asn 730 Gln Met Phe Glu Glu 735,\n\nGln Ala Glu Ser 740 Met Pro Glu Ile Glu 745 Thr Glu Gln Glu Tyr 750 Lys Glu\n\nTle Phe Tle 755 Thr Pro His Gin Tle 760 Lys His Tle Lys Asp 765 Phe Lys Asp\n\nLys 770 Tyr Ser His Arg Val 775, Asp Lys Lys Pro Asn 780 Arg Lys Leu\n\nAsn 7385, Asp Thr Leu Tyr Ser 790 Thr Arg Lys Asp Asp 735, Lys Gly Asn Thr Leu 800\n\nVal Asn Asn Leu 805 Asn Gly Leu Tyr Asp 810 Lys Asp Asn Asp Lys 815\n\nLys Lys Leu Ile 820 Asn Lys Ser Pro Glu 825 Lys Leu Leu Met Tyr 830 His His\n\nAsp Pro Gin 835 Thr Tyr Gin Lys Leu 840 Lys Leu Tle Met Glu 845 Glin Tyr Gly\n\nGlu 850 Lys Asn Pro Leu Tyr 855 Lys Tyr Tyr Glu Glu 860 Thr Gly Asn Tyr\n\nLeu 865 Thr Lys Tyr Ser Lys 870 Lys Asp Asn Gly Pro 875, Val Ile Lys Lys Tle 880\n\nLys Tyr Tyr Gly Asn 885 Lys Leu Asn Ala His 890 Leu Asp Tle Thr Asp 895 Asp\n\nTyr Pro Asn Ser 900 Arg Asn Lys val Val 905 Lys Leu Ser Leu Lys 910 Pro Tyr\n\nArg Phe Asp 915 val Tyr Leu Asp Asn 920 Gly Val Tyr Lys Phe 925 val Thr Val\n\nLys Asn 930 Leu Asp Val Tle Lys 935 Lys Glu Asn Tyr Tyr 940 Glu Val Asn Ser\n\nLys cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Tle Ser Asn Gin Ala\n\nMet\n\nGlu\n\nAsp 545\n\nSer\n\nPhe\n\nAla\n\n705,\n\nLeu\n\nTyr\n\nIle\n\nAsp\n\nPro\n\n560\n\nIle\n\nLeu\n\nLys 720\n\nLys\n\nTle\n\nLeu\n\nUS 10,975,364 B2\n\n36\n\n35\n\ncontinued\n\n945\n\n955\n\n950\n\n960\n\nGlu Phe Ile Ala Ser Phe Tyr Lys Asn Asp Leu Ile Lys Ile Asn Gly\n\n975\n\n970\n\n965\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile\n\n985\n\n990\n\n980\n\nTyr Arg Glu Tyr Leu\n\nGlu Val Asn Met Ile Asp Ile Thr\n\nGlu Asn Met\n\n1000\n\n1005\n\n995\n\nAsn Asp\n\nLys Arg Pro Pro His\n\nAla Ser Lys\n\nIle Ile Lys Thr Ile\n\n1015\n\n1020\n\n1010\n\nSer Ile Lys Lys Tyr\n\nGly Asn Leu\n\nSer Thr Asp Ile Leu\n\nThr Gln\n\n1035\n\n1025\n\n1030\n\nLys Lys Gly\n\nTyr Glu\n\nVal Lys Ser Lys Lys\n\nHis Pro Gln Ile Ile\n\n1045\n\n1050\n\n1040\n\nPro Lys Lys Lys Arg\n\nTyr Lys Asp\n\nGly Ser\n\nLys Val Ser Ser Asp\n\n1065\n\n1060\n\n1055\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr\n\nLys Asp Asp\n\n1070\n\n1075\n\n1080\n\nAsp Asp\n\nLys\n\n1085\n\n< 210 > SEQ ID NO 5\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 5\n\ncaaggcgagg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 6\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE :\n\n6\n\ncaaggcgagg agctgttctg cggggt\n\n26\n\n< 210 > SEQ ID NO 7\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 7\n\ncaaggcgagg agctgttagc cggggt\n\n26\n\n< 210 > SEQ ID NO 8\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 8\n\ncaaggcgagg agctgcacac cggggt\n\n26\n\n< 210 > SEQ ID NO 9\n\nUS 10,975,364 B2\n\n36\n\n35\n\n-cont inued\n\n945\n\nGlu Phe Ile Ala Ser Phe Tyr Lys Asn Asp Leu Ile Lys Ile Asn Gly 965 970 975\n\nGlu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 980 985 990\n\nGlu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met 995 1000 1005\n\nAsn Asp Lys Arg Pro Pro His Ile Ile Lys Thr Ile Ala Ser Lys 1010 1015 1020\n\nThr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu 1025 1030 1035\n\nTyr Glu val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050\n\nGly Ser Pro Lys Lys Lys Arg Lys Val Ser Ser Asp Tyr Lys Asp 1055 1060 1065\n\nHis Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp 1070 1075 1080\n\nAsp Asp Lys 1085\n\n<210> SEQ ID NO 5 <211> <212> <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 5\n\ncaaggcgagg agetgttcac cggggt\n\n26\n\n<210> SEQ ID NO 6 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 6\n\ncaaggcgagg agetgttctg cggggt\n\n26\n\n<210> SEQ ID NO 7 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 7\n\ncaaggcgagg agetgttage eggggt\n\n26\n\n<210> SEQ ID No 8 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 8\n\ncaaggcgagg agctgcacac eggggt\n\n26\n\n<210> SEQ ID NO 9\n\n950\n\n955\n\n960\n\nUS 10,975,364 B2\n\n38\n\n37\n\ncontinued\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE :\n\n9\n\ncaaggcgagg agcgattcac cggggt\n\n26\n\n< 210 > SEQ ID NO 10\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 10\n\ncaaggcgagg atctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 11\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 11\n\ncaaggcgagc cgctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 12\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 12\n\ncaaggcgctg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 13\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 13\n\ncaaggcgagg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 14\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 14\n\ncaacccgagg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 15\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 15\n\nUS 10,975,364 B2\n\n37\n\n38\n\n-cont inued\n\n<211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 9\n\n26\n\ncaaggcgagg agegattcac eggggt\n\nSEQ ID NO 10 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 10\n\ncaaggcgagg atetgttcac eggggt\n\n26\n\n<210> SEQ ID NO 11 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 11\n\ncaaggegage cgctgttcac eggggt\n\n26\n\n<210> SEQ ID NO 12 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 12\n\ncaaggcgctg agetgttcac eggggt\n\n26\n\n<210> SEQ ID NO 13 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 13\n\n26\n\ncaaggcgagg agetgttcac cggggt\n\nSEQ ID NO 14 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: OTHER INFORMATION:\n\n<400> SEQUENCE: 14\n\n26\n\ncaacccgagg agetgttcac cggggt\n\n<210> SEQ ID NO 15 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 15\n\n<210>\n\n<210>\n\n<223>\n\nSynthesized\n\nUS 10,975,364 B2\n\n40\n\n39\n\ncontinued\n\ncttggcgagg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 16\n\n< 211 > LENGTH : 26\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 16\n\ngtaggcgagg agctgttcac cggggt\n\n26\n\n< 210 > SEQ ID NO 17\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 17\n\ngcaaccacaa acccacgagg gnngrrt\n\n27\n\n< 210 > SEQ ID NO 18\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 18\n\ngcaaccacaa acccacgagg gcagagt\n\n27\n\n< 210 > SEQ ID NO 19\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 19\n\nacaaacacat acccacaagg acagagt\n\n27\n\n< 210 > SEQ ID NO 20\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 20\n\ngcaatcacaa taccacaagg gaagagg\n\n27\n\n< 210 > SEQ ID NO 21\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 21\n\ngcttccaccc agccacgaag gcagggt\n\n27\n\nUS 10,975,364 B2\n\n39\n\n40\n\n-cont inued\n\n26\n\ncttggcgagg agctgttcac cggggt\n\n<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 16 gtaggcgagg agetgttcac cggggt <210> SEQ ID NO 17 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23 <223> OTHER INFORMATION: n is a, \u00a2, g <400> SEQUENCE: 17 geaaccacaa acccacgagg gnngrrt <210> SEQ ID NO 18 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 18 geaaccacaa acccacgagg gcagagt <210> SEQ ID NO 19 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 19 acaaacacat acccacaagg acagagt <210> SEQ ID NO 20 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 20 geaatcacaa taccacaagg gaagagg toru\n\n26\n\n27\n\n27\n\n27\n\n27\n\n<210> SEQ ID NO 21 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 21\n\n27\n\ngettccacce agccacgaag gcagggt\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n16\n\n<211>\n\nLENGTH:\n\n26\n\nUS 10,975,364 B2\n\n42\n\n41\n\ncontinued\n\n< 210 > SEQ ID NO 22\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 22\n\ngccacccctc acccactagg ataccaa\n\n27\n\n< 210 > SEQ ID NO 23\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 23\n\ngccatcacac acccacgctt tgctgat\n\n27\n\n< 210 > SEQ ID NO 24\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 24\n\nacaaccacaa agccacaggg gtagagt\n\n27\n\n< 210 > SEQ ID NO 25\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 25\n\n27\n\ngggtgagtga gtgtgtgcgt gnngrrt\n\n< 210 > SEQ ID NO 26\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 26\n\ngggtgagtga gtgtgtgcgt gtggggt\n\n27\n\n< 210 > SEQ ID NO 27\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 27\n\ngggtgagtca gtg\n\nagt gg gagt\n\n27\n\n< 210 > SEQ ID NO 28\n\n< 211 > LENGTH : 27\n\nUS 10,975,364 B2\n\n42\n\n41\n\n-cont inued\n\n<220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 22 gccacccctc acccactagg ataccaa <210> SEQ ID NO 23 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 23 gccatcacac acccacgctt tgetgat <210> SEQ ID NO 24 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 24 acaaccacaa agecacaggg gtagagt <210> SEQ ID NO 25 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, c, g, <400> SEQUENCE: 25 gggtgagtga gtgtgtgegt gnngrrt <210> SEQ ID NO 26 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 26 gggtgagtga gtgtgtgegt gtggggt <210> SEQ ID NO 27 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: toru 27 27 27 27 27\n\n<400> SEQUENCE: 27\n\n27\n\ngggtgagtca gtgtgtgagt ggagagt\n\n<210> SEQ ID NO 28 <211> LENGTH: 27\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n22\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\nUS 10,975,364 B2\n\n44\n\n43\n\ncontinued\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 28\n\ngagtgaatga gtgtgtgtgt gtggggt\n\n27\n\n< 210 > SEQ ID NO 29\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 29\n\ngggtgagtga gtgagtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 30\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 30\n\ngggtgagtca gtgagtgcgt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 31\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 31\n\ngggtgagtca gtgtgtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 32\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 32\n\ngggtgagtca gtgagtgcgt gatgagt\n\n27\n\n< 210 > SEQ ID NO 33\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 33\n\ngagcgagtgg gtgtgtgcgt ggggggt\n\n27\n\n< 210 > SEQ ID NO 34\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 34\n\nUS 10,975,364 B2\n\n44\n\n43\n\n-cont inued\n\n<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 28\n\ngagtgaatga gtgtgtgtgt gtggggt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 29\n\ngggtgagtga gtgagtgagt ggtgagt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 30\n\ngggtgagtca gtgagtgegt ggtgagt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 31\n\ngggtgagtca gtgtgtgagt ggtgagt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 32\n\ngggtgagtca gtgagtgegt gatgagt\n\n27\n\n<210> SEQ ID NO 33 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 33\n\n27\n\ngagegagtgg gtgtgtgyegt ggggggt\n\n<210> SEQ ID NO 34 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 34\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n29\n\n<210>\n\nID\n\nNO\n\n30\n\n<210>\n\nID\n\nNO\n\n31\n\n<210>\n\nID\n\nNO\n\n32\n\nUS 10,975,364 B2\n\n46\n\n45\n\ncontinued\n\ngagtgagtga gtgtgtgtgt ggggggg\n\n27\n\n< 210 > SEQ ID NO 35\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 35\n\ngggtgagtca gtgtgtgggt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 36\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 36\n\nggatgagtga gtgagtgagt ggggagt\n\n27\n\n< 210 > SEQ ID NO 37\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 37\n\ngggtgagtga gtgagtgagt ggtgggt\n\n27\n\n< 210 > SEQ ID NO 38\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 38\n\ngggtgtgtgt ctgtgtgcgt gtggggt\n\n27\n\n< 210 > SEQ ID NO 39\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 39\n\nggatgagtga gtgagtgcat gttgagt\n\n27\n\n< 210 > SEQ ID NO 40\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 40\n\ngggtgagtga gtgagtgagt gagtggt\n\n27\n\n< 210 > SEQ ID NO 41\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\nUS 10,975,364 B2\n\n45\n\n46\n\n-cont inued\n\n27\n\ngagtgagtga gtgtgtgtgt ggggggg\n\n<210> SEQ ID NO 35 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 35\n\n27\n\ngggtgagtca gtgtgtgggt ggtgagt\n\n<210> SEQ ID NO 36 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 36\n\n27\n\nggatgagtga gtgagtgagt ggggagt\n\n<210> SEQ ID NO 37 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 37\n\n27\n\ngggtgagtga gtgagtgagt ggtgggt\n\n<210> SEQ ID NO 38 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE:\n\n27\n\ngggtgtgtgt ctgtgtgegt gtggggt\n\n<210> SEQ ID NO 39 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 39\n\n27\n\nggatgagtga gtgagtgeat gttgagt\n\n<210> SEQ ID NO 40 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 40\n\ngggtgagtga gtgagtgagt gagtggt\n\n27\n\n<210> SEQ ID NO 41 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence\n\n38\n\nUS 10,975,364 B2\n\n48\n\n47\n\ncontinued\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 41\n\naggtgaccgt gtgtgtgcgt ggagggt\n\n27\n\n< 210 > SEQ ID NO 42\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 42\n\ngggtgagtca ctgtgtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 43\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 43\n\ngagtgagtga gtgagtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 44\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 44\n\ngggtgaaaga gtatgatggg gtggtgg\n\n27\n\n< 210 > SEQ ID NO 45\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 45\n\ngagtgagtga gtgagtgagt gatgaat\n\n27\n\n< 210 > SEQ ID NO 46\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 46\n\naggtgagtga gtgtgtgtgt gttgggg\n\n27\n\n< 210 > SEQ ID NO 47\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 47\n\ngggtgagtga gtgagtgggt ggtgagt\n\n27\n\nUS 10,975,364 B2\n\n48\n\n47\n\n-cont inued\n\n<220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 41\n\n27\n\naggtgacegt gtgtgtgegt ggagggt\n\n<210> SEQ ID NO 42 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 42\n\n27\n\ngggtgagtca etgtgtgagt ggtgagt\n\n<210> SEQ ID NO 43 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 43\n\n27\n\ngagtgagtga gtgagtgagt ggtgagt\n\n<210> SEQ ID NO 44 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 44\n\n27\n\ngggtgaaaga gtatgatggy gtggtgg\n\n<210> SEQ ID NO 45 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 45\n\n27\n\ngagtgagtga gtgagtgagt gatgaat\n\n<210> SEQ ID NO 46 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 46\n\n27\n\naggtgagtga gtgtgtgtgt gttgggg\n\n<210> SEQ ID NO 47 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 47\n\n27\n\ngggtgagtga gtgagtgggt ggtgagt\n\nSynthesized\n\nUS 10,975,364 B2\n\n49\n\n50\n\ncontinued\n\n< 210 > SEQ ID NO 48\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 48\n\ngaatgagtga gtgtgtgagt ggagaat\n\n27\n\n< 210 > SEQ ID NO 49\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 49\n\ngggtgagtga gtgagtgaga ggtgagt\n\n27\n\n< 210 > SEQ ID NO 50\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 50\n\ngggtgagtca gtgcgtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 51\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 51\n\ngtgtgagcgt gtgtgtgcgt ggagatg\n\n27\n\n< 210 > SEQ ID NO 52\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 52\n\ntggtgagtga gtgagtgagt gagtgag\n\n27\n\n< 210 > SEQ ID NO 53\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 53\n\ntggtgagtga gtgagtgagt gatgggt\n\n27\n\n< 210 > SEQ ID NO 54\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\nUS 10,975,364 B2\n\n50\n\n49\n\n-cont inued\n\nSEQ ID NO 48 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 48\n\ngaatgagtga gtgtgtgagt ggagaat\n\n27\n\n<210> SEQ ID NO 49 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 49\n\ngggtgagtga gtgagtgaga ggtgagt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 50\n\ngggtgagtca gtgegtgagt ggtgagt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE:\n\ngtgtgagegt gtgtgtgegt ggagatg\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 52\n\n27\n\ntggtgagtga gtgagtgagt gagtgag\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 53\n\n27\n\ntggtgagtga gtgagtgagt gatgggt\n\n<210> SEQ ID NO 54 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<210>\n\nSynthesized\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n50\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n51\n\n51\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n52\n\nSynthesized\n\n<210>\n\nID\n\nNO\n\n53\n\nUS 10,975,364 B2\n\n52\n\n51\n\ncontinued\n\n< 400 > SEQUENCE : 54\n\ngggtgagtga gtgagtgagt ggtgaat\n\n27\n\n< 210 > SEQ ID NO 55\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 55\n\ngagtgagtca gtgtgtgagt ggtgagt\n\n27\n\n< 210 > SEQ ID NO 56\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 56\n\ngggtgagtca gtgagtgagt gacgagt\n\n27\n\n< 210 > SEQ ID NO 57\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 57\n\ngtgtgggtga gtgtgtgcgt gaggaca\n\n27\n\n< 210 > SEQ ID NO 58\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 58\n\ngtgtgtgtga gtgtgtgtgt gtggggg\n\n27\n\n< 210 > SEQ ID NO 59\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 59\n\ngggagagaga gagagagaga gagagag\n\n27\n\n< 210 > SEQ ID NO 60\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 60\n\ngggagaggga gagggagaga gottttt\n\n27\n\n< 210 > SEQ ID NO 61\n\nUS 10,975,364 B2\n\n52\n\n51\n\n-cont inued\n\n<400> SEQUENCE: 54\n\n27\n\ngggtgagtga gtgagtgagt ggtgaat\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 55\n\ngagtgagtca gtgtgtgagt ggtgagt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 56\n\ngggtgagtca gtgagtgagt gacgagt\n\n27\n\nSEQ <211> <212> <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 57\n\ngtgtgggtga gtgtgtgegt gaggaca\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 58\n\ngtgtgtgtga gtgtgtgtgt gtggggg\n\n27\n\n<210> SEQ ID NO 59 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 59\n\ngggagagaga gagagagaga gagagag\n\n27\n\n<210> SEQ ID NO 60 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 60\n\n27\n\ngggagaggga gagggagaga gettttt\n\n<210> SEQ ID NO 61\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n55\n\n<210>\n\nID\n\nNO\n\n56\n\n<210>\n\nID\n\nNO\n\n57\n\n<210>\n\nID\n\nNO\n\n58\n\nSynthesized\n\nUS 10,975,364 B2\n\n54\n\n53\n\ncontinued\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 61\n\ngggagaggga gagggagagg gaactga\n\n27\n\n< 210 > SEQ ID NO 62\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 62\n\ngggagaggga gagggagagg gctatta\n\n27\n\n< 210 > SEQ ID NO 63\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 63\n\ngggtaagtga gtgagtgagt gagtggt\n\n27\n\n< 210 > SEQ ID NO 64\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 64\n\ngggtgagggg ttgtgggtgg agcttat\n\n27\n\n< 210 > SEQ ID NO 65\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 65\n\ngggtgggtag gtttgttggt atcctag\n\n27\n\n< 210 > SEQ ID NO 66\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 23 ) .. ( 24 )\n\n< 223 > OTHER INFORMATION : n is a , C , g , t or u\n\n< 400 > SEQUENCE : 66\n\ngtgtggttcc agaaccggag gannarrt\n\n28\n\n< 210 > SEQ ID NO 67\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\nUS 10,975,364 B2\n\n54\n\nS3\n\n-cont inued\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE:\n\n27\n\ngggagaggga gagggagagg gaactga\n\n<210> SEQ ID NO 62 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 62\n\n27\n\ngggagaggga gagggagagg gctatta\n\n<210> SEQ ID NO 63 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 63\n\n27\n\ngggtaagtga gtgagtgagt gagtggt\n\n<210> SEQ ID NO 64 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 64\n\n27\n\ngggtgagggg ttgtgggtgg agettat\n\n<210> SEQ ID NO 65 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 65\n\n27\n\ngggtgggtag gtttgttggt atcctag\n\n<210> SEQ ID NO 66 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (23). .(24) <223> OTHER INFORMATION: n is a, c, g,\n\n<400> SEQUENCE: 66\n\ngtgtggttce agaaccggag gannarrt\n\n28\n\n<210> SEQ ID NO 67 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence\n\n61\n\ntoru\n\nUS 10,975,364 B2\n\n56\n\n55\n\ncontinued\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 67\n\ngtgtggttcc agaaccggag gacaaagt\n\n28\n\n< 210 > SEQ ID NO 68\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 68\n\ngtgtggttcc agaaccgaag gatgaagt\n\n28\n\n< 210 > SEQ ID NO 69\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 69\n\natctggttcc agaaccggag gatgaagt\n\n28\n\n< 210 > SEQ ID NO 70\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 70\n\ngtgtggtttc agaaccggag gatgaagc\n\n28\n\n< 210 > SEQ ID NO 71\n\n< 211 > LENGTH : 29\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 71\n\natcgtggttc cagaaccgaa ggatgaagt\n\n29\n\n< 210 > SEQ ID NO 72\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c ,\n\ng\n\nt or u\n\n< 400 > SEQUENCE : 72\n\ngcaaggcccg gcgcacggtg gnngrrt\n\n27\n\n< 210 > SEQ ID NO 73\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\nUS 10,975,364 B2\n\n56\n\nSS\n\n-cont inued\n\n<220> FEATURE:\n\n<223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 67\n\n28\n\ngtgtggttcc agaaccggag gacaaagt\n\n<210> SEQ ID NO 68 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE:\n\n28\n\ngtgtggttce agaaccgaag gatgaagt\n\n<210> SEQ ID NO 69 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 69\n\n28\n\natctggttce agaaccggag gatgaagt\n\n<210> SEQ ID NO 70 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 70\n\n28\n\ngtgtggtttc agaaccggag gatgaage\n\n<210> SEQ ID NO 71 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n29\n\natcgtggttc cagaaccgaa ggatgaagt\n\n<210> SEQ ID NO 72 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23 <223> OTHER INFORMATION: n is a, \u00a2, g\n\n<400> SEQUENCE: 72\n\ngeaaggeceg gcgcacggtg gnngrrt\n\n27\n\n<210> SEQ ID NO 73 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n68\n\n<400>\n\nSEQUENCE:\n\n71\n\ntoru\n\nUS 10,975,364 B2\n\n58\n\n57\n\ncontinued\n\n< 400 > SEQUENCE : 73\n\ngcaaggcccg gcgcacggtg gcggggt\n\n27\n\n< 210 > SEQ ID NO 74\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 74\n\ngcaaggcctg gcccactgtg gcaggat\n\n27\n\n< 210 > SEQ ID NO 75\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 75\n\ngcaagggctg gggagcggtg ggaggaa\n\n27\n\n< 210 > SEQ ID NO 76\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 76\n\ngtaaggccaa gtacacagtg ggtgagt\n\n27\n\n< 210 > SEQ ID NO 77\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 77\n\n27\n\ngcaaggccag gagcacgggt ggcagag\n\n< 210 > SEQ ID NO 78\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 78\n\nctgaggcccg gcccacggtg gtgagga\n\n27\n\n< 210 > SEQ ID NO 79\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 79\n\n???? ctcg goccacgggg gctgagg\n\n27\n\n< 210 > SEQ ID NO 80\n\n< 211 > LENGTH : 27\n\nUS 10,975,364 B2\n\n58\n\nS7\n\n-cont inued\n\n<400> SEQUENCE: 73\n\n27\n\ngcaaggcccg gcgcacggtg geggggt\n\n<210> SEQ ID NO 74 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 74\n\n27\n\ngcaaggcctg gcccactgtg gcaggat\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 75\n\ngcaagggctg gggagcggtg ggaggaa\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 76\n\ngtaaggccaa gtacacagtg ggtgagt\n\n27\n\n<210> SEQ ID NO 77 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 77\n\ngcaaggccag gagcacgggt ggcagag\n\n27\n\n<210> SEQ ID NO 78 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE:\n\n27\n\nctgaggcccg geecacggtg gtgagga\n\n<210> SEQ ID NO 79 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 79\n\n27\n\nacaaggctcg geecacgggg getgagg\n\n<210> SEQ ID NO 80 <211> LENGTH: 27\n\nSynthesized\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n75\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n76\n\n78\n\nUS 10,975,364 B2\n\n59\n\n60\n\ncontinued\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 80\n\ncagaggccag gcgcacggag agggagt\n\n27\n\n< 210 > SEQ ID NO 81\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 81\n\nacaaggccag agacacagtt ggggagt\n\n27\n\n< 210 > SEQ ID NO 82\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 82\n\ngctgggccag gagcacagtg gtgggga\n\n27\n\n< 210 > SEQ ID NO 83\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 83\n\nacaaggctca gaacacggtg agaaagt\n\n27\n\n< 210 > SEQ ID NO 84\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , 9 , t or u\n\n< 400 > SEQUENCE : 84\n\ngtagggcctt cgcgcacctc anngrrt\n\n27\n\n< 210 > SEQ ID NO 85\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 85\n\ngtagggcctt cgcgcacctc anngaat\n\n27\n\n< 210 > SEQ ID NO 86\n\nUS 10,975,364 B2\n\nS9\n\n60\n\n-cont inued\n\n<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 80\n\ncagaggccag gcgcacggag agggagt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 81\n\nacaaggccag agacacagtt ggggagt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 82\n\ngetgggecag gagcacagtg gtgggga\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 83\n\nacaaggetca gaacacggtg agaaagt\n\n27\n\n<400> SEQUENCE: 84\n\ngtagggeett egegeaccte anngrrt\n\n27\n\n<210> SEQ ID NO 85 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, cr g, toru\n\n<400> SEQUENCE: 85\n\n27\n\ngtagggeett egegeaccte anngaat\n\n<210> SEQ ID NO 86\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n81\n\n<210>\n\nID\n\nNO\n\n82\n\n<210>\n\nID\n\nNO\n\n83\n\n<210>\n\nSEQ LENGTH:\n\nID\n\nNO\n\n84\n\n<211>\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<220>\n\nFEATURE: NAME/KEY: LOCATION:\n\n<221>\n\nmisc_feature (22). . (23) INFORMATION:\n\n<222>\n\n<223>\n\nOTHER\n\nn\n\nis\n\na,\n\nc,\n\n\u53ef\n\ntoru\n\nUS 10,975,364 B2\n\n62\n\n61\n\ncontinued\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 86\n\ngaaagagaga tgtagggcta gnngrrt\n\n27\n\n< 210 > SEQ ID NO 87\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 87\n\ngaaagagaga tgtagggcta gnngggt\n\n27\n\n< 210 > SEQ ID NO 88\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 88\n\ngaaagaaagc tgcagggcaa gnngaat\n\n27\n\n< 210 > SEQ ID NO 89\n\n< 211 > LENGTH : 29\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 24 ) .. ( 25 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 89\n\ngtactcacct ctcatgaagc actnngrrt\n\n29\n\n< 210 > SEQ ID NO 90\n\n< 211 > LENGTH : 29\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n?\n\n< 222 > LOCATION :\n\n( 24 ) .. ( 25 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 90\n\ngtactcacct ctcatgaagc actnngggt\n\n29\n\nUS 10,975,364 B2\n\n62\n\n61\n\n-cont inued\n\n<211> LENGTH: 27\n\n<220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, c, g, <400> SEQUENCE: 86 gaaagagaga tgtagggcta gnngrrt <210> SEQ ID NO 87 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, c, g, <400> SEQUENCE: 87 gaaagagaga tgtagggcta gnngggt <210> SEQ ID NO 88 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, c, \u53ef <400> SEQUENCE: 88 gaaagaaage tgcagggeaa gnngaat <210> SEQ ID NO 89 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (24). . (25) <223> OTHER INFORMATION: n is a, c, \u53ef <400> SEQUENCE: 89 gtactcacct ctcatgaagc actnngrrt <210> SEQ ID NO 90 <211> LENGTH: 29 toru toru toru toru\n\n27\n\n27\n\n27\n\n29\n\n<400> SEQUENCE: 90\n\n29\n\ngtactcacct ctcatgaage actnngggt\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<220>\n\nFEATURE:\n\n<221>\n\nNAME/KEY:\n\nmisc\n\nfeature\n\n<222>\n\nLOCATION:\n\n(24).. (25)\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nn\n\nis\n\na,\n\nc,\n\ng,\n\ntoru\n\nUS 10,975,364 B2\n\n64\n\n63\n\ncontinued\n\n< 210 > SEQ ID NO 91\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 91\n\ngctcagcctg agtgttgagg cnncrrt\n\n27\n\n< 210 > SEQ ID NO 92\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 92\n\nctgcagactg agtgttaagg ccggagt\n\n27\n\n< 210 > SEQ ID NO 93\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 93\n\ncctcagcctg agtgttgagg ctgcggt\n\n27\n\n< 210 > SEQ ID NO 94\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 94\n\ngctcagcctg tgtgttcagg caggagg\n\n27\n\n< 210 > SEQ ID NO 95\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 95\n\ngctcagcctg agtgttgagg ccccagt\n\n27\n\n< 210 > SEQ ID NO 96\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 96\n\nggctctccga ggagaaggcc anntrrt\n\n27\n\nUS 10,975,364 B2\n\n64\n\n63\n\n-cont inued\n\n<210> SEQ ID NO 91\n\n<223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, \u00a2, g, <400> SEQUENCE: 91 gctcagcctg agtgttgagg cnncrrt <210> SEQ ID NO 92 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 92 ctgcagactg agtgttaagg ceggagt <210> SEQ ID NO 93 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 93 cctcagcctg agtgttgagg etgeggt <210> SEQ ID NO 94 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 94 gctcagcctg tgtgttcagg caggagg <210> SEQ ID NO 95 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 95 gctcagcctg agtgttgagg ccccadgt toru 27 27 27 27 27\n\n<400> SEQUENCE: 96\n\n27\n\nggctctccga ggagaaggcc anntrrt\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n96\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<220>\n\nFEATURE:\n\n<221>\n\nNAME/KEY:\n\nmisc\n\nfeature\n\n<222>\n\nLOCATION:\n\n(22). .(23)\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nn\n\nis\n\na,\n\nc,\n\ng,\n\ntoru\n\nUS 10,975,364 B2\n\n66\n\n65\n\ncontinued\n\n< 210 > SEQ ID NO 97\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , g , t or u\n\n< 400 > SEQUENCE : 97\n\nggctctccga tgggagggcc anngaat\n\n27\n\n< 210 > SEQ ID NO 98\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 98\n\nagctctccga ggagaagagc anngagg\n\n27\n\n< 210 > SEQ ID NO 99\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 99\n\nggctctctggggagaaagcc anngago\n\n27\n\n< 210 > SEQ ID NO 100\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 100\n\natctctccga ggaggaggcg anngagt\n\n27\n\n< 210 > SEQ ID NO 101\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C ,\n\nt or u\n\n< 400 > SEQUENCE : 101\n\nggctctcaga ggagaaggcc gnnggga\n\n27\n\nUS 10,975,364 B2\n\n65\n\n66\n\n-cont inued\n\n<223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, \u00a2, g, <400> SEQUENCE: 97 ggctctccga tgggagggcc anngaat <210> SEQ ID NO 98 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22).. (23) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 98 agetctcega ggagaagage anngagg <210> SEQ ID NO 99 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 99 ggctctctgg ggagaaagee anngage <210> SEQ ID NO 100 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (22) .. (23) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 100 atctctccga ggaggaggeg anngagt <210> SEQ ID NO 101 toru toru toru toru\n\n27\n\n27\n\n27\n\n27\n\n<400> SEQUENCE: 101\n\n27\n\nggetctcaga ggagaaggee gnnggga\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n97\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<220>\n\nFEATURE:\n\n<221>\n\nNAME/KEY:\n\nmisc_feature (22). . (23) INFORMATION:\n\n<222>\n\nLOCATION:\n\n<223>\n\nOTHER\n\nn\n\nis\n\na,\n\n\u00a2,\n\ng,\n\ntoru\n\nUS 10,975,364 B2\n\n68\n\n67\n\ncontinued\n\n< 210 > SEQ ID NO 102\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 102\n\nggctctccga ggagaaggcc anntggt\n\n27\n\n< 210 > SEQ ID NO 103\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 23 ) .. ( 24 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 103\n\ngcgcccactg caaggcccgg cgnncrrt\n\n28\n\n< 210 > SEQ ID NO 104\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 23 ) .. ( 24 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 104\n\ngcgcccactg cagggcccgg ctnnggag\n\n28\n\n< 210 > SEQ ID NO 105\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 23 ) .. ( 24 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 105\n\ngcgcccactg caaggcccgg cgnncggt\n\n28\n\n< 210 > SEQ ID NO 106\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 106\n\nUS 10,975,364 B2\n\n67\n\n68\n\n-cont inued\n\n<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22).. (23) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 102 ggctctccga ggagaaggee anntggt <210> SEQ ID NO 103 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (23). . (24) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 103 gcgcccactg caaggecegg egnnerrt <210> SEQ ID NO 104 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (23) .. (24) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 104 gegeecactg cagggcccgg ctnnggag <210> SEQ ID NO 105 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc feature <222> LOCATION: (23).. (24) <223> OTHER INFORMATION: n is a, cr g, <400> SEQUENCE: 105 gcgcccactg caaggcccgg egnneggt <210> SEQ ID NO 106 <211> LENGTH: 27 toru toru toru toru\n\n27\n\n28\n\n28\n\n28\n\n<400> SEQUENCE: 106\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n102\n\n<211>\n\nLENGTH:\n\n27\n\n<212>\n\nTYPE:\n\nDNA\n\n<212>\n\nTYPE:\n\nDNA\n\n<213>\n\nORGANISM:\n\nArtificial\n\nSequence\n\n<220>\n\nFEATURE:\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\n<220>\n\nFEATURE:\n\n<221>\n\nNAME/KEY:\n\nmisc_feature (22). (23)\n\n<222>\n\nLOCATION:\n\n.\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nn\n\nis\n\na,\n\ncr\n\ng,\n\ntoru\n\nUS 10.975,364 B2\n\n70\n\n69\n\ncontinued\n\nggggtcccag gtgctgacgt anntrrt\n\n27\n\n< 210 > SEQ ID NO 107\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , c , g , t or u\n\n< 400 > SEQUENCE : 107\n\nggggtcccag gtgctgacgt anntagt\n\n27\n\n< 210 > SEQ ID NO 108\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 220 > FEATURE :\n\n< 221 > NAME / KEY : misc_feature\n\n< 222 > LOCATION :\n\n( 22 ) .. ( 23 )\n\n< 223 > OTHER INFORMATION : n is a , C , 9 , t or u\n\n< 400 > SEQUENCE : 108\n\ngaagtcccag ttgctgacat annggat\n\n27\n\n< 210 > SEQ ID NO 109\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 109\n\ngaaaccacaa acccacaggg agaaatg\n\n27\n\n< 210 > SEQ ID NO 110\n\n< 211 > LENGTH : 29\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 110\n\ngtactcacct ctcatgaagc acttggggt\n\n29\n\n< 210 > SEQ ID NO 111\n\n< 211 > LENGTH : 29\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 111\n\ntacctcacct gccaggaagc acttgaaat\n\n29\n\n< 210 > SEQ ID NO 112\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 112\n\nUS 10,975,364 B2\n\n69\n\n70\n\n-cont inued\n\n27\n\nggggtcccag gtgctgacgt anntrrt\n\n<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, cr \u53ef <400> SEQUENCE: 107 ggggteccag gtgetgacgt anntagt <210> SEQ ID NO 108 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (22). . (23) <223> OTHER INFORMATION: n is a, c, \u53ef <400> SEQUENCE: 108 gaagtcccag ttgetgacat annggat <210> SEQ ID NO 109 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 109 gaaaccacaa acccacaggg agaaatg <210> SEQ ID NO 110 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 110 gtactcacct ctcatgaage acttggggt <210> SEQ ID NO 111 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 111 toru toru 27 27 27 29\n\ntacctcacct gccaggaagc acttgaaat\n\n29\n\n<210> SEQ ID NO 112 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 112\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n107\n\n<211>\n\nLENGTH:\n\n27\n\nUS 10,975,364 B2\n\n72\n\n71\n\ncontinued\n\ngaaagagaga tgtagggcta gaggggt\n\n27\n\n< 210 > SEQ ID NO 113\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 113\n\ngaaagagaga aatagggcta gaacaaa\n\n27\n\n< 210 > SEQ ID NO 114\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 114\n\ngaaagaggca tgtagggcta cagaggo\n\n27\n\n< 210 > SEQ ID NO 115\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 115\n\ngtaagagaga agtagagcta gaaaaaa\n\n27\n\n< 210 > SEQ ID NO 116\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 116\n\ngcaaggcccc aggcatggtg gcacagt\n\n27\n\n< 210 > SEQ ID NO 117\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 117\n\ngcagggccag gcccacggag gtacaat\n\n27\n\n< 210 > SEQ ID NO 118\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 118\n\ncccaggcctg cagcacagtg gtgcagt\n\n27\n\n< 210 > SEQ ID NO 119\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\nUS 10,975,364 B2\n\n71\n\n72\n\n-cont inued\n\n27\n\ngaaagagaga tgtagggcta gaggggt\n\n<210> SEQ ID NO 113 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 113\n\n27\n\ngaaagagaga aatagggcta gaacaaa\n\n<210> SEQ ID NO 114 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 114\n\n27\n\ngaaagaggea tgtagggcta cagagge\n\n<210> SEQ ID NO 115 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 115\n\n27\n\ngtaagagaga agtagagcta gaaaaaa\n\n<210> SEQ ID NO 116 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 116\n\n27\n\ngeaaggecee aggcatggtg geacagt\n\n<210> SEQ ID NO 117 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 117\n\n27\n\ngcagggccag gcccacggag gtacaat\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 118\n\n27\n\ncccaggcctg cagcacagtg gtgeagt\n\n<210> SEQ ID NO 119 <211> LENGTH: 27 <212> TYPE: DNA\n\n<210>\n\nID\n\nNO\n\n118\n\nUS 10,975,364 B2\n\n74\n\n73\n\ncontinued\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 119\n\nctgaggcccg gagcacggag gggagat\n\n27\n\n< 210 > SEQ ID NO 120\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 120\n\ngcagggcctg tggcacagag ggcaagg\n\n27\n\n< 210 > SEQ ID NO 121\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 121\n\nacagggcccg gcacacggtg tgttggt\n\n27\n\n< 210 > SEQ ID NO 122\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 122\n\nctggggcccg gagcacagtg gggagag\n\n27\n\n< 210 > SEQ ID NO 123\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 123\n\ngcagggccct cggcacggtg ggcacca\n\n27\n\n< 210 > SEQ ID NO 124\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 124\n\ngtagggcctt cgcgcacctc atggaat\n\n27\n\n< 210 > SEQ ID NO 125\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 125\n\ngagtgagtaa gtgtgtgtgt gtgtggt\n\n27\n\nUS 10,975,364 B2\n\n73\n\n74\n\n-cont inued\n\n<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 119\n\nctgaggcccg gagcacggag gggagat <210> SEQ ID NO 120 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 120 gcagggcctg tggeacagag ggcaagg <210> SEQ ID NO 121 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 121 acagggcccg geacacggtg tgttggt <210> SEQ ID NO 122 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 122 ctggggcccg gagcacagtg gggagag <210> SEQ ID NO 123 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 123 gcagggccct cggcacggtg ggcacca <210> SEQ ID NO 124 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n27\n\n27\n\n27\n\n27\n\n27\n\ngtagggeett egegeaccte atggaat\n\n27\n\n<210> SEQ ID NO 125 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 125\n\ngagtgagtaa gtgtgtgtgt gtgtggt\n\n27\n\n<400>\n\nSEQUENCE:\n\n124\n\nUS 10.975,364 B2\n\n76\n\n75\n\ncontinued\n\n< 210 > SEQ ID NO 126\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 126\n\ngaatgagtgt gtgtgtgtgt gtgcagt\n\n27\n\n< 210 > SEQ ID NO 127\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 127\n\ngggagagaga gtgtgtgcgt gtgtggt\n\n27\n\n< 210 > SEQ ID NO 128\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 128\n\ngaatgagtga gtgtgtgtgt gtgagag\n\n27\n\n< 210 > SEQ ID NO 129\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 129\n\ngagtgagtga gtgtgtgtgt aagaggt\n\n27\n\n< 210 > SEQ ID NO 130\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 130\n\ngtgtgagtga gtgtgtgtgt gtgagag\n\n27\n\n< 210 > SEQ ID NO 131\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 131\n\ngtgtgggtga gtgtgtgcgt gagagcg\n\n27\n\n< 210 > SEQ ID NO 132\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\nUS 10,975,364 B2\n\n76\n\n75\n\n-cont inued\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 126\n\ngaatgagtgt gtgtgtgtgt gtgcagt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 127\n\ngggagagaga gtgtgtgegt gtgtggt\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 128\n\ngaatgagtga gtgtgtgtgt gtgagag\n\n27\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 129\n\ngagtgagtga gtgtgtgtgt aagaggt\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 130\n\ngtgtgagtga gtgtgtgtgt gtgagag\n\n27\n\n<210> SEQ ID NO 131 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 131\n\n27\n\ngtgtgggtga gtgtgtgegt gagagceg\n\n<210> SEQ ID NO 132 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n126\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n127\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n128\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n129\n\n<210>\n\nID\n\nNO\n\n130\n\nUS 10.975,364 B2\n\n78\n\n77\n\ncontinued\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 132\n\ngaatgagtga gtgtgtgtgt aagaagt\n\n27\n\n< 210 > SEQ ID NO 133\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 133\n\ngagtgagtga gtgtgtatgt gtaagaa\n\n27\n\n< 210 > SEQ ID NO 134\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 134\n\naggtgagaga gtgtgtgcgt aggagga\n\n27\n\n< 210 > SEQ ID NO 135\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 135\n\nggctgaatgt gtgtgtgcgt gaatgat\n\n27\n\n< 210 > SEQ ID NO 136\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 136\n\ngactgagtga gtgtgtgagt gagtagt\n\n27\n\n< 210 > SEQ ID NO 137\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 137\n\ngtatgggtga gagtgtgcgt gcacagt\n\n27\n\n< 210 > SEQ ID NO 138\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 138\n\ngtgtgaatga gtgtgtgtgt gagtgga\n\n27\n\nUS 10,975,364 B2\n\n77\n\n78\n\n-cont inued\n\n<223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 132\n\n27\n\ngaatgagtga gtgtgtgtgt aagaagt\n\n<210> SEQ ID NO 133 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 133\n\ngagtgagtga gtgtgtatgt gtaagaa\n\n27\n\n<210> SEQ ID NO 134 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 134\n\n27\n\naggtgagaga gtgtgtgegt aggagga\n\n<210> SEQ ID NO 135 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 135\n\n27\n\nggctgaatgt gtgtgtgcgt gaatgat\n\n<210> SEQ ID NO 136 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 136\n\n27\n\ngactgagtga gtgtgtgagt gagtagt\n\n<210> SEQ ID NO 137 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 137\n\n27\n\ngtatgggtga gagtgtgegt geacagt\n\n<210> SEQ ID NO 138 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 138\n\n27\n\ngtgtgaatga gtgtgtgtgt gagtgga\n\nUS 10.975,364 B2\n\n79\n\n80\n\ncontinued\n\n< 210 > SEQ ID NO 139\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 139\n\ngggtgagtga gtgagtgagt gagtgag\n\n27\n\n< 210 > SEQ ID NO 140\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 140\n\naagtgagtga gtgtgtgtgt gcaaaac\n\n27\n\n< 210 > SEQ ID NO 141\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 141\n\ngagtgagtga gtgtgtgtgt gtgagag\n\n27\n\n< 210 > SEQ ID NO 142\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 142\n\naggtgtgtga gtgtgtgtgt gtgaaac\n\n27\n\n< 210 > SEQ ID NO 143\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 143\n\ngggtgggtga gtgagtgagt gaggagt\n\n27\n\n< 210 > SEQ ID NO 144\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 144\n\ngagtgagtga gtgtgtgtgt gtaaaaa\n\n27\n\n< 210 > SEQ ID NO 145\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\nUS 10,975,364 B2\n\n80\n\n79\n\n-cont inued\n\n<210> SEQ ID NO 139 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 139\n\n27\n\ngggtgagtga gtgagtgagt gagtgag\n\n<210> SEQ ID NO 140 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 140\n\n27\n\naagtgagtga gtgtgtgtgt gcaaaac\n\n<210> SEQ ID NO 141 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 141\n\n27\n\ngagtgagtga gtgtgtgtgt gtgagag\n\n<210> SEQ ID NO 142 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 142\n\n27\n\naggtgtgtga gtgtgtgtgt gtgaaac\n\n<210> SEQ ID NO 143 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 143\n\n27\n\ngggtgggtga gtgagtgagt gaggagt\n\n<210> SEQ ID NO 144 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 144\n\ngagtgagtga gtgtgtgtgt gtaaaaa\n\n27\n\n<210> SEQ ID NO 145 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\nUS 10,975,364 B2\n\n82\n\n81\n\ncontinued\n\n< 400 > SEQUENCE : 145\n\ngagtgagtga gtgagtgagt gaaaggt\n\n27\n\n< 210 > SEQ ID NO 146\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 146\n\nggatgagtgt gtgtgtgcgt gtaacaa\n\n27\n\n< 210 > SEQ ID NO 147\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 147\n\ngtgtggttcc agaaccggcg gatgaagt\n\n28\n\n< 210 > SEQ ID NO 148\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 148\n\natctggttcc agaaccgcag gatgaagt\n\n28\n\n< 210 > SEQ ID NO 149\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 149\n\ngtatggtttc agaaccgaag aacaaagt\n\n28\n\n< 210 > SEQ ID NO 150\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 150\n\nttatggttcc agaaacgaag gaagcaat\n\n28\n\n< 210 > SEQ ID NO 151\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 151\n\ngtgtggttcc agaaccgcag\n\n28\n\n< 210 > SEQ ID NO 152\n\n< 211 > LENGTH : 28\n\nUS 10,975,364 B2\n\n82\n\n81\n\n-cont inued\n\n<400> SEQUENCE: 145\n\n27\n\ngagtgagtga gtgagtgagt gaaaggt\n\n<210> SEQ ID NO 146 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 146 ggatgagtgt gtgtgtgegt gtaacaa <210> SEQ ID NO 147 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 147 gtgtggttce agaaccggcg gatgaagt <210> SEQ ID NO 148 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 148 atctggttce agaaccgcag gatgaagt <210> SEQ ID NO 149 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 149 gtatggtttc agaaccgaag aacaaagt <210> SEQ ID NO 150 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 150\n\n27\n\n28\n\n28\n\n28\n\nttatggttce agaaacgaag gaagcaat\n\n28\n\n<210> SEQ ID NO 151 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 151\n\n28\n\ngtgtggttcc agaaccgcag gaccaagt\n\n<210> SEQ ID NO 152 <211> LENGTH: 28\n\nUS 10,975,364 B2\n\n84\n\n83\n\ncontinued\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 152\n\nacctggttcc agaaccagag gatgaaat\n\n28\n\n< 210 > SEQ ID NO 153\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 153\n\ngtctggttcc agaaccgaag ggccaagt\n\n28\n\n< 210 > SEQ ID NO 154\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 154\n\natctggtttc agaaccggag gatgaagt\n\n28\n\n< 210 > SEQ ID NO 155\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 155\n\nccaaggtccc ggaaccgaag gaggaagg\n\n28\n\n< 210 > SEQ ID NO 156\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 156\n\natttggttcc agaaccggcg gatgaaat\n\n28\n\n< 210 > SEQ ID NO 157\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 157\n\natctggttcc agaaccgcag gatgaaaa\n\n28\n\n< 210 > SEQ ID NO 158\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 158\n\nUS 10,975,364 B2\n\n84\n\n83\n\n-cont inued\n\n<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\nacetggttce agaaccagag gatgaaat <210> SEQ ID NO 153 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 153 gtctggttcc agaaccgaag ggecaagt <210> SEQ ID NO 154 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 154 atetggttte agaaceggag gatgaagt <210> SEQ ID NO 155 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 155 ccaaggtccc ggaaccgaag gaggaagg <210> SEQ ID NO 156 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized <400> SEQUENCE: 156 atttggttce agaaccggcg gatgaaat <210> SEQ ID NO 157 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:\n\n28\n\n28\n\n28\n\n28\n\n28\n\n<400> SEQUENCE: 157\n\n28\n\natctggttce agaaccgcag gatgaaaa\n\n<210> SEQ ID NO 158 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 158\n\n<400>\n\nSEQUENCE:\n\n152\n\n<223>\n\nOTHER\n\nINFORMATION:\n\nSynthesized\n\nUS 10,975,364 B2\n\n86\n\n85\n\ncontinued\n\nacgtggttcc agaaccggcg gatgaagc\n\n28\n\n< 210 > SEQ ID NO 159\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 159\n\nacgtggtacc agaatcggag gatgaagt\n\n28\n\n< 210 > SEQ ID NO 160\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 160\n\nacacagccag agggttgagg cggaggt\n\n27\n\n< 210 > SEQ ID NO 161\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 161\n\ngttcagcoca agtgttgaga ctcaggt\n\n27\n\n< 210 > SEQ ID NO 162\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 162\n\nactgagcctg agggttgagg ctgcagt\n\n27\n\n< 210 > SEQ ID NO 163\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 163\n\ngcccagccag gatgttgagg ctgcaat\n\n27\n\n< 210 > SEQ ID NO 164\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 164\n\nggctctccga ggagaaggcc aagtggt\n\n27\n\n< 210 > SEQ ID NO 165\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\nUS 10,975,364 B2\n\n86\n\n85\n\n-cont inued\n\n28\n\nacgtggttcc agaaccggcg gatgaage\n\n<210> SEQ ID NO 159 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 159\n\nacgtggtacc agaatcggag gatgaagt\n\n28\n\n<210> SEQ ID NO 160 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 160\n\n27\n\nacacagccag agggttgagg cggaggt\n\n<210> SEQ ID NO 161 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 161\n\ngttcagecea agtgttgaga ctcaggt\n\n27\n\n<210> SEQ ID NO 162 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 162\n\n27\n\nactgagcctg agggttgagg ctgcagt\n\n<210> SEQ ID NO 163 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 163\n\n27\n\ngeecagecag gatgttgagg ctgcaat\n\n<210> SEQ ID NO 164 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 164\n\nggctctccga ggagaaggcc aagtggt\n\n27\n\n<210> SEQ ID NO 165 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence\n\nUS 10.975,364 B2\n\n88\n\n87\n\ncontinued\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 165\n\nggctctccga tgggagggcc agagaat\n\n27\n\n< 210 > SEQ ID NO 166\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 166\n\nagctctccga ggagaagagc agcaagg\n\n27\n\n< 210 > SEQ ID NO 167\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 167\n\nggctctctgg ggagaaagcc agggago\n\n27\n\n< 210 > SEQ ID NO 168\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 168\n\naactctccca ggagaaggcc cagaaat\n\n27\n\n< 210 > SEQ ID NO 169\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 169\n\ngcctctccaa ggagaagggg ccagaag\n\n27\n\n< 210 > SEQ ID NO 170\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 170\n\nggctctctggggagaaggga caaggag\n\n27\n\n< 210 > SEQ ID NO 171\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 171\n\natctctccga ggaggaggcg aaggagt\n\n27\n\nUS 10,975,364 B2\n\n88\n\n87\n\n-cont inued\n\n<223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 165\n\n27\n\nggctctccga tgggagggee agagaat\n\n<210> SEQ ID NO 166 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 166\n\n27\n\nagetctcega ggagaagage agcaagg\n\n<210> SEQ ID NO 167 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 167\n\n27\n\nggctctctgg ggagaaagcc agggage\n\n<210> SEQ ID NO 168 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 168\n\n27\n\naactctccca ggagaaggec cagaaat\n\n<210> SEQ ID NO 169 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n27\n\ngectctccaa ggagaagggg ccagaag\n\n<210> SEQ ID NO 170 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 170\n\n27\n\nggctctctgg ggagaaggga caaggag\n\n<210> SEQ ID NO 171 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 171\n\n27\n\natctctccga ggaggaggcg aaggagt\n\n<220>\n\nFEATURE:\n\n<400>\n\nSEQUENCE:\n\n169\n\nSynthesized\n\nUS 10,975,364 B2\n\n90\n\n89\n\ncontinued\n\n< 210 > SEQ ID NO 172\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 172\n\nggctctcaga ggagaaggcc gagggga\n\n27\n\n< 210 > SEQ ID NO 173\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 173\n\ngtctctccca ggagactggc caaagagg\n\n28\n\n< 210 > SEQ ID NO 174\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 174\n\nagctctccaa ggagaagcca aaaaatc\n\n27\n\n< 210 > SEQ ID NO 175\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 175\n\nggctccccca ggagatgacc agatagt\n\n27\n\n< 210 > SEQ ID NO 176\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 176\n\nagttctccaa ggagaagacc acgtggt\n\n27\n\n< 210 > SEQ ID NO 177\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 177\n\ngcgcccactg caaggcccgg cgcacggt\n\n28\n\n< 210 > SEQ ID NO 178\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\nUS 10,975,364 B2\n\n90\n\n89\n\n-cont inued\n\n<210> SEQ ID NO 172 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 172\n\n27\n\nggetctcaga ggagaaggee gagggga\n\n<210> SEQ ID NO 173 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:\n\n<400> SEQUENCE: 173\n\ngtctctccca ggagactgge caaagagg\n\n28\n\n<211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 174\n\nagctctccaa ggagaageca aaaaate\n\n27\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 175\n\n27\n\nggctccccca ggagatgacc agatagt\n\nSEQ <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 176\n\n27\n\nagttctccaa ggagaagace acgtggt\n\nSEQ <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 177\n\n28\n\ngcgcccactg caaggcccgg egeacggt\n\n<210> SEQ ID NO 178 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthesized\n\nSynthesized\n\nSynthesized\n\n<210>\n\nSEQ\n\nID\n\nNO\n\n174\n\n<210>\n\nID\n\nNO\n\n175\n\n<210>\n\nID\n\nNO\n\n176\n\n<210>\n\nID\n\nNO\n\n177\n\nUS 10.975,364 B2\n\n92\n\n91\n\ncontinued\n\n< 400 > SEQUENCE : 178\n\naggcccactg caaggcccag tgggcggc\n\n28\n\n< 210 > SEQ ID NO 179\n\n< 211 > LENGTH : 28\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 179\n\ngcgcccactg cagggcccgg ctgcggag\n\n28\n\n< 210 > SEQ ID NO 180\n\n< 211 > LENGTH : 27\n\n< 212 > TYPE : DNA\n\n< 213 > ORGANISM : Artificial Sequence\n\n< 220 > FEATURE :\n\n< 223 > OTHER INFORMATION : Synthesized\n\n< 400 > SEQUENCE : 180\n\nggggtcccag gtgctgacgt aggtagt\n\n27\n\nsequence , an affinity tag or a fusion base editor protein ,\n\nThe invention claimed is :\n\n1. A modified Streptococcus aureus Cas9 protein with a\n\nwherein the modified protein comprises the amino acid\n\nmutation at an N413 position , and optionally one or more of 30 sequence selected from SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ\n\na nuclear localization sequence , a cell penetrating peptide\n\nID NO : 3 , SEQ ID NO : 4 or a homologue thereof having at\n\nsequence , an affinity tag or a fusion base editor protein ,\n\nleast 90 % overall sequence identity to the amino acid\n\nwherein the modified protein comprises the amino acid\n\nsequence .\n\nsequence selected from SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ\n\n12. The method of claim 11 , wherein the modified protein\n\nID NO : 3 , SEQ ID NO : 4 or a homologue thereof having at 35 is expressed in the cell or the cell is contacted with the\n\nleast 90 % overall sequence identity to the amino acid\n\nmodified protein and a guide RNA having a region comple\n\nmentary to a selected portion of the genome of the cell .\n\nsequence .\n\n2. The modified protein of claim 1 , wherein the modified\n\n13. The method of claim 11 , wherein the modified protein\n\nprotein comprises the amino acid sequence of SEQ ID NO :\n\ncomprises the amino acid sequence of SEQ ID NO : 1 .\n\n14. The method of claim 11 , wherein the modified protein\n\n1 .\n\n40\n\n3. The modified protein of claim 1 , wherein the modified\n\ncomprises the amino acid sequence of SEQ ID NO : 2 .\n\nprotein comprises the amino acid sequence of SEQ ID NO :\n\n15. The method of claim 11 , wherein the modified protein\n\nfurther comprises one or more mutations at R245 , N419 or\n\n2 .\n\n4. The modified protein of claim 1 , further comprising one\n\nR654 positions .\n\nor more mutations at R245 , N419 or R654 positions .\n\n16. The method of claim 11 , wherein the modified protein\n\n45\n\n5. The modified protein of claim 1 , wherein the modified\n\ncomprises an amino acid sequence of SEQ ID NO : 3 .\n\nprotein comprises the amino acid sequence of SEQ ID NO :\n\n17. The method of claim 14 , wherein the modified protein\n\nfurther comprises one or more mutations at R245 , N419 and\n\n3 .\n\n6. The modified protein of claim 3 , further comprising\n\nR654 positions .\n\nmutations at R245 , N419 and R654 positions .\n\n18. The method of claim 11 , wherein the modified protein\n\n50\n\n7. The modified protein of claim 1 , wherein the modified\n\ncomprises the amino acid sequence of SEQ ID NO : 4 .\n\nprotein comprises the amino acid sequence of SEQ ID NO :\n\n19. The method of claim 11 , wherein the modified protein\n\nwith optionally at least one additional mutation selected\n\n4 .\n\n8. The modified protein of claim 1 , wherein the modified\n\nfrom the group consisting of R245 , N419 and R654 posi\n\nprotein with optionally at least one additional mutation 55 tions decreases nuclease activity at one or more off - target\n\nselected from the group consisting of R245 , N419 and R654\n\nsites on a target DNA molecule of the cell .\n\npositions decreases nuclease activity at one or more sites on\n\n20. The method of claim 11 , wherein the mutation is a\n\nsingle amino acid substitution .\n\na target DNA molecule .\n\n9. The modified protein of claim 8 , wherein the one or\n\n21. A kit comprising a modified Streptococcus aureus\n\nmore sites are off - target sites on the target DNA molecule . 60 Cas9 protein with a mutation at an N413 position , and\n\n10. The modified protein of claim 1 , wherein the mutation\n\noptionally one or more of a nuclear localization sequence , a\n\ncell penetrating peptide sequence , an affinity tag or a fusion\n\nis a single amino acid substitution .\n\n11. An in vitro method for altering the genome of an\n\nbase editor protein , wherein the modified protein comprises\n\nisolated host cell , the method comprising the step of using\n\nthe amino acid sequence selected from SEQ ID NO : 1 , SEQ\n\na modified Streptococcus aureus Cas9 protein with a muta- 65 ID NO : 2 , SEQ ID NO : 3 , SEQ ID NO : 4 or a homologue\n\ntion at an N413 position , and optionally one or more of a\n\nthereof having at least 90 % overall sequence identity to the\n\nnuclear localization sequence , a cell penetrating peptide\n\namino acid sequence .\n\nUS 10,975,364 B2\n\n92\n\n91\n\n-cont inued\n\n<400> SEQUENCE: 178\n\naggcccactg caaggeecag tgggegge\n\n28\n\n<210> <211> <212> <213> <220> <223> SEQ ID NO 179 LENGTH: 28 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 179\n\ngegeceactg cagggcccgg ctgcggag\n\n28\n\n<210> <211> <212> <213> <220> <223> SEQ ID NO 180 LENGTH: 27 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Synthesized\n\n<400> SEQUENCE: 180\n\nggggtcccag gtgctgacgt aggtagt\n\n27\n\nsequence, an affinity tag or a fusion base editor protein, wherein the modified protein comprises the amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a homologue thereof having at least 90% overall sequence identity to the amino acid sequence.\n\nThe invention claimed is:\n\n1. A modified Streptococcus aureus Cas9 protein with a mutation at an N413 position, and optionally one or more o a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag or a fusion base editor protein, wherein the modified protein comprises the amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a homologue thereof having at least 90% overall sequence identity to the amino acid sequence.\n\n12. The method of claim 11, wherein the modified protein expressed in the cell or the cell is contacted with modified protein and a guide RNA having a region comple- mentary to a selected portion of the genome of the cell.\n\n13. The method of claim 11, wherein the modified comprises the amino acid sequence of SEQ ID NO: 1.\n\n[he modified protein of claim 1, wherein the modified comprises the amino acid sequence of SEQ ID NO:\n\n14. The method of claim 11, wherein the modified comprises the amino acid sequence of SEQ ID NO: 2.\n\nThe modified protein of claim 1, wherein the modified comprises the amino acid sequence of SEQ ID NO:\n\n15. The method of claim 11, wherein the modified protein further comprises one or more mutations at R245, N419 R654 positions.\n\n4, The modified protein of claim 1, further comprising one or more mutations at R245, N419 or R654 positions.\n\n16. The method of claim 11, wherein the modified an amino acid sequence of SEQ ID NO: 3.\n\n5. The modified protein of claim 1, wherein the modified protein comprises the amino acid sequence of SEQ ID NO:\n\n17. The method of claim 14, wherein the modified protein further comprises one or more mutations at R245, N419 R654 positions.\n\n6. The modified protein of claim 3, further com mutations at R245, N419 and R654 positions. rising\n\n18. The method of claim 11, wherein the modified protein comprises the amino acid sequence of SEQ ID NO: 4.\n\n7. The modified protein of claim 1, wherein the modified protein comprises the amino acid sequence of SEQ ID NO:\n\n19. The method of claim 11, wherein the modified protein with optionally at least one additional mutation selected from the group consisting of R245, N419 and R654 posi- tions decreases nuclease activity at one or more off-target sites on a target DNA molecule of the cell.\n\n8. The modified protein of claim 1, wherein the modified protein with optionally at least one additional mutation selected from the group consisting of R245, N419 and R654 positions decreases nuclease activity at one or more sites on target DNA molecule.\n\n20. The method of claim 11, wherein the mutation amino acid substitution.\n\n9. The modified protein of claim 8, wherein the one sites are off-target sites on the target DNA molecule.\n\n21. A kit comprising a modified Streptococcus aureus Cas9 protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag or a fusion base editor protein, wherein the modified protein comprises the amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a homologue thereof having at least 90% overall sequence identity to the amino acid sequence.\n\n10. The modified protein of claim 1, wherein the mutation a single amino acid substitution.\n\n11. An in vitro method for altering the genome of an isolated host cell, the method comprising the step of using modified Streptococcus aureus Cas9 protein with a muta- tion at an N413 position, and optionally one or more of nuclear localization sequence, a cell penetrating peptide\n\n3.\n\n4.\n\na\n\nor\n\nmore\n\nis\n\na\n\na\n\n30\n\n35\n\n40\n\n45\n\n50\n\n35\n\n60\n\n65\n\nis\n\nthe\n\nprotein\n\nprotein\n\nor\n\nprotein\n\ncomprises\n\nand.\n\nis a\n\nsingle\n\nUS 10,975,364 B2\n\n94\n\n93\n\n22. The kit of claim 21 , wherein the modified protein\n\ncomprises the amino acid sequence of SEQ ID NO : 1 .\n\n23. The kit of claim 22 , wherein the modified protein\n\ncomprises the amino acid sequence of SEQ ID NO : 2 .\n\n24. The kit of claim 21 , the modified protein further 5\n\ncomprising one or more mutations at R245 , N419 or R654\n\npositions .\n\n25. The kit of claim 23 , the modified protein further\n\ncomprising one or more mutations at R245 , N419 and R654\n\npositions .\n\n10\n\n26. The kit of claim 23 , wherein the modified protein\n\ncomprises the amino acid sequence of SEQ ID NO : 3 .\n\n27. The kit of claim 23 , wherein the modified protein\n\ncomprises the amino acid sequence of SEQ ID NO : 4 .\n\n28. The kit of claim 23 , wherein the modified protein 15\n\ncomprising optionally at least one additional mutation\n\nselected from the group consisting of R245 , N419 and R654\n\ndecreases nuclease activity at one or more off - target sites on\n\na target DNA molecule .\n\n20\n\nUS 10,975,364 B2\n\n93\n\n94\n\n22. The it of claim 21, wherein the modified protein comprises the amino acid sequence of SEQ ID NO: 1.\n\n23. The kit of claim 22, wherein the modified protein comprises the amino acid sequence of SEQ ID NO: 2.\n\n24. The it of claim 21, the modified protein further comprising one or more mutations at R245, N419 or R654\n\n25. Th it of claim 23, the modified protein further comprising one or more mutations at R245, N419 and R654 positions.\n\n10\n\n26. The kit of claim 23, wherein the modified protein comprises the amino acid sequence of SEQ ID NO: 3.\n\n27. The it of claim 23, wherein the modified protein comprises the amino acid sequence of SEQ ID NO: 4.\n\n28. The it of claim 23, wherein the modified protein comprising optionally at least one additional mutation selected from the group consisting of R245, N419 and R654 decreases nuclease activity at one or more off-target sites on DNA molecule.\n\n20\n\n\u5b66 \u5b66 \u4e8b \u515a \u515a\n\npositions.\n\na target", "type": "Document"}}